WO1991017148A1

WO1991017148A1 - 1h-substituted-1,2,4-triazole compounds for treatment of cardiovascular disorders

Info

Publication number: WO1991017148A1
Application number: PCT/US1991/002926
Authority: WO
Inventors: David B. Reitz
Original assignee: G.D. Searle & Co.
Priority date: 1990-05-04
Filing date: 1991-05-06
Publication date: 1991-11-14
Also published as: EP0527851A1; IE911533A1; DE69130671D1; JPH05507079A; ATE174910T1; GR3029772T3; CA2082074A1; PT97581B; AU7792491A; DK0527851T3; EP0527851B1; JP3098772B2; US5098920A; IE62867B1; ES2125868T3; PT97581A; CA2082074C; DE69130671T2

Abstract

A class of 1H-substituted-1,2,4-triazole compounds is described for use in treatment of circulatory disorders, especially cardiovascular disorders. Compounds of interest are angiotensin II antagonists of formula (II), wherein R1 is selected from hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, adamantyl, adamantylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, dimethoxymethyl, diethoxymethyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxypropyl, halo, monofluoromethyl, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, pentafluoroethyl, heptafluoropropyl, phenylacetyl, phenyldifluoroethyl, aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein R2 is selected from carboxyethyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl and neopentyl; wherein each of R3 through R11 is hydrido with the proviso that at least one of R?5 and R9¿ must be selected from COOH, SH, PO¿3?H2, SO3H, CONHNH2, CONHNHSO2CF3, OH, (III), (IV) and (V), wherein each of R?40 and R41¿ is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.

Description

1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS

Related Application

This is a continuation-in-part of U.S. Application Serial No. 07/519,380 filed on May 4, 1990.

Field of the Invention

Non-peptidic 1H-substituted-1,2,4-triazole compounds are described for use in treatment of

cardiovascular disorders such as hypertension and

congestive heart failure. Of particular interest are angiotensin II antagonist compounds provided by 1,2,4- triazoles having a biphenylmethyl moiety attached to the nitrogen atom at the one-position of the 1,2,4-triazole.

Background of the Invention

The renin-angiotensin system is one of the hormonal mechanisms involved in regulation of

pressure/volume homeostasis and in expression of

hypertension. Activation of the renin-angiotensin cascade begins with renin secretion from the juxtaglomerular apparatus of the kidney and culminates in the formation of angiotensin II, the primary active species of this system. This octapeptide, angiotensin II, is a potent

vasoconstrictor agent and also produces other physiological effects such as promoting aldosterone secretion, promoting sodium and fluid retention, inhibiting renin secretion, increasing sympathetic nervous system activity, increasing vasopressin secretion, causing positive cardiac inotropic effect and modulating other hormonal systems.

Previous studies have shown that antagonizing angiotensin II at its receptors is a viable approach to inhibit the renin-angiotensin system, given the pivotal role of this octapeptide which mediates the actions of the renin-angiotensin system through interaction with various tissue receptors. There are several known angiotensin II antagonists, most of which are peptidic in nature. Such peptidic compounds are of limited use due to their lack of oral bioavailability or their short duration of action. Also, commercially-available peptidic angiotensin II antagonists (e.g., Saralasin) have a significant residual agonist activity which further limit their therapeutic application.

Non-peptidic compounds with angiotensin II antagonist properties are known. For example, the sodium salt of 2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5- acetic acid has specific competitive angiotensin II antagonist activity as shown in a series of binding experiments, functional assays and in vivo tests [P. C. Wong et al, J. Pharmacol. Exp. Ther., 247 (1), 1-7 (1988)]. Also, the sodium salt of 2-butyl-4-chloro-1-(2- nitrobenzyl)imidazole-5-acetic acid has specific

competitive angiotensin II antagonist activity as shown in a series of binding experiments, functional assays and in vivo tests [A. T. Chiu et al, European J. Pharmacol., 157, 3121 (1988)]. A family of l-benzylimidazole-5-acetate derivatives has been shown to have competitive angiotensin II antagonist properties [A. T. Chiu et al, J. Pharmacol. Exp. Ther., 250(3), 867-874 (1989)]. U.S. Patent No.

4,816,463 to Blankey et al describes a family of 4,5,6,7- tetrahydro-1H-imidazo(4,5-c)-tetrahydro-pyridine

derivatives useful as antihypertensives, some of which are reported to antagonize the binding of labelled angiotensin II to rat adrenal receptor preparation and thus cause a significant decrease in mean arterial blood pressure in conscious hypertensive rats. EP No. 253,310, published 20 January 1988, describes a series of aralkyl imidazole compounds, including in particular a family of biphenylmethyl substituted imidazόles, as antagonists to the angiotensin II receptor. EP No. 323,841 published 12 July 1989 describes four classes of angiotensin II

antagonists, namely, biphenylmethylpyrroles,

biphenylmethylpyrazoles, biphenylmethyl-1,2,3-triazoles and biphenylmethyl 4-substituted-4H-1,2,4-triazoles, including the compound 3,5-dibutyl-4-[(2'-carboxybiphenyl-4- yl)methyl]-4H-1,2,4-triazole. U.S. Patent No. 4,880,804 to Carini et al describes a family of

biphenylmethylbenzimidazole compounds as angiotensin II receptor blockers for use in treatment of hypertension and congestive heart failure.

There are several families of 1,2,4-triazole compounds having substituents attached to the nitrogen atom at the one-position of the 1H-triazole. For example, U.S. Patent No. 4,118,487 to Regel et al describes a family azol-1-ylmethane compounds for use as antimycotic and antibacterial agents including, specifically, the compound (1-biphenyl-4-yl-1-phenyl)methyl-1H-1,2,4-triazole. U.S. Patent No. 4,381,306 to Regel et al describes a family of hydroxypropyl-triazole compounds for use as antimycotic agents including, specifically, the compound (1,2,4- triazol-1-yl)methyl-4-chlorobenzyl-biphenyl-4-ylcarbinol. U.S. Patent No. 4,480,114 to Regel describes a family of 2- (4-biphenyl)-2-(halophenyl)-oxoirane compounds having antimycotic activity including, specifically, the compound (1,2,4-triazol-1-yl)methyl-4-chlorophenyl-4-chlorobiphenyl- 4-yl carbinol. DESCRIPTION OF THE INVENTION

A class of 1H-substituted-1,2,4-triazole

compounds useful in treating circulatory and cardiovascular disorders is defined by Formula I :

wherein m is a number selected from one to four,

inclusive; wherein each of R¹ through R¹¹ is independently selected from hydrido, formyl, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl,

aralkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, polycycloalkyl,

polycycloalkylalkyl, thienylalkyl, phenylacyl,

phenylhaloalkyl, aminoalkyl, acylaminoalkyl,

alkoxycarbonylaminoalkyl, glutamic acid alkyl ester, alkylcarbonyloxy, mercaptocarbonyl, mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio, alkylthiocarbonyl,

alkylcarbonylthio, alkylthiocarbonyloxy,

alkylthiocarbonylthio, alkylthiothiocarbonyl,

alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy,

arylthiocarbonylthio, arylthiothiocarbonyl,

arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,

aralkylthiocarbonylthio, alkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto, alkylsulfinyl,

alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,

arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R¹² and R¹³ taken together, R¹⁴ and R¹⁵ taken together and R¹⁶ and R¹⁷ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R^{1 2} and R¹³ taken together and each of R¹⁴ and R¹⁵ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and wherein each of R³ through R¹¹ may be further

independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

-Y_nA wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; wherein B is a single bond connecting the phenyl rings to form a biphenyl moiety or B is a group selected from |

and -CH=CH-, wherein p is a number selected from one through three, inclusive; wherein R¹⁸ is selected from hydrido, alkyl, aryl, formyl, alkylcarbonyl, arylcarbonyl, carboxyl, alkoxycarbonyl, aryloxycarbonyl and

aralkoxycarbonyl; and wherein any of the foregoing R¹ through R¹⁸, Y, A and B groups having a substitutable position may be substituted by one or more groups selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl,

hydroxyalkyl, trifluoromethyl, halo, oxo, difluoroalkyl, alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy,

alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl,

aralkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, aralkyIsulfinyl, aralkylsulfonyl,

wherein X is selected from oxygen atom and sulfur atom; wherein R¹⁹ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, DR²⁴ and .

wherein D is selected from oxygen atom and sulfur atom and R²⁴ is selected from hydrido, alkyl, cycloalkyl,

cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁰, R²¹, R²², R²³, R²⁵ and R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl,

alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl,

haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁰, R²¹, R²², R²³ R²⁵ and R²⁶ is further independently selected from amino and amido radicals of the formula

wherein each of R²⁷, R²⁸, R²⁹, R³⁰ R³¹ and R³² is

independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl,

haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁰ and R²¹ taken together and each of R²² and R²³ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R²⁰ and R²¹ taken together and each of R²⁵ and R²⁶ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. Compounds of Formula I would be useful in treating a variety of circulatory disorders including cardiovascular disorders, such as hypertension, congestive heart failure and arteriosclerosis, and to treat other disorders such as glaucoma. These compounds would also be useful as adjunctive therapies. For example, compounds of Formula I may be used in combination with other drugs, such as a diuretic, to treat hypertension. Also, compounds of Formula I could be used in conjunction with certain

surgical procedures. For example, these compounds could be used to prevent post-angioplasty re-stenosis. Compounds of Formula I are therapeutically effective in treatment of cardiovascular disorders by acting as antagonists to, or blockers of, the angiotensin II (All) receptor. Compounds of Formula I would be therapeutically effective in

treatment of the above-mentioned circulatory and

cardiovascular disorders or would be precursors to, or prodrugs of, therapeutically-effective compounds.

Preferred compounds of Formula I are all

characterized in having a substituent, other than hydrido, attached to one or both of the three- and five-positions of the triazole ring. Such substituents are selected from the aforementioned R¹ and R² groups. Compounds having alkyl groups, especially lower alkyl groups, at both of the R¹ and R² positions are particularly useful as angiotensin II antagonists. Also especially useful are compounds having one of the R¹ and R² substituents selected from

alkylcarbonyl, monoalkoxyalkyl, dialkoxyalkyl and

difluoroalkyl groups. When the selected substituent for R¹ and R² is difluoroalkyl, then it is particularly useful for both of the fluoro atoms of the difluoroalkyl group to be substituted on the difluoroalkyl group carbon atom attached at the R¹ or R² positions of the triazole ring. Such difluoroalkyl group may be characterized as an "alpha- carbon difluoro-substituted difluoroalkyl group", or as an "alpha,alpha-difluoro-substituted alkyl group". When the selected substituent for R¹ or R² is monoalkoxyalkyl or dialkoxyalkyl, then it is particularly useful for the single alkoxy group or the two alkoxy groups, respectively, to be substituted on the carbon atom of the selected substituent which is attached at the R¹ or R² positions of the triazole ring. Such alkoxyalkyl groups may be

characterized as "alpha-carbon monoalkoxy- or dialkoxy- substituted alkoxyalkyl groups", respectively, or "alpha- monoalkoxy-substituted or alpha, alpha-dialkoxy-substituted alkyl groups", respectively. When the selected substituent is alkylcarbonyl, then it is particularly useful for the carbonyl group to be attached at the R¹ or R² positions of the triazole ring. Such alkylcarbonyl group may be characterized as an "alpha-oxo-sύbstituted alkyl group", and may be exemplified by the substituents 1-oxoethyl, 1- oxopropyl and 1-oxobutyl. Where compounds of Formula I contain any of these above-mentioned particularly-useful alpha-carbon substituted R¹ or R² groups at the triazole ring three- or five-position, it is preferred that such particularly-useful group be attached at the three- position, that is, as an R¹ substituent.

The phrase "acidic group selected to contain at least one acidic hydrogen atom", as used to define the -Y_nA moiety, is intended to embrace chemical groups which, when attached to any of the R³ through R¹¹ positions of Formula I, confers acidic character to the compound of Formula I. "Acidic character" means proton-donor capability, that is, the capacity of the compound of Formula I to be a proton donor in the presence of a proton-receiving substance such as water. Typically, the acidic group should be selected to have proton-donor capability such that the product compound of Formula I has a pK_a in a range from about one to about twelve. More typically, the Formula I compound would have a pK_a in a range from about two to about seven.

An example of an acidic group containing at least one acidic hydrogen atom is carboxyl group (-COOH). Where n is zero and A is -COOH, in the -Y_nA moiety, such carboxyl group would be attached directly to one of the R³ through R¹¹ positions. The Formula I compound may have one -Y_nA moiety attached at one of the R³ through R¹¹ positions, or may have a plurality of such -Y_nA moieties attached at more than one of the R³ through R¹¹ positions, up to a maximum of nine such -Y_nA moieties. There are many examples of acidic groups other than carboxyl group, selectable to contain at least one acidic hydrogen atom. Such other acidic groups may be collectively referred to as

"bioisosteres of carboxylic acid" or referred to as "acidic bioisosteres". Specific examples of such acidic

bioisosteres are described hereinafter. Compounds of

Formula I having the -Y_nA moiety attached at one of positions R⁵, R⁶, R⁸ and R⁹ would be expected to have preferred properties, while attachment at R⁵ or R⁹ would be more preferred.

A preferred class of compounds consists of those compounds of Formula I wherein m is one; wherein each of R¹ through R¹¹ is independently selected from hydrido, formyl, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, polycycloalkyl,

polycycloalkylalkyl, thienylalkyl, phenylacyl,

phenylhaloalkyl, aminoalkyl, acylaminoalkyl,

alkylcarbonylthio, alkylthiocarbonyloxy, alkylthio- arbonylthio, alkylthiothiocarbonyl, alkylthiothio- carbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio,

arylthiothiocarbonyl, arylthiothiocarbonylthio,

aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio,

aralkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,

aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms and amino and amido radicals of the formula

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R³ through R¹¹ may be further

-Y_nA wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl,

cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; wherein B is a single bond or is a group selected from |

and -CH=CH-, wherein p is one or two; wherein R¹⁸ is selected from hydrido, alkyl, aryl, formyl, alkylcarbonyl, arylcarbonyl, carboxyl, alkoxycarbonyl, aryloxycarbonyl and aralkoxycarbonyl; and wherein any of the foregoing R¹ through R¹⁸, Y, A and B groups having a substitutable position may be substituted by one or more groups selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl, difluoroalkyl, oxo, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom; wherein R¹⁹ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, and DR²⁴ and

-

wherein D is selected from oxygen atom and sulfur atom, and R²⁴ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁰, R²¹, R²², R²³, R²⁵ and R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl. cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁰, R²¹, R²², R²³, R²⁵, and R²⁶ is further independently selected from amino and amido radicals of the formula

wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and R³² _is

haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A more preferred class of compounds consists of those compounds of Formula I wherein m is one; wherein each of R¹ through R¹¹ is independently selected from hydrido, hydroxy, formyl, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,

alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl,

cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, polycycloalkyl, polycycloalkylalkyl, haloalkyl,

thienylalkyl, phenylacyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl, alkoxycarbonylaminoalkyl, glutamic acid alkyl ester, alkylcarbonyloxy, mercaptocarbonyl,

alkoxycarbonyloxy, alkylthio, arylthio, aralkylthio, aralkylthiocarbonylthio, mercapto, alkylsulfinyl,

alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,

arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and amino and amido radicals of the formula

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

-Y_nA wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁷; wherein each of R³³, R³⁴, R³⁵, R³⁶ and R³⁷ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl,

cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R³³, R³⁴, R³⁵ and R³⁶ may be further independently selected from amino radical of the formula

wherein each of R³⁸ and R³⁹ is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl,

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R³⁸ and R³⁹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R³⁸ and R³⁹ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R³⁴ and R³⁵ may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially

unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; wherein B is a single bond or is a group selected from

and -CH=CH-, wherein p is a number selected from one

through three, inclusive; wherein R¹⁸ is selected from hydrido, alkyl, aryl, formyl, alkylcarbonyl, arylcarbonyl, carboxyl, alkoxycarbonyl, aryloxycarbonyl and

aralkoxycarbonyl; and wherein any of the foregoing R¹ through R¹⁸, Y, A and B groups having a substitutable position may be substituted by one or more groups selected from alkyl, alkenyl, aralkyl, hydroxyalkyl, trifluoromethyl,

difluoroalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom;

wherein R¹⁹ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl and DR²⁴ and

wherein D is selected from oxygen atom and sulfur atom, wherein R²⁴ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁰, R²¹, R²², R²³, R²⁵ and R²⁶ is

independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. An even more preferred class of compounds consists of those compounds of Formula I wherein m is one; wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, alkyl, carboxyalkyl, phenyl, phenylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl,

alkylcarbonyl, alkoxyalkyl, hydroxyalkyl, halo, haloalkyl, thienylalkyl, phenylacyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl, alkoxycarbonylaminoalkyl and glutamic acid alkyl ester; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkyIsulfonyl, arylsulfinyl, arylsulfonyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties of the formula

-Y_nA

wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁷; wherein each of R³³, R³⁶ and R³⁷ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,

cycloalkylalkyl, aryl and aralkyl; wherein each of R³³ and R³⁶ may be further independently selected from amino radical of the formula

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R³⁸ and R³⁹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially unsaturated; wherein R³⁸ and R³⁹ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups;

wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; wherein B is a single bond or is a group selected from

and -CH=CH-, wherein p is one or two; wherein R¹⁸ is

selected from hsdrido, alkyl, aryl, formyl, alkylcarbonyl, arylcarbonyl, carboxyl, alkoxycarbonyl, aryloxycarbonyl and aralkoxycarbonyl; wherein each of R¹ through R¹¹, Y, A and B independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl,

haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and

aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A highly preferred class of compounds consists of those compounds wherein m is one; wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, alkyl, carboxyalkyl, phenyl, phenylalkyl, cycloalkyl,

cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl,

alkylcarbonyl, dialkoxyalkyl, hydroxyalkyl, halo, haloalkyl, thienylalkyl, phenylacetyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl, alkoxycarbonylaminoalkyl and glutamic acid alkyl ester; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio, mercapto and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties of the formula

-Y_nA wherein n is a number selected from zero through two,

inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁷; wherein each of R³³, R³⁶ and R³⁷ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R³³ and R³⁶ may be further

independently selected from amino radical of the formula

alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl; wherein B is a single bond or is a group selected from

and -CH=CH-, wherein p is one; wherein R¹⁸is

selected from hydrido, alkyl, aryl, formyl, alkylcarbonyl, arylcarbonyl, carboxyl, alkoxycarbonyl, aryloxycarbonyl and aralkoxycarbonyl; wherein each of R¹ through R¹⁸, Y, A and B and independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

An even more highly preferred class of compounds consists of those compounds of Formula I wherein m is one; wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl,

cyclohexyl, cyclopentylmethyl, cyclohexylmethyl,

cyclohexylethyl, cyclohexylpropyl, adamantyl, adamantyImethyl, 1-oxoethyl, oxobutyl, 1-oxopentyl, dimethoxymethyl,

diethoxymethyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxypropyl, halo, monofluoromethyl, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl,

1,1-difluorobutyl, 1,1-difluoropentyl, pentafluoroethyl, heptafluoropropyl, thienylmethyl, 2(2-thienyl)ethyl,

2(3-thienyl)ethyl, phenylacetyl, phenyldifluoroethyl,

aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, acetyl,

alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties consisting of CO₂H, CO₂CH₃, SH, CH₂SH, C₂H₄SH, PO₃H₂, NHSO₂CF₃,

NHSO₂C₆F_5, SO₃H, CONHNH_2, CONHNHSO₂CF₃, CONHOCH₃, CONHOC₂H_5, CONHCF₃, OH, CH₂OH, C₂H₄OH, OPO₃H₂, OSO₃H and heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein B is a single bond or is one or more groups selected from

wherein p is one; wherein R¹⁸ is selected from

hydrido, alkyl, aryl, formyl, alkylcarbonyl, arylcarbonyl, carboxyl, alkoxycarbonyl, aryloxycarbonyl and

aralkoxycarbonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A class of compounds of particular interest consists of those compounds of Formula I wherein m is one; wherein R¹ is selected from hydrido, hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n- heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl,

adamantyl, adamantylmethyl, 1-oxoethyl, 1-oxopropyl, 1- oxobutyl, 1-oxopentyl, dimethoxymethyl, diethoxymethyl, 1,1- dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxypropyl, halo, monofluoromethyl, difluoromethyl,

1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, pentafluoroethyl, heptafluoropropyl, thienylmethyl, 2(2-thienyl)ethyl, phenylacetyl,

phenyldifluoroethyl, aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein R² is selected from hydrido, carboxyethyl, cyclohexyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,

4-methylbutyl, tert-butyl, n-pentyl and neopentyl; with the proviso that both R¹ and R² cannot be hydrido simultaneously; wherein each of R³, R⁴, R⁷, R⁹, R¹⁰ and R¹¹ is hydrido; wherein at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic moiety selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH_2, CONHNHSO₂CF₃, OH,

wherein each of R⁴⁰ and R⁴¹ is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃; and the amide, ester and salt derivatives of said acidic moieties; wherein B is a single bond or is a group selected from

,

wherein p is one; wherein R¹⁸ is selected from hydrido, alkyl, aryl, formyl, alkylcarbonyl, arylcarbonyl, carboxyl, alkoxycarbonyl, aryloxycarbonyl and

A class of compounds of more particular interest consists of those compounds of Formula I wherein m is one;

wherein R¹ is selected from hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl,

n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, adamantyl, adamantylmethyl, 1-oxoethyl, 1 -oxopropyl, 1-oxobutyl, 1-oxopentyl,

dimethoxymethyl, diethoxymethyl, 1,1-dimethoxypropyl,

1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxypropyl, halo, monofluoromethyl, difluoromethyl, 1,1-difluoroethyl,

1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, pentafluoroethyl, heptafluoropropyl, phenylacetyl,

phenyldifluoroethyl, aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein R² is selected from carboxyethyl, cyclohexyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl and neopentyl; wherein each of R³, R⁴, R⁷, R⁹, R¹⁰ and R¹¹ is hydrido; wherein at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic moiety selected from CO₂H, SH, PO₃H₂ SO₃H, CONHNH_2, CONHNHSO₂CF₃, OH,

wherein p is one; wherein R¹⁸ is selected from

aralkoxycarbonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. Of even more particular interest are compounds wherein at least one of R⁵ and R⁹ is selected from the acidic groups specified for this class of compounds of more

particular interest.

A sub-class of compounds within Formula I, consisting of biphenylmethyl 1H-substituted-1,2,4-triazole compounds useful in treating circulatory and cardiovascular disorders, is defined by Formula II:

wherein m is a number selected from one to four, inclusive; wherein each of R¹ through R¹¹ is independently selected from hydrido, formyl, hydroxy, alkyl, hydroxyalkyl, halo,

haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl,

alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl,

polycycloalkylalkyl, thienylalkyl, phenylacyl,

phenylhaloalkyl, aminoalkyl, acylaminoalkyl,

alkoxycarbonylaminoalkyl, glutamic acid alkyl ester,

alkylcarbonyloxy, mercaptocarbonyl, mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio, alkylthiocarbonyl,

alkylcarbonylthio, alkylthiocarbonyloxy,

alkylthiocarbonylthio, alkylthiothiocarbonyl,

alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio,

aralkylthiocarbonyloxy, aralkylthiocarbonylthio,

alkylthiocarbonyl, aralkylthiocarbonylthio, mercapto,

alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,

aralkyIsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl,

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R¹² and R¹³ taken together, R¹⁶ and R¹⁶ taken together and R¹⁶ and R¹⁷ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R¹² and R¹³ taken together and each of R¹⁴ and R¹⁵ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and wherein each of R³ through R¹¹ may be further

-Y_nA wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R¹ through R¹⁷, Y and A groups having a substitutable position may be substituted by one or more groups selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, halo, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, carboxyl, mercapto,

mercaptocarbonyl, alkylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,

aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom;

wherein R¹⁹ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, DR²⁴ and

wherein D is selected from oxygen atom and sulfur atom and R²⁴ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁰, R²¹, R²², R²³, R²⁵ and R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁰, R²¹, R²², R²³, R²⁵ and R²⁶ is further independently selected from amino and amido radicals of the formula 1

wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and R³² is

cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl,

haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁰ and R²¹ taken together and each of R²² and R²³ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R²⁰ and R²¹ taken together and each of R²⁵ and R²⁶ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; or a tautomer thereof or a pharmaceutically- acceptable salt thereof. Compounds of Formula II are all characterized in having a substituent, other than hydrido, at each of the three- and five-positions of the triazole ring. Such

substituents are selected from the aforementioned R¹ and R² groups. Compounds having alkyl groups, especially lower alkyl groups, at both of the R¹ and R² positions are particularly useful as angiotensin II antagonists. Also especially useful are compounds having one of the R¹ and R² substituents

selected from alkylcarbonyl, monoalkoxyalkyl, dialkoxyalkyl and difluoroalkyl groups. When the selected substituent for R¹ and R² is difluoroalkyl, then it is particularly useful for both of the fluoro atoms of the difluoroalkyl group to be substituted on the difluoroalkyl group carbon atom attached at the R¹ or R² positions of the triazole ring. Such

difluoroalkyl group may be characterized as an "alpha-carbon difluoro-substituted difluoroalkyl group", or as an

"alpha, alpha-difluoro-substituted alkyl group". When the selected substituent for R¹ or R² is monoalkoxyalkyl or dialkoxyalkyl, then it is particularly useful for the single alkoxy group or the two alkoxy groups, respectively, to be substituted on the carbon atom of the selected substituent which is attached at the R¹ or R² positions of the triazole ring. Such alkoxyalkyl groups may be characterized as "alpha- carbon monoalkoxy- or dialkoxy-substituted alkoxyalkyl groups", respectively, or "alpha-monoalkoxy-substituted or alpha, alpha-dialkoxy-substituted alkyl groups", respectively. When the selected substituent is alkylcarbonyl, then it is particularly useful for the carbonyl group to be attached at the R¹ or R² positions of the triazole ring. Such

alkylcarbonyl group may be characterized as an "alpha-oxo- substituted alkyl group", and may be exemplified by the substituents 1-oxoethyl, 1-oxopropyl and 1-oxobutyl. Where compounds of Formula II contain any of these above-mentioned particularly-useful alpha-carbon substituted R¹ or R² groups at the triazole ring three- or five-position, it is preferred that such particularly-useful group be attached at the three- position, that is, as an R¹ substituent. As described above for the Formula I compounds, the

Formula II compounds may have one -Y_nA moiety attached at one of the R³ through R¹¹ positions of the biphenyl moiety, or may have a plurality of such -Y_nA moieties attached at more than one of the R³ through R¹¹ positions, up to a maximum of nine such -Y_nA moieties. Compounds of Formula II having the -Y_nA. moiety attached at one of positions R⁵, R⁶, R⁸ and R⁹ of the biphenyl moiety of Formula II would be expected to have preferred properties, while attachment at R⁵ or R⁹ would be more preferred.

A preferred class of compounds within the sub-class defined by Formula II consists of those compounds wherein m is one; wherein each of R¹ through R¹¹ is independently selected from hydrido, formyl, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,

alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, polycycloalkyl,

polycycloalkylalkyl, thienylalkyl, phenylacyl,

phenylhaloalkyl, aminoalkyl, acylaminoalkyl,

alkoxycarbonylaminoalkyl, glutamic acid alkyl ester,

alkylcarbonylthio, alkylthiocarbonyloxy, alkylthioarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl,

arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio, aralkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto,

alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,

aralkyIsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms and amino and amido radicals of the formula

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R³ through R¹¹ may be further

-Y_nA wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R¹ through R¹⁷, Y and A groups having a substitutable position may be substituted by one or more groups selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom;

wherein R¹⁹ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, and DR²⁴ and

wherein D is selected from oxygen atom and sulfur atom, and R²⁴ is selected from hydrido, alkyl, cycloalkyl,

cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁰, R²¹, R²², R²³, R²⁵ and R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl,

cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁰, R²¹, R²², R²³, R²⁵, and R²⁶ is further independently selected from amino and amido radicals of the formula

wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and R³² is

cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl,

A more preferred class of compounds within the subclass defined by Formula II consists of those compounds wherein m is one; wherein each of R¹ through R¹¹ is

independently selected from hydrido, hydroxy, formyl, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl,

polycycloalkyl, polycycloalkylalkyl, haloalkyl, thienylalkyl, phenylacyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl, alkoxycarbonylaminoalkyl, glutamic acid alkyl ester,

alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylthio, arylthio, aralkylthio, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and amino and amido radicals of the formula

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from hydrido and haloalkyl, and from acidic moieties of the formula

wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁷; wherein each of R³³, R³⁴, R³⁵, R³⁶ and R³⁷ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,

cycloalkylalkyl, aryl and aralkyl; wherein each of R³³, R³⁴, R³⁵ and R³⁶ may be further independently selected from amino radical of the formula

unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula II; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; and wherein any of the foregoing R¹ through R¹⁷, Y and A groups having a substitutable position may be substituted by one or more groups selected from alkyl, alkenyl, aralkyl, hydroxyalkyl, haloalkyl, alkoxy, aryloxy, aralkoxy,

alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl,

mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom;

independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl,

alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl,

An even more preferred class of compounds within the sub-class defined by Formula II consists of those

compounds wherein m is one; wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, alkyl, carboxyalkyl, phenyl, phenylalkyl, cycloalkyl,

cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl,

alkylcarbonyl, alkoxyalkyl, hydroxyalkyl, halo, haloalkyl, thienylalkyl, phenylacyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl, alkoxycarbonylaminoalkyl and glutamic acid alkyl ester; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties of the formula

wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; wherein each of R¹ through R¹¹, Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A highly preferred class of compounds within the sub-class defined by Formula II consists of those compounds wherein m is one; wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, alkyl, carboxyalkyl, phenyl, phenylalkyl, cycloalkyl, cycloalkylalkyl,

polycycloalkyl, polycycloalkylalkyl, alkylcarbonyl. dialkoxyalkyl, hydroxyalkyl, halo, haloalkyl, thienylalkyl, phenylacetyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl, alkoxycarbonylaminoalkyl and glutamic acid alkyl ester; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio, mercapto and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties of the formula

-Y_nA wherein n is a number selected from zero through two,

-

m wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁷; wherein each of R³³, R³⁶ and R³⁷ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R³³ and R³⁶ may be further

independently selected from amino radical of the formula

alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of

heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula II; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl; wherein each of R¹ through R¹¹, Y and A and independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

An even more highly preferred class of compounds within the sub-class defined by Formula II consists of those compounds wherein m is one; wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl,

cyclohexyl, cyclopentylmethyl, cyclohexylmethyl,

cyclohexylethyl, cyclohexylpropyl, adamantyl, adamantylmethyl, 1-oxoethyl, oxobutyl, 1-oxopentyl, dimethoxymethyl,

2(3-thienyl)ethyl, phenylacetyl, phenyldifluoroethyl,

alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties consisting of CO₂H, CO₂CH_3, SH, CH₂SH, C₂H₄SH, PO₃H_2, NHSO₂CF₃,

NHSO₂C₆F_5, SO₃H, CONHNH_2, CONHNHSO₂CF₃, CONHOCH₃, CONHOC₂H_5, CONHCF₃, OH, CH₂OH, C₂H₄OH, OPO₃H_2, OSO₃H ,

wherein each of R⁴⁰, R⁴¹ and R⁴² is independently selected from H, Cl, CN, NO₂, CF_3, C₂F₅, C₃F₇, CHF₂, CH₂F, CO₂CH₃, CO₂C₂H₅, SO₂CH_3, SO₂CF₃ and SO₂C₆F₅; wherein Z is selected from O, S, NR⁴³ and CH_2; wherein R⁴³ is selected from hydrido, CH₃ and CH₂C₆H_5; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R³ through R¹¹ so as to form a fused ring system with one of the biphenyl rings of the biphenyl moiety of Formula II, said fused ring system selected from

and the esters, amides and salts of said acidic moieties,

A class of compounds of particular interest within the sub-class defined by Formula II consists of those

compounds wherein m is one; wherein R¹ is selected from hydrido, hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl,

cyclohexyl, cyclopentylmethyl, cyclohexylmethyl,

cyclohexylethyl, cyclohexylpropyl, adamantyl, adamantylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl,

dimethoxymethyl, diethoxymethyl, 1,1-dimethoxypropyl,

1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, pentafluoroethyl, heptafluoropropyl, thienylmethyl,

2(2-thienyl)ethyl, phenylacetyl, phenyldifluoroethyl,

aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein R² is selected from hydrido, carboxyethyl, cyclohexyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n- pentyl and neopentyl; with the proviso that both R¹ and R² cannot be hydrido simultaneously; wherein each of R³ through R¹¹ is hydrido with the proviso that at least one of R⁵ and R⁹ must be selected from COOH, SH, PO-₃H_2, SO₃H, CONHNH_2,

CONHNHSO₂CF₃, OH, Λ

wherein each of R⁴⁰ and R⁴¹ is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethyIsulfonyl; wherein at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂ SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

wherein each of R⁴⁰ and R⁴¹ is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃. A class of compounds of more particular interest within the sub-class defined by Formula II consists of those compounds wherein m is one; wherein R¹ is selected from hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl,

cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl,

cyclohexylpropyl, adamantyl, adamantylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, dimethoxymethyl, diethoxymethyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl,

1,1-dimethoxypentyl, hydroxypropyl, halo, monofluoromethyl, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, pentafluoroethyl, heptafluoropropyl, phenylacetyl, phenyldifluoroethyl,

aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein R² is selected from carboxyethyl, cyclohexyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl and neopentyl; wherein at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H_2, SO₃H, CONHNH_2, CONHNHSO₂CF₃, OH,

wherein each of R⁴⁰ and R⁴¹ is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃. A class of compounds of even more particular interest within the sub-class defined by

Formula II consists of those compounds wherein at least one of R⁵ and R⁹ is selected from the acidic groups selectable for the compounds of more particular interest.

The term "hydrido" denotes a single hydrogen atom (H) . This hydrido group may be attached, for example, to an oxygen atom to form a hydroxyl group; or, as another example, one hydrido group may be attached to a carbon atom to form a

group; or, as another example, two hydrido groups may be attached to a carbon atom to form a -CH₂- group. Where the term "alkyl" is used, either alone or within other terms such as "haloalkyl" and "hydroxyalkyl", the term "alkyl" embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about five carbon atoms. The term "cycloalkyl" embraces mono-carbocyclic saturated radicals having three to about ten ring carbon atoms, preferably three to about six carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "cycloalkylalkyl" denotes a cycloalkyl radical attached to an alkyl radical which is attachable to a substitutable position of Formula I or II. Examples of "cycloalkylalkyl" radicals are

cyclopentylmethyl and cyclohexylethyl. The term

"polycycloalkyl" denotes a ring system radical formed by two, or by three, or by more, cycloalkyl radicals joined together through one common carbon atom, or through two common adjacent carbon atoms to form a two-ring fused ring system, or formed by an alkylene bridge across a cycloalkyl ring. Such ring systems may contain from four to about twenty carbon atoms, and more preferably from eight to about ten carbon atoms. An example of a "polycycloalkyl" radical is adamantyl, also known as tricyclodecyl radical. The term "polycycloalkylalkyl" denotes a polycycloalkyl radical attached to an alkyl radical which is attachable to a substitutable position of Formula I or II. Examples of "polycycloalkylalkyl" radicals are adamantylmethyl and adamantylethyl. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with one or more halo groups, preferably selected from bromo, chloro and fluoro. Specifically embraced by the term "haloalkyl" are monohaloalkyl, dihaloalkyl and polyhaloalkyl groups. A monohaloalkyl group, for example, may have either a bromo, a chloro, or a fluoro atom within the group, such as monofluoromethyl. Dihaloalkyl and

polyhaloalkyl groups may be substituted with two or more of the same halo groups, or may have a combination of different halo groups. A dihaloalkyl group, for example, may have two fluoro atoms, such as difluoromethyl and difluorobutyl groups, or two chloro atoms, such as a dichloromethyl group, or one fluoro atom and one chloro atom, such as a fluoro-chloromethyl group. Examples of a polyhaloalkyl are trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl, perfluoroethyl, 2,2,3,3-tetrafluoropropyl and perfluoropropyl groups. The term "difluoroalkyl" embraces alkyl groups having two fluoro atoms substituted on any one or two of the alkyl group carbon atoms. The terms "alkylol" and "hydroxyalkyl" embrace linear or branched alkyl groups having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl groups. The term "alkenyl" embraces linear or branched radicals having two to about twenty carbon atoms, preferably three to about ten carbon atoms, and containing at least one carbon-carbon double bond, which carbon-carbon double bond may have either cis or trans geometry within the alkenyl moiety. The term "alkynyl" embraces linear or branched radicals having two to about twenty carbon atoms, preferably two to about ten carbon atoms, and containing at least one carbon-carbon triple bond. The term "cycloalkenyl" embraces cyclic radicals having three to about ten ring carbon atoms including one or more double bonds involving adjacent ring carbons. The terms

"alkoxy" and "alkoxyalkyl" embrace linear or branched oxy- containing radicals each having alkyl portions of one to about ten carbon atoms. An example of alkoxy is methoxy group. The term "alkoxyalkyl" also embraces alkyl radicals having two or more alkoxy groups attached to an alkyl radical. The term "dialkoxyalkyl" is exemplified by dimethoxymethyl and

2,2-diethoxyethyl. The "alkoxy" or "alkoxyalkyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy or

haloalkoxyalkyl groups. The term "alkylthio" embraces radicals containing a linear or branched alkyl group, of one to about ten carbon atoms attached to a divalent sulfur atom, such as a methythio group. Preferred aryl groups are those consisting of one, two, or three benzene rings. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl and biphenyl. The term "aralkyl" embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, phenylbutyl and diphenylethyl. The terms

"benzyl" and "phenylmethyl" are interchangeable. The terms "aryloxy" and "arylthio" denote radical respectively, aryl groups having an oxygen or sulfur atom through which the radical is attached 'to a nucleus, examples of which are phenoxy and phenylthio. The terms "sulfinyl" and "sulfonyl", whether used alone or linked to other terms, denotes

respectively divalent radicals SO and SO₂. The term

"aralkoxy", alone or within another term, embraces an aryl group attached to an alkoxy group to form, for example, benzyloxy. The term "acyl" whether used alone, or within terms such as acyloxy and acylaminoalkyl, denotes a radical provided by the residue after removal of hydroxyl from an organic acid, examples of such radical being acetyl and benzoyl. "Lower alkanoyl" is an example of a more prefered sub-class of acyl. The term "amido" denotes a radical consisting of nitrogen atom attached to a carbonyl group, which radical may be further substituted in the manner described herein. The amido radical can be attached to the nucleus of a compound of the invention through the carbonyl moiety or through the nitrogen atom of the amido radical. The term "alkenylalkyl" denotes a radical having a double-bond unsaturation site between two carbons, and which radical may consist of only two carbons or may be further substituted with alkyl groups which may optionally contain additional double- bond unsaturation. The term "heteroaryl" embraces aromatic ring systems containing one or two hetero atoms selected from oxygen, nitrogen and sulfur in a ring system having five or six ring members, examples of which are thienyl, furanyl, pyridinyl, thiazolyl, pyrimidyl and isoxazolyl. Such

heteroaryl may be attached as a substituent through a carbon atom of the heteroaryl ring system, or may be attached through a carbon atom of a moiety substituted on a heteroaryl ring- member carbon atom, for example, through the methylene substituent of imidazolemethyl moiety. Also, such heteroaryl may be attached through a ring nitrogen atom as long as aromaticity of the heteroaryl moiety is preserved after attachment. For any of the foregoing defined radicals, preferred radicals are those containing from one to about ten carbon atoms.

Specific examples of alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, methylbutyl, dimethylbutyl and neopentyl. Typical alkenyl and alkynyl groups may have one unsaturated bond, such as an allyl group, or may have a plurality of unsaturated bonds, with such plurality of bonds either adjacent, such as allene-type structures, or in conjugation, or separated by several saturated carbons.

Compounds of Formula I have been found to inhibit the action of angiotensin II in mammals. Angiotensin II is a potent vasoconstrictor and participates in the formation of aldosterone which regulates sodium and water balance in mammals. Thus, compounds of Formula I are therapeutically useful in methods for treating hypertension by administering to a hypertensive subject or patient a therapeutically- effective amount of a compound of Formula I. The phrase "hypertensive subject or patient" means, in this context, a mammalian subject suffering from or afflicted by the effects of hypertension or susceptible to a hypertensive condition if not treated to prevent or control such hypertension. Included within the family of compounds of Formula I are the tautomeric forms of the described compounds, as well as the stereoisomers and pharmaceutically-acceptable salts thereof. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is

pharmaceutically-acceptable. Suitable pharmaceutically- acceptable acid addition salts of compounds of Formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric,

hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, p-hydroxybenzoic, salicyclic, phenylacetic, mandelic, embonic (pamoic), methansulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic,

benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic, algenic, β-hydroxy

butyric, malonic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I include metallic salts made from aluminium, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine,

chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the

corresponding compound of Formula I by reacting, for example, the appropriate acid or base with the compound of Formula I. A family of specific compounds of particular interest within Formula I, and more specifically within

Formula II, consists of the following compounds:

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-carboxylic acid, hydrazide;

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-carboxyl[ic acid, 2-[(trifluoromethyl)sulfonyl]hydrazide;

4'-[(5-butyl-3-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3-butyl-5-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylate;

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-carboxylic acid;

4'-[(5-butyl-3-secbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-isobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-tertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-pentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-mercapto-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid; 4 ' - [ (5-butyl-3-thiomethyl-1H-1, 2, 4-triazol-1-yl) methyl] [1, 1 ' - biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-thioethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-thiopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-hydroxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-methoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-ethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-propoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-butoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-cyclohexyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-butyl-3-(2-cyclohexylethyl))-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-cyclohexanoyl-1,2,4,-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-phenyl-1,2,4,-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-3-phenylmethyl-1,2,4,-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-butyl-1,2,4,-triazol-1-yl)methyl][1,1'-biphenyl]-2- carboxylic acid;

4'-[(3-butyl-1,2,4,-triazol-1-yl)methyl][1,1'-biphenyl]-2- carboxylic acid; 4 '- [ [5-butyl-3- (2-phenylethyl) -1H-1, 2, 4-triazol-1- yl]methyl] [1, 1 '-biphenyl] -2-carboxylic acid;

4 '- [ (5-butyl-3-benzoyl-1, 2, 4, -triazol-1-yl) methyl] [1, 1 '- biphenyl]-2-carboxylic acid;

4'-[[5-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-butyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-butyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-butyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3,5-dipropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3,5-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid; 4 '- [ (5-propyl-3-isopropyl-1H-1, 2, 4-triazol-1-yl) methyl] [1, 1 ' - biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-secbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-isobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-tertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-pentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-isopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-mercapto-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-thiomethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-thioethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-thiopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- bi-henyl]-2-carboxylic acid;

4'-[(5-propyl-3-hydroxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylie acid;

4'-[(5-propyl-3-methoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-ethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-propoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-cyclohexyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid; 5-[4'-[[5-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

5-[4'-[[5-propyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-phenyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-phenylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-benzoyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-propyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-propyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-propyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-propyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[3,5-bis(heptafluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-propyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[[5-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-propyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(3,5-diethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-carboxylic acid;

4'-[(5-ethyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-secbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-isobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-tertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5--thyl-3-pentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-isopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-mercapto-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-thiomethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-thioethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-thiopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-hydroxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-methoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid; 4 '- [ (5-ethyl-3-ethoxy-1H-1, 2, 4-triazol-1-yl) methyl] [1, 1 ' - biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-propoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-cyclohexyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-ethyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-ethyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-ethyl-3-phenyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4 '-[(5-ethyl-3-phenylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-ethyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4 '-[(5-ethyl-3-benzoyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-ethyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-ethyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-ethyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-ethyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-ethyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-ethyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4 ' - [ [5-ethyl-3- (1-oxopentyl) -1H-1, 2, 4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-ethpyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-ethyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-ethyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-isopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3,5-disecbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-isobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-tertbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-pentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-isopentyl-1H-1,2,4-triazol-1- yl) methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-mercapto-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-thiomethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-thioethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid; 4 ' - [ (5-secbutyl-3-thiopropyl-1H-1, 2, 4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-hydroxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-methoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-ethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-propoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl] [1, 1 ' -biphenyl] -2-carboxylie acid;

4 ' - [ (5-secbutyl-3-cyclohexylmethyl-1H-1, 2, 4-triazol-1- yl) methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-secbutyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-secbutyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-phenyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-phenylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-secbutyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-secbutyl-3-benzoyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-secbutyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-secbutyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-secbutyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[[5-secbutyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-secbutyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-secbutyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-secbutyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-secbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-secbutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4 '-[[5-secbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-secbutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-isopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-secbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3,5-diisobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-tertbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-pentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4 '-[(5-isobutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid; 4 ' - [ (5-isobutyl-3-mercapto-1H-1, 2, 4-triazol-1-yl) methyl] [ 1, 1 ' - biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-thiomethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-thioethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-thiopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-hydroxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-methoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-ethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-propoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4 '-[[5-isobutyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isobutyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol- l-yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-phenyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-phenylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isobutyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isobutyl-3-benzoyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid; 4 ' - [ [5-isobutyl-3-(1-oxo-2-phenylethyl) -1H-1, 2, 4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isobutyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isobutyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isobutyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isobutyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isobutyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isobutyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isobutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isobutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isobutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isobutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-te-rtbutyl-3-isopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-secbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-isobutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid; 4 ' - [ (3, 5-ditertbutyl-1H-1, 2, 4-triazol-1-yl) methyl] [ 1, 1 ' - biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-pentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-mercapto-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[(5-tertbutyl-3-thiomethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-thioethyl-1H-1,2,4-triazol-1- yl)methyl] [1, 1 '-biphenyl] -2-carboxylic acid;

4 ' - [ (5-tertbutyl-3-thiopropyl-1H-1, 2, 4-triazol-1 - yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-hydroxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-methoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-ethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-propoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-tertbutyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[(5-tertbutyl-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-tertbutyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-phenyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid; 4'-[(5-tertbutyl-3-phenylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-tertbutyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-tertbutyl-3-benzoyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-tertbutyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-tertbutyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-tertbutyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-tertbutyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-tertbutyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-tertbutyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-tertbutyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-tertbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-tertbutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-tertbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-tertbutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid; 4 ' - [ (5-pentyl-3-butyl-1H-1, 2, 4-triazol-1-yl) methyl] [1, 1 ' - biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-secbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-isobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-tertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3,5-dipentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-isopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-mercapto-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-thiomethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-thioethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-thiopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-hydroxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-methoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-ethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-propoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-cyclohexyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4 '- [ (5-pentyl-3-cyclohexanoyl-1H-1, 2, 4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-phenyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylie acid;

4'-[(5-pentyl-3-phenylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-pentyl-3-benzoyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4 ' - [ (5-isopentyl-3-ethyl-1H-1, 2, 4-triazol-1-yl) methyl] [ 1, 1 ' - biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-isopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-secbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-isobutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-tertbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[(5-isopentyl-3-pentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3,5-diisopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4 '-[(5-isopentyl-3-mercapto-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-thiomethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-thioethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-thiopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-hydroxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-methoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-ethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-propoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid; 4 ' - [ (5-isopentyl-3-cyclohexyl-1H-1, 2, 4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isopentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-phenyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-phenylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isopentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(5-isopentyl-3-benzoyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-isopentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isopentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isopentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isopentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isopentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isopentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isopentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isopentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid; 4'-[[5-isopentyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isopentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isopentyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-ethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-isopropyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-butyl-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-secbutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-isobutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-tertbutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-pentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-isopentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-mercapto-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-thiomethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-thioethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-thiopropyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-hydroxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[[5-(1-butenyl)-3-methoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-ethoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-propoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-cyclohexyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-(1-butenyl)-3-phenyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-phenylmethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-(1-butenyl)-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-(1-butenyl)-3-benzoyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4 '-[[5-(1-butenyl)-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4 ' - [ [5- (1-butenyl) -3- (1-oxobutyl) -1H-1, 2, 4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4 '-[[5-(1-butenyl)-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butenyl)-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-ethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-isopropyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-butyl-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-secbutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-isobutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-tertbutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-pentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-isopentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-mercapto-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-thiomethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4 ' - [ [5- (2-but.enyl) -3-thioethyl-1H-1, 2, 4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-thiopropyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-hydroxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-methoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-ethoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-propoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-cyclohexyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-(2-butenyl)-3-phenyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-phenylmethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-(2-butenyl)-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[[5-(2-butenyl)-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-(2-butenyl)-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-ethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-isopropyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-butyl-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-secbutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-isobutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-tertbutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-pentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-isopentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-mercapto-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4 ' - [ [5- (3-butenyl) -3-thiomethyl-1H-1, 2, 4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-thioethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-thiopropyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-hydroxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-methoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-ethoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-propoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-cyclohexyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-phenyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-phenylmethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-benzoyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[[5-(3-butenyl)-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-ethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-butyl-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-secbutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-isobutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-tertbutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-pentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[[5-(1-butynyl)-3-isopentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-mercapto-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-thiomethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-thioethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-thiopropyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-hydroxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-methoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-ethoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-propoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-cyclohexyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-phenyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-phenylmethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4 ' - [ [5- (1-butynyl) -3-benzoyl-1H-1, 2, 4-triazol-1 - yl] methyl] [ 1, 1 ' -biphenyl] -2-carboxylic acid;

4 ' - [ [5- (1-butynyl) -3- (1-oxo-2-phenylethyl) -1H-1, 2, 4-triazol-1- yl] methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(1-butynyl)-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-ethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-butyl-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-secbutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-isobutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4 '- [ [5- (2-butynyl) -3-tertbutyl-1H-1, 2, 4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-pentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-isopentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-mercapto-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-thiomethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-thioethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-thiopropyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-hydroxy-1H-1,2,4-triazol-1- yljmethyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-methoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-ethoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-propoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-cyclohexyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-phenyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4 ' - [ [5- (2-butynyl) -3-phenylmethyl-1H-1, 2, 4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-benzoyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(2-butynyl)-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-ethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-isopropyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[[5-(3-butynyl)-3-butyl-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-secbutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-isobutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-tertbutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-isopentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-pentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-mercapto-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-thiomethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-thioethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-thiopropyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-hydroxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-methoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-ethoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-propoxy-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-cyclohexyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[[5-(3-butynyl)-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-phenyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-phenylmethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-benzoyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-(3-butynyl)-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[(3,5-diethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(3,5-dipropoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(3,5-diisopropoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3,5-dibutoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3,5-dithiomethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3,5-dithioethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3,5-dithiopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3,5-dithioisopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[3,5-di(1-butenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[3,5-di(2-butenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[3,5-di(3-butenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[3,5-di(1-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[3,5-di(2-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[3,5-di(3-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

5-[4'-[(5-butyl-3-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-5-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(5-butyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-buty1-3-isopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-secbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-isobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-buty1-3-tertbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-buty1-3-pentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-buty1-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-mercapto-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-thiomethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-thioethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-thiopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-hydroxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-methoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-ethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(5-butyl-3-propoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-butoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(2-cyclohexylethyl))-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-cyclohexanoyl-1,2,4,-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-buty1-3-pheny1-1,2,4,-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-buty1-3-phenylmethyl-1,2,4,-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-benzoyl-1,2,4,-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(l,l dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1,1 dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(1,1 dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl] methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dipropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-isopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-secbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-isobutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-tertbutyl-1H-1,2,4-triazol-1- yl)methyl] [1, 1 '-biphenyl] -2-yl] -1H-tetrazole;

5- [4 '- [ (5-propyl-3-pentyl-1H-1, 2, 4-triazol-1-yl)methyl] [1, 1 '- biphenyl] -2-yl] -1H-tetrazole;

5- [4 ' - [ (5-propyl-3-isopentyl-1H-1, 2, 4-triazol-1 - yl)methyl] [1, 1 ' -biphenyl] -2-yl] -1H-tetrazole;

5- [4 ' - [ (5-propyl-3-mercapto-1H-1, 2, 4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(5-propyl-3-thiomethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-thioethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-thiopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-hydroxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-methoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-ethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-propoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[5-[4'-[[5-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[5-[4'-[[5-propyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-phenyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-phenylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-benzoyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-propyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3,5-bis(heptafluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-diethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-isopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-secbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-isobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(5-ethyl-3-tertbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-pentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-mercapto-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-thiomethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-thioethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-thiopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-hydroxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-methoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-ethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-propoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-phenyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole; 5- [4 ' - [ (5-ethyl-3-phenylmethyl-1H-1, 2, 4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-ethyl-3-benzoyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethpyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-isopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(5-secbutyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-disecbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-isobutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-tertbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-pentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-mercapto-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-thiomethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-thioethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-thiopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-hydroxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-methoxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-ethoxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-propoxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5- [4 '- [ (5-secbutyl-3-cyclohexanoyl-1H-1, 2, 4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-phenyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-phenylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5- [4 '- [ [5-secbutyl-3- (2-phenylethyl) -1H-1, 2, 4-triazol-1- yl]methyl] [1, 1 ' -biphenyl] -2-yl] -1H-tetrazole;

5- [4 ' - [ (5-secbutyl-3-benzoyl-1H-1, 2, 4-triazol-1- yl) methyl] [1, 1 ' -biphenyl] -2-yl] -1H-tetrazole;

5- [4 '- [ [5-secbutyl-3-(1-oxo-2-phenylethyl) -1H-1, 2, 4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(5-isobutyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-isopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-secbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-diisobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-tertbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-pentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-mercapto-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-thiomethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-thioethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-thiopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-hydroxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-methoxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-ethoxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-propoxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(5-isobutyl-3-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-phenyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-phenylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-benzoyl-1H-1,2,4-triazol-l- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-isobutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-ethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-isopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-secbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-isobutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-ditertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-pentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-mercapto-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-thiomethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-thioethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-thiopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-hydroxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(5-tertbutyl-3-methoxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-ethoxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-propoxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl] methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-phenyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-phenylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-y1]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-benzoyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-tertbutyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-isopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-secbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-isobutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-tertbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dipentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-mercapto-1H-1,2,4-triazol-1- yl)methyl][1,1--biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-thiomethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(5-pentyl-3-thioethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-thiopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-hydroxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-methoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-ethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-propoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5- [4 ' - [ (5-pentyl-3-cyclohexanoyl-1H-1, 2, 4-triazol-1- yl)methyl] [1, 1 ' -biphenyl] -2-yl] -1H-tetrazole;

5-[4'-[[5-pentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol- l-yl]methyl] [1, 1 '-biphenyl]-2-yl] -1H-tetrazole;

5- [4 '- [ (5-pentyl-3-phenyl-1H-1, 2, 4-triazol-1-yl) methyl] [1, 1 ' - biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-phenylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-benzoyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-pentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-ethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-isopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-secbutyl-1H-1,2,4-triazol-1- yl) methyl] [1, 1 ' -biphenyl] -2-yl] -1H-tetrazole;

5-[4'-[(5-isopentyl-3-isobutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-tertbutyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-pentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(3,5-diisopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-mercapto-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-thiomethyl-1H-1,2,4-triazol-1- yl)methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-thioethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-thiopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-hydroxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-methoxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-ethoxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-propoxy-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-cyclohexanoyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-phenyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-phenylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,11-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(5-isopentyl-3-benzoyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1*-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-ethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-isopropyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-butyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-secbutyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5- (1-butenyl)-3-isobutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-tertbutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-pentyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-isopentyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-mercapto-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-thiomethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-thioethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-thiopropyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-hydroxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-methoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-ethoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-propoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-cyclohexyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-cyclohexylmethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-cyclohexanoyl-1H-1,2,4-triazol-1-yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-(1-butenyl)-3-phenyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-phenylmethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-benzoyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1-oxopropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1-oxobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1-oxopentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1,1-difluoroethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1,1-difluoropropyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1,1-difluoropentyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-ethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-(2-butenyl)-3-isopropyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-butyl-1H-1,2,4-triazol-1-yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-secbutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-isobutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-tertbutyl-1H-1,2,4-triazol-1-yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-pentyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-isopentyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-mercapto-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-thiomethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-thioethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-thiopropyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-hydroxy-1H-1,2,4-triazol-1-yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-methoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-ethoxy-1H-1,2,4-triazol-1-yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-propoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-cyclohexyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-cyclohexylmethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-(2-butenyl)-3-(2-cyclohexylethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-cyclohexanoyl-1H-1,2,4-triazol-1-yl]methyl] [1, 1 ' -biphenyl] -2-yl] -1H-tetrazole;

5- [4 ' - [ [5- (2-butenyl) -3-(1-oxo-2-cyclohexylethyl) -1H-1, 2, 4-triazol-1-yl]methyl] [1, 1 '-biphenyl] -2-yl] -1H-tetrazole;

5- [4 '- [ [5- (2-butenyl) -3-phenyl-1H-1, 2, 4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-phenylmethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(1-oxopropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(1-oxobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(1-oxopentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(1,1-difluoroethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(1,1-difluoropropyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(1,1-difluoropentyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-ethyl-1H-1,2,4-triazol-1- yl]methyy][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-(3-butenyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-isopropyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-butyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-secbutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-isobutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-tertbutyl-1H-1,2,4-triazol-1-yl]metryl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-pentyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-isopentyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-mercapto-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-thiomethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-thioethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-thiopropyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-hydroxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-methoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-ethoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-propoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-cyclohexyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-(3-butenyl)-3-cyclohexylmethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(2-cyclohexylethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-cyclohexanoyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-phenyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-phenylmethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-benzoyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]e1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(1,1-difluoroethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(1,1-difluoropropyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5- 3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5- 3-butenyl)-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5- 1-butynyl)-3-ethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-propyl-1H-1,2,4-triazol-1-yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-butyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-secbutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-isobutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-lertbutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-pentyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-isopentyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-mercapto-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-thiomethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-thioethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-thiopropyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-hydroxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-methoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-ethoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-(1-butynyl)-3-propoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-cyclohexyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-cyclohexylmethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(2-cyclohexylethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-cyclohexanoyl-1H-l1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-phenyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-phenylmethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-benzoyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1,1-dimethoxypropyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1,1-dimethoxypentyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-(1-butynyl)-3-(1,1-difluoroethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1,1-difluoropropyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1,1-difluoropentyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-ethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-propyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-butyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-secyutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-isobutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-tertbutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-pentyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-isopentyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-mercapto-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-thiomethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-thioethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-thiopropyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-hydroxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-(2-butynyl)-3-methoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-ethoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-propoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-cyclohexyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-cyclohexylmethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(2-cyclohexylethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-cyclohexanoyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-phenyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-phenylmethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-benzoyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1-oxo-2-phenylethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1,1-dimethoxypropyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1,1-dimethoxypentyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1-oxopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-(2-butynyl)-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1-oxopentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1,1-difluoroethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1,1-difluoropropyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1,1-difluoropentyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-ethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-propyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-isopropyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-butyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-secbutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-isobutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-tertbutyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-isopentyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-pentyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-mercapto-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-thiomethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-(3-butynyl)-3-thioethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-thiopropyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-hydroxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-methoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-ethoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-propoxy-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-cyclohexyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-cyclohexylmethyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(2-cyclohexylethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-cyclohexanoyl-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5- [4 ' - [ [5- (3-butynyl) -3-phenyl-1H-1, 2, 4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-phenylmethyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-benzoyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1-oxopropyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1-oxobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1-oxopentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1,1-difluoroethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1,1-difluoropropyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-diethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dipropoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(3,5-dithiomethyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dithioethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dithiopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dithioisopropyl-1H-1,2,4-triazol-1- yl)methyl] [1-1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3,5-di(1-butenyl)-1H-1,2,4-triazol-1-yl]methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3,5-di(2-butenyl)-1H-1,2,4-triazol-1-yl]methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3,5-di(3-butenyl)-1H-1,2,4-triazol-1-yl]methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3,5-di(1-butynyl)-1H-1,2,4-triazol-1-yl]methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3,5-di(2-butynyl)-1H-1,2,4-triazol-1-yl]methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole; and

5-[4'-[[3,5-di(3-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole.

A family of specific compounds of more particular interest within Formula I consists of compounds having an acidic group attached at the R⁵ or R⁹ "ortho" position as follows:

2-[[4-[(5-butyl-3-chloro-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3-butyl-5-chloro-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(5-butyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-dibutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-dibutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid; 2- [ [4- [ (5-butyl-3-isopentyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-butyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-butyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl] methyl]phenyl]methyl]benzoic acid;

2-[[4-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-dipropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-isopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(5-propyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-propyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-propyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-propyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

2-[[4-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid; 2-[[4-[(3,5-disecbutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-secbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-diisobutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-isobutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-ditertbutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-tertbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-dipentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-diisopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-isopentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-(1-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-(2-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-(3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-(3-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-diethoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid; 2- [ [4- [ (3, 5-dipropoxy-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-diisopropoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-dibutoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-dithioethyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-dithiopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-dithioisopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[[3,5-di(1-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[3,5-di(2-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[3,5-di(3-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[3,5-di(1-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[3,5-di(2-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[3,5-di(3-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

5-[2-[[4-[(5-butyl-3-chloro-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3-butyl-5-chloro-1H-1,2,4-triazol-1- yl) methyl]phenyl]methyl] phenyl-1H-tetrazole;

5- [2- [ [4- [ (5-butyl-3-propyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl] methyl]phenyl] -1H-tetrazole;

5- [2- [ [4- [ (3, 5-dibutyl-1H-1, 2, 4-triazol-1 - yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5-[2-[[4-[[5-butyl-3-(1,1 dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-butyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-butyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl][-1H-tetrazole;

5-[2-[[4-[(3,5-dipropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-isopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-propyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-propyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-propyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl][1,1'-biphenyl]-2-yl]-1H- tetrazole;

5-[2-[[4-[[5-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-propyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-2-yl]-1H-tetrazole;

5-[2-[[4-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5- [2- [ [4- [ (5-secbutyl-3-propyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-secbutyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-disecbutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-secbutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-secbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-secbutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-secbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]IH-tetrazole;

5-[2-[[4-[[5-secbutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-isobutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-isobutyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-diisobutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-isobutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-isobutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-isobutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[A-[[5-isobutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-isobutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-tertbutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5- [2- [ [4- [ (5-tertbutyl-3-butyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-ditertbutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-tertbutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-tertbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-tertbutyl-3-(1,1-difluoropropyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-tertbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-tertbutyl-3-(1,1-difluoropentyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-pentyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-pentyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-dipentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-pentyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-pentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-pentyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-pentyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-isopentyl-3-ethyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-isopentyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5- [2- [ [4- [ (5-isopentyl-3-butyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-diisopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-isopentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-isopentyl-3-(1,1-difluoropropyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-isopentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-isopentyl-3-(1,1-difluoropentyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-(1-butenyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-(1-butenyl)-3-butyl-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-(1-butenyl)-3-isopentyl-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-(1-butenyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-(1-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-(2-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-(3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-(3-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-dipropoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5-[2-[[4-[(3,5-diisopropoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-dibutoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-dithioethyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-dithiopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-dithioisopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[3,5-di(1-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[3,5-di(2-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[3,5-di(3-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[3,5-di(1-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl][-1H-tetrazole;

5-[2-[[4-[[3,5-di(2-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole; and

5-[2-[[4-[[3,5-di(3-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole.

Another family of specific compounds of more particular interest within Formula I consists of compounds having an acidic group attached at the R⁶ or R⁸ "meta" position as follows:

3-[[4-[(5-butyl-3-chloro-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3-butyl-5-chloro-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(5-butyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-dibutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid; 3- [ [4- [ (3, 5-dibutyl-1H-1, 2, 4-triazol-1 - yl) methyl] phenyl] methyl]benzoic acid;

3- [ [4- [ (5-butyl-3-isopentyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-butyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-butyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-butyl-3-(l,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-dipropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-isopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(5-propyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-propyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-propyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-propyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 3-[[4-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-disecbutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-secbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-diisobutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-isobutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-ditertbutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-tertbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-dipentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-diisopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl1methyl]benzoic acid;

3-[[4-[[5-isopentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-(1-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-(2-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-(3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-(3-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid; 3- [ [4- [ (3, 5-diethoxy-1H-1, 2, 4-triazol-1 - yl) methyl]phenyl] methyl] benzoic acid;

3- [ [4- [ (3, 5-dipropoxy-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-diisopropoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-dibutoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-dithioethyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-1[4-[(3,5-dithiopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-dithioisopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[[3,5-di(1-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[3,5-di(2-butenyl)-1H-1,2,4-triazol-l- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[3,5-di(3-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[3,5-di(1-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[3,5-di(2-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[3,5-di(3-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

5-[3-[[4-[(5-butyl-3-chloro-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3-butyl-5-chloro-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl-1H-tetrazole;

5-[3-[[4-[(5-butyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3,5-dibutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5- [3- [ [4- [ (5-butyl-3-isopentyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-butyl-3-(1,1 dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-butyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-butyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl][-1H-tetrazole;

5-[3-[[4-[(3,5-dipropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazolh;

5-[3-[[4-[(3,5-isopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-propyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-propyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-propyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl][1,1'-biphenyl]-2-yl]-1H- tetrazole;

5-[3-[[4-[[5-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-propyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-2-yl]-1H-tetrazole; 5-[3-[[4-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-secbutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-secbutyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3,5-disecbutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-secbutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-secbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-secbutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-secbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]1H-tetrazole;

5-[3-[[4-[[5-secbutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-isobutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-isobutyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3,5-diisobutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-isobutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-isobutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-isobutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-isobutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl] methyl]phenyl] -1H-tetrazole;

5-[3-[[4-[[5-isobutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5-[3-[[4-[(5-tertbutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-tertbutyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3,5-ditertbutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-tertbutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-tertbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-tertbutyl-3-(1,1-difluoropropyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-tertbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-tertbutyl-3-(1,1-difluoropentyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-pentyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-pentyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3,5-dipentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-pentyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-pentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-pentyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-pentyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-isopentyl-3-ethyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5- [3- [ [4- [ (5-isopentyl-3-propyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-isopentyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3,5-diisopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-isopentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-isopentyl-3-(1,1-difluoropropyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-isopentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-isopentyl-3-(1,1-difluoropentyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-(1-butenyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-(1-butenyl)-3-butyl-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-(1-butenyl)-3-isopentyl-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-(1-butenyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-(1-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-(2-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-(3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-(3-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5- [3- [ [4- [ (3, 5-dipropoxy-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3,5-diisopropoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3,5-dibutoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3,5-dithioethyl-1H-1,2,4-triazol-1- yl) methyl]phenyl] methyl]phenyl] -1H-tetrazole;

5- [3- [ [4- [ (3, 5-dithiopropyl-1H-1, 2, 4-triazol-1- yl) methyl]phenyl] methyl]phenyl] -1H-tetrazole;

5-[3-[[4-[(3,5-dithioisopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[3,5-di(1-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[3,5-di(2-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[3,5-di(3-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[3,5-di(1-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl][-1H-tetrazole;

5-[3-[[4-[[3,5-di(2-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole; and

5-[3-[[4-[[3,5-di(3-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole. Another family of specific compounds of more particular interest within Formula I, and more specifically within Formula II, consists of compounds having an acidic group attached at the R⁵ or R⁹ "ortho" position of the biphenyl moiety as follows:

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]- 2-carboxylic acid, hydrazide;

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]- 2-carboxylic acid, 2-[(trifluoromethyl)sulfonyl]hydrazide; 4 '- [ (5-buty1-3-chloro-1H-1, 2, 4-triazol-1-yl)methyl] [1, 1 ' - biphenyl]-2-carboxylic acid;

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]- 2-carboxylic acid;

4'-[[5-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-l- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(3,5-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(5-propyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid; 4'-[[5-propyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-propyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-secbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[(3,5-ditertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[[5-(2-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[[5-(3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-(3-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[(3,5-diethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3,5-dipropoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4 '- [ [3, 5-di (3-butenyl) -1H-1, 2, 4-triazol-1-yl]methyl] [1, 1 ' - biphenyl]-2-carboxylic acid;

4'-[[3,5-di(3-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid; 5-[4'-[(5-buty1-3-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-buty1-3-propyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-buty1-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(1,1 dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-isopropyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-bi-henyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-prαpyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-isobutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-pentyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-propyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-diisopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-y1]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-isopentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-(3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl] [1, 1 '-biphenyl] -2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dipropoxy-1H-1,2,4-triazol-1-yl)methyl][1,1' - biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-diisopropoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dibutoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dithioisopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3,5-di(1-butenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5- [4 '- [ [3, 5-di (2-butenyl) -1H-1, 2, 4-triazol-1-yl]methyl] [1, 1 '- biphenyl] -2-yl] -1H-tetrazole;

5- [4 '- [ [3, 5-di (3-butenyl) -1H-1, 2, 4-triazol-1-yl]methyl] [1, 1 ' - biphenyl] -2-yl] -1H-tetrazole;

5-[4'-[[3,5-di(1-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3,5-di(2-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole; and

Another family of specific compounds of more particular interest within Formula I, and more specifically within Formula II, consists of compounds having an acidic group attached at the R⁶ or R⁸ "meta" position of the biphenyl moiety as follows:

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]- 3-carboxylic acid, hydrazide;

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

3-carboxylic acid, 2-[(trifluoromethyl)sulfonyl]hydrazide;

4'-[(5-butyl-3-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[(3-butyl-5-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[(5-butyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylate;

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

3-carboxylic acid;

4'-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[5-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl] methyl] [1, 1 ' -biphenyl] -3-carboxylic acid;

4 ' - [ [5-butyl-3- (1-oxopentyl) -1H-1, 2, 4-triazol-1- yl]methyl] [1, 1 ' -biphenyl] -3-carboxylic acid;

4'-[[5-butyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-butyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylie acid;

4'-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid; 4 ' - [ (3, 5-dipropyl-1H-1, 2, 4-triazol-1-yl) methyl] [1, 1 ' - biphenyl]-3-carboxylic acid;

4'-[(3,5-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[(5-propyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[5-propyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4*-[[5-propyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-propyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-ethyl-3-(l,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[(3,5-disecbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[5-secbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[(3,5-diisobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[5-isobutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[(3,5-ditertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[5-tertbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[(3,5-dipentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[5-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[(3,5-diisopentyl-1H-1,2,4-tria-ol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid; 4'-[[5-isopentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-(1-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-(2-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-(3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-(3-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[(3,5-diethoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[(3,5-dipropoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[(3,5-diisopropoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[(3,5-dibutoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[(3,5-dithioethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[(3,5-dithiopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[(3,5-dithioisopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[3,5-di(1-butenyl)-1b-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[3,5-di(2-butenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[3,5-di(3-butenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-carboxylic acid; 4'-[[3,5-di(1-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[3,5-di(2-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[3,5-di(3-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-carboxylic acid;

5-[4'-[(5-butyl-3-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3-butyl-5-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1,1 dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-dipropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole; 5-[4'-[(5-propyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl] [1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-disecbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-secbutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole; 5-[4'-[(5-isobutyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-diisobutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-ditertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-tertbutyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole; 5-[4'-[(3,5-dipentyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl] [1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-ethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-diisopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-butyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-isopentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole; 5-[4'-[[5-(1-butenyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazόle;

5-[4'-[(3,5-dipropoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-diisopropoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-dibutoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-dithioethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-dithiopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-dithioisopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[3,5-di(1-butenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[3,5-di(2-butenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[3,5-di(3-butenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[3,5-di(1-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole; 5-[4'-[[3,5-di(2-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole; and

5-[4'-[[3,5-di(3-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole.

A family of apecific compounds of highest interest within Formula I, and more specifically within Formula II, consists of the following compounds:

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-carboxylic acid;

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-carboxylic acid, hydrazide;

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-carboxylic acid, 2-[(trifluoromethyl)sulfonyl]hydrazide;

5'-[(5-butyl-3-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5'-[(3-butyl-5-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dipentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(5-butyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl]-[1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-5-propyl-1H-1,2,4-triazol-1-yl)methyl]-[1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-5-isopentyl-1H-1,2,4-triazol-1-yl)methyl]-

[1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1-yl]methyl)-

[1,1'-biphenyl]-2-yl]-1H-tetrazole;

4'-[(5-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2- carboxylic acid;

4'-[(3-butyl-1H-1,2,4-triazol-1-yl)methyl][1.1'-biphenyl]-2- carboxylic acid;

4'-[(3,5-di-perfluoropropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid;

5-[4'-[(3-phenyl-5-butyl-1H-1,2,4-triazol-1-yl)methyl](1,1'- biphenyl)-2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-5-phenyl-1H-1,2,4-triazol-1-yl)methyl](1,1'- biphenyl) -2-yl] -1H-tetrazole;

5- [4 ' - [ [3-butyl-5- (dimethoxymethy1) -1H-1, 2, 4-triazol-1- yl]methyl] [1, 1 ' -biphenyl] -2-yl] -1H-tetrazole;

5- [4 ' - [ (5-butyl-3-dimethoxymethyl-1H-1, 2, 4-triazol-1- yl)methyl](1,1'-biphenyl-2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-5-phenylethyl-1H-1,2,4-triazol-1- yl)methyl](1,1'-biphenyl-2-yl]-1H-tetrazole;

5-[4'[(5-butyl-3-phenylethyl-1H-1,2,4-triazol-1- yl)methyl](1,1'-biphenyl-2-yl]-1H-tetrazole;

5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-

1H-1,2,4-triazole-3-methanamine;

5-[4'-[(3-butyl-5-octyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-octyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

1-[[5-butyl-1-[2'-(1H-teHrazol-5-yl)[1,1'-biphenyl]-4- ylmethyl]-1H-1,2,4-triazol-3-yl]methyl]-1-butanone; N- [ [5-butyl-1-[2 ' - (1H-tetrazol-5-yl) [1, 1 ' -biphenyl] -4 - ylmethyl] -1H-1, 2, 4-triazol-3-yl] methyl] acetamide;

5- [4 ' - [ (5-buty1-3-methyl-1H-1, 2, 4-triazol-1-yl) methyl] - [1, 1 ' - biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-5-methyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

1,1-dimethylethyl [3-butyl-[1-2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-ylmethyl]-1H-1,2,4-triazol-5-yl]methylcarbamate;

1,1-dimethylethyl[5-butyl-[1-[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-ylmethyl]-1H-1,2,4-triazol-3-yl]methylcarbamate;

3-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-

1H-1,2,4-triazole-5-methanamine;

5-[4'-[[3-butyl-5-(2,2-diethyoxyethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(2,2-diethyoxyethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-5-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

N2-acetyl-N-[[5-butyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl]-1H-1,2,4-triazol-3-yl]methyl]-L- glutamine, 1,1-dimethylethyl ester;

5-[4'-[[3-butyl-5-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(phenylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-

1H-1,2,4-triazole-3-propanol;

3-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-lylmethyl]-1H-

1,2,4-triazole-5-propanol;

5-[4'-[[5-butyl-3-(difluoromethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[3-butyl-5-(difluoromethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-

1H-1,2,4-triazole-3-carboxaldehyde;

5-[4'-[[5-butyl-3-(difluoromethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1,1-difluoro-2-phenylethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-1-yl]-1H-tetrazole;

5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]- 1H-1,2,4-triazole-3-carboxylic acid;

5-[4'-[(5-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-yl]-1H-tetrazole;

5-[4'-[[3-butyl-5-(tricyclo[3.3.1^3.7]dec-1-yl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(tricyclo[3.3.1.1^3.7]dec-1-yl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3-butyl-5-(3-cyclohexylpropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(3-cyclohexylpropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(fluoromethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3-butyl-5-(fluoromethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3-butyl-5-(tricyclo[3.3.1.1^3.7]dec-1-ylmethyl]-1H-

1,2,4-triazole-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(tricyclo[3.3.1.1^3.7]dec-1-ylmethyl]-1H- 1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]- 1H-1,2,4-triazole-3-propanoic acid;

3-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]- 1H-1,2,4-triazole-5-propanoic acid; 5-[4'-[(3-butyl-5-cyclohexyl-1H-1,2,'4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-cyclohexyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

1,1-dimethylethyl 3-butyl-[1-[2'-(1H-tetrazol-5-yl) [1,1'- biphenyl]-4-ylmethyl]-1H-1,2,4-triazol-5-yl]propylcarbamate;

1,1-dimethylethyl 5-butyl-[1-[2'-(1H-tetrazol-5yl) [1,1'- biphenyl]-4-ylmethyl]-1H-1,2,4-triazol-3-yl]propylcarbamate;

5-[4'-[[3-(1,1,2,2,2-pentafluoroethyl)-5-butyl-1H-1,2,4- triazol-1-yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazol;

5-[4'-[[3-(1,1,2,2,3,3,3-heptafluoropropyl)-5-buty1-1H-1,2,4- triazol-1-yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3-butyl-5-(3-aminopropyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3-(3-aminopropyl)-5-butyl-1H-1,2,4-triazol-1- yl)methyl] (1,1'-(iphenyl)-2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-5-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3-cyclohexylmethyl-5-butyl-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

4'-[(3-ethyl-5-butyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-carboxylic acid;

4'-[(3-butyl-5-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4'-[(3-butyl-5-methyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

4-[(3-methyl-5-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

5-[4'-[[5-propyl-3-(2-thienyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(3-thienyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(2-thienylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-propyl-3-(3-thienylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-[2-(2-thienyl)ethyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-[2-(3-thienyl)ethyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-[3-(2-thienyl)propyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-[3-(3-thienyl)propyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(2-thieniophencarbonyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(3-thieniophencarbonyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-[1,1-difluoro-2-(2-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-[1,1-difluoro-2-(3-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-[1-oxo-2-(2-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-[1-oxo-2-(3-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-[1-oxo-(2-thienyl)propyl-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-[1-oxo-3-(3-thienyl)propyl-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(2-thienyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(3-thienyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(2-thienylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(3-thienylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-butyl-3-[2-(2-thienyl)ethyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-[2-(3-thienyl)ethyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-[3-(2-thienyl)propyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-[3-(3-thienyl)propyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(2-thieniophencarbonyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(3-thieniophencarbonyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-[1,1-difluoro-2-(2-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-[1,1-difluoro-2-(3-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-[1-oxo-2-(2-thienyl)ethyl]-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-[1-oxo-2-(3-thienyl)ethyl]-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-[1-oxo-2-(2-thienyl)propyl-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-[1-oxo-2-(3-thienyl)propyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(2-thienyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(3-thienyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(2-thienylmethyl)-1H-1,2,4-triazol-1- yl] methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(3-thienylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-[2-(2-thienyl)ethyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-pentyl-3-[2-(3-thienyl)ethyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-[3-(2-thienyl)propyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-[3-(3-thienyl)propyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(2-thieniophencarbonyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(3-thieniophencarbonyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-[1,1-difluoro-2-(2-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-[1,1-difluoro-2-(3-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-[1-oxo-2-(2-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-[1-oxo-2-(3-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl] [1, 1 ' -biphenyl] -2-yl] -1H-tetrazole;

5- [4 '- [ [5-pentyl-3- [1-oxo-3- (2-thienyl)propyl] -1H-1, 2, 4- triazol-1-yl]methyl] [1, 1 '-biphenyl] -2-yl] -1H-tetrazole; and

5- [4 '- [ [5-pentyl-3- [1-oxo-3- (3-thienyl) propyl] -1H-1, 2, 4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole.

General Synthetic Procedures

The compounds of the invention can be synthesized according to the following procedures of Schemes I-VI.

Synthetic Scheme I shows 'the preparation of 1H- 1,2,4-triazoles 1 from ethyl iminoesters 2 and the

corresponding hydrizide 3 via the general proceure outlined by H. Paul, G. Hilgetog, and G. Jahnchen, Chem. Ber., 101, 2033 (1968). The free, iminoesters 2 can be prepared from the corresponding iminoester hydrochlorides 4, which in turn can be prepared from the corresponding nitrile 5 ; the procedures for the preparation of 2 and 4 from 5 are outlined by P.

Reynaud and R. D. Moreau, Bull. Soc. Chim. France, 2997

(1964). The hydrazides 3 can be either purchased or prepared from the corresponding methyl esters 6 and hydrazine.

Synthetic Scheme II shows the preparation of the alkylating agent 7 from the corresponding precursor 8. When R⁵ equals CO₂CH₃ and B is a carbon-carbon single bond, 8 was purchased from Chemo Dynamics Inc .

Synthetic Scheme III shows the preparation of the alkylating agent precursor 8 where R⁵ equal CN₄C(C₆H₅)₃ from the corresponding methyl ester 8 (R⁵=CO₂CH₃). In step 1, the methyl ester is converted to the corresponding acid (R⁵=CO₂H) by the action of sodium hydroxide/hydrochloric acid. In step 2, the acid is converted to the corresponding acid chloride (R⁵=COCl) by the action of oxalyl chloride. In step 3, the acid chloride is converted to the corresponding primary amide (R⁵=CONH₂) by the action of ammonium. In step 4, the amide is converted to the corresponding nitrile 9 by the action of thionyl chloride at reflux. The nitrile 9 is reacted with trimethyltinazide in toluene at reflux to give the

corresponding trimethytin protected tetrazole 10; deprotection with acetic acid/water and reprotection with triphenylmethyl chloride/triethyl-amine gives the N-trityl tetrazole 8

(R⁵=CN₄C(C₆H₅)₃).

Synthetic Scheme IV shows the coupling reaction of the 1H-1,2, 4-triazole 1 with the appropriate alkylating reagent 7 . In the first step, 1 is treated with a base, such as sodium hydride, to generate the corresponding anion 11. Anion 11 is reacted with an alkylating agent 7 to give a mixture of regioisomers 12a and 12b. The isomer mixture may be converted to mixtures of the corresponding acids 13a and 13b or tetrazoles 14a and 14b by treatment with the

appropriate reagent. Or, the isomers 12a and 12b may be separated by chromatographic methods, and each isomer may be reacted with the appropriate reagent to provide the acid- or tetrazole-substituted end product.

Synthetic Scheme V shows. the regioselective synthesis of isomer 13a or 14a from Scheme IV. In the first step of the reaction, an alkylating agent 7 is reacted with an appropriate hydrazide 3 to provide substituted hydrazide 15. An imidate 2 is reacted with hydrazide 15 to provide

intermediate 16 which cyclizes upon heating to provide the corresponding product compound 13a or 14a.

Synthetic Scheme VI shows the regioselective synthesis of isomer 13b or 14b from Scheme IV. In the first step of the reaction, imidate 2 is reacted with hydrazine to give amidazone 17. This intermediate is reacted with

alkylating agent 7 to give intermediate 18 which is then cyclized in the presence of heat and an appropriate orthoester 19 to yield the corresponding product compound 13b or 14b. The following Examples 1-78 are detailed descriptions of the methods of preparation of compounds of Formula I and, more specifically, within Formula II. These detailed preparations fall within the scope of, and serve to exemplify, the above described General Synthetic Procedures which form part of the invention. These Examples 1-78 are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All parts are by weight unless otherwise indicated.

Example 1

methyl 4'-[ (3 ,5-dibutyl-1H-1,2 ,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-carboxylate

Step 1: Preparation of 4-bromomethyl-2'-methoxycarbonylbiphenyl .

A 47.46 g (210 mmol) sample of methyl 2-(p- tolyl)benzoate (Chemo Dynamics Inc.) was dissolved in 3L of carbon tetrachloride and treated with 37.33 g (209 mmol) of N- bromosuccinimide (NBS) and 1.17 g (7.13 mmol) of

azobisisobutyronitrile (AIBN) at reflux under nitrogen for 24 hours. The reaction mixture was treated again with 1.0 g (6.1 mmol) of AIBN and stirred at reflux for an additional 24 hours. The reaction was filtered and the solvent removed in in vacuo. Purification by silica gel chromatography (Waters

Prep-500A) using ethyl acetate/hexane (5:95) as eluent provided 50.0 g (78%) of a colorless solid: mp 48-51°C; NMR (CDCI₃) δ 3.64 (s, 3H), 4.54 (s, 2H), 7.23-7.63 (m, 7H), 7.81-

7.89 (m, 1H). NMR indicated that this material was only 91% pure; it contained 9% of the corresponding dibromocompound (δ 6.70); however, no further attempts at purification were made and this mixture was used in all subsequent alkylation

reactions.

step 2: Preparation of 3,5-dibutyl-1H-1, 2,4-triazole.

A solution of 64.5 g (0.50 mol) of ethyl iminovalerate [P. Reynaud and R. C. Moreau, Bull. Soc. Chim. France , 2997 (1964)] in 100 mL of methanol was added slowly to 58.0 g (0.50 mol) of valeric acid hydrazide (Lancaster Synthesis) in 400 mL of methanol at 0°C under a nitrogen atmosphere. After the addition was complete, the reaction was allowed to warm to ambient temperature and then stir at reflux for 2 days. The solvent was removed in vacuo; purification by silica gel chromatography (Waters Prep-500A) using ethyl acetate/hexane (80:20) gave 78.9 g (93%) of a colorless solid: mp 50.5-51.5°C; NMR (CDCl₃) δ 0.88 (t, J=7 Hz, 6H), 1.28-1.33

(m, 4H), 1.63-1.77 (m, 4H) , 2.72 (t, J=7 Hz, 4H); MS (FAB) m/e (rel intensity) 183 (12%), 182 (100), 181 (3), 180 (6), 152 (8), 139 (4); HRMS. Calcd for M+H: 182.1657. Found:

182.1661.

Step 3: Preparation of methyl 4'-[(3,5-dibutyl-1H-1,2,4- triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate.

Under a static nitrogen atmosphere, 2.01 g (11 .0 mmol) of solid 3, 5-dibutyl-1H-1, 2, 4-triazole was added in small portions to 12 mmol of sodium hydride in 50 ml of dimethylformamide (DMF); stirring was continued until hydrogen evolution had ceased. The anion solution was cooled to -10ºC (ice/methanol) and treated with a solution of 3.37 g (11.0 mmol) of 4-bromomethyl-2'-methoxycarbonyl-biphenyl in 20 ml of dry DMF. The reaction was allowed to warm to ambient temperature and stir overnight. Methanol (10 ml) was added to destroy any unreacted sodium hydride and the DMF was removed in vacuo. The residue was dissolved in ethyl acetate, washed with water, and dried (MgSO₄). Silica gel chromatography

(Waters Prep-500A) using 40% ethyl acetate/hexane gave 2.0 g (41%) of compound as an oil: NMR (CDCI₃) δ 0.90 (t, J = 7 HZ, 3H), 0.94 (t, J = 7 Hz, 3H), 1.28-1.47 (m, 4H), 1.62-1.80 (m, 4H), 2.63-2.75 (m, 4H), 3.63 (s, 3H), 5.27 (s, 2H), 7.13- 7.18 (m, 2H), 7.25-7.35 (m, 3H), 7.37-7.44 (m, 1H), 7.48-7.55 (m, 1H), 7.80-7.85 (m, 1H).

Example 2

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'-biphenyl]- 2-carboxylic acid

A 2.0 g (4.9 mmol) sample of the methyl ester product compound from Example 1 was dissolved in 80 ml of ethanol and treated with 80 ml of 10% NaOH at ambient

temperature for 3 days. The ethanol was removed in vacuo and the aqueous phase acidified to pH 1 with hydrochloric acid which caused the product to precipitate; filtration and drying in vacuo gave 1.65 g (86%) of colorless compound: mp 134- 135°C; NMR (DMSO-d₆) δ 0.85 (t, J = 7 Hz, 3H), 0.90 (t, J = 7 Hz, 3H), 1.23-1.39 (m, 4H), 1.53-1.68 (m, 4H), 2.59 (t, J = 7 Hz, 2H), 2.78 (t, J = 7 Hz, 2H), 5.37 (s, 2H), 5.37 (s, 2H),

7.18-7.26 (m, 2H), 7.28-7.37 (m, 3H), 7.42-7.48 (m, 1H), 7.53- 7.60 (m, 1H), 7.70-7.75 (m, 1H).

Example 3

5-[4'-[(3,5-dibntyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole

Step 1: Preparation of N-Triphenylmethyl-5-[2- (4'- bromomethylbiphen-2-yl]tetrazole. A 542.5 g (2.4 mol) sample of methyl 2-(p- tolyl)benzoate (Chemo Dynamics Inc.) was dissolved in 5.5 L of ethanol and treated with 3 L (7.5 mol) of 2.5 N sodium hydroxide. The reaction was stirred overnight at ambient temperature and treated with an additional 480 ml (6.0 mol) of sodium hydroxide; stirring was continued for an additional 24 h and the ethanol removed in vacuo. The remaining solution was cooled in ice and acidified to pH 1 with hydrochloric acid which caused the product to precipitate; filtration and drying in vacuo gave 510 g (100%) of crude 2-(p-tolyl)benzoic acid: mp 145.0-147.5°C; NMR (CDCI₃) δ 2.40 (s, 3H), 7.17-7.28 (m,

4H), 7.35-7.45 (m, 2H), 7.51-7.59 (m, 1H), 7.90-7.97 (m, 1H). The crude acid was suspended in 1 L of toluene and slowly treated with 400 g (3.15 mol) of oxalyl chloride under nitrogen. The reaction was allowed to stir at ambient temperature for 4.5 h and concentrated in vacuo to remove excess oxalyl chloride. The residue was redissolved in 2L of toluene and treated with 92.8 g (5.46 mol) of anhydrous ammonia. The reaction was filtered and the filtrate

concentrated in vacuo producing 424 g (84%) of crude 2-(p- tolyDbenzamide: mp 128-130°C; NMR (CDCl₃) δ 2.40 (s, 3H),

5.28 (br s, 1H), 5.77 (br s, 1H), 7.21-7.53 (m, 7H), 7.76-7.83 (m, 1H). The crude amide was treated with 1420 ml (19.5 mol) of thionyl chloride at reflux for 3.5 h. The reaction was filtered and the thionyl chloride removed in vacuo. The residue was dissolved in 800 ml of toluene and reconcentrated in vacuo. On standing overnight, the residue crystallized. The crystals were collected and washed with hexane to give 296 g (64%) of 2-(p-tolyl)benzonitrile: mp 50.5-52.0°C; NMR

(CDCI₃) 82.42 (s, 3H), 7.22-7.34 (m, 2H), 7.37-7.52 (m, 3H),

7.58-7.66 (m, 1H), 7.72-7.78 (m, 1H). A 286 g (1.48 mol) sample of the crude nitrile was dissolved in 1630 mL to toluene and treated with 377 g (1.8 mol) of trimethyltinazide at reflux for 24 h. The reaction was cooled; filtration gave 600 g of crude N-trimethylstannyl-5-[2-(4'-methylbiphen-2- yl]tetrazole: mp 271-272°C (dec); NMR (DMSO-d₆) δ 0.36 (br t, J =34 HZ, 9H), 2.24 (s, 3H), 6.89-7.06 (m, 4H), 7.35-7.55 (m, 4H). The crude N-trimethylstannyl tetrazole was suspended in 4270 mL of toluene and 287 mL of anhydrous tetrahydrofuran (THF) and treated with 63.4 g (173 mol) of anhydrous hydrogen chloride at ambient temperature under nitrogen with stirring. The reaction was allowed to stand overnight and filtered;

recrystallization from toluene gave 217 g (62%) of 5-[2-

(4''ethylbiphen-2-yl)]tetrazole as a solid: mp 149-152°C; NMR (DMSO-d₆) 82.28 (s, 3H), 6.94-7.02 (m, 2H), 7.08-7.15 (m,

2H), 7.50-7.59 (m, 2H), 7.62-7.72 (m, 2H). A 200 g (0.85 mol) sample of the tetrazole was suspended in 3.3 L of

dichloromethane and treated with 262 g (0.91 mol) of

triphenylmethyl chloride and 141 mL (1.0 mol) of anhydrous triethylamine. The reaction was stirred at reflux for 3 h under nitrogen, washed with water, dried (MgSO₄), and

concentrated in vacuo. Recrystallization gave 338 g (83%) of

N-triphenylmethyl-5-[2-(4'-methylbiphen-2-yl)]tetrazole as a colorless solid: mp 170-173°C; NMR (CDCI₃) δ 2.27 (s, 3H),

6.86-6.96 (m, 8H), 6.98-7.04 (m, 2H), 7.09-7.52 (m, 12H), 7.86-7.94 (m, 1H). The N-triphenylmethyl tetrazole was dissolved in 4260 mL of carbon tetrachloride and treated with 126.4 g (0.71 mol) of N-bromosuccinimide (NBS) and 11.9 g (49 mmol) of benzoyl peroxide at reflux for 3.5 h. The reaction was filtered and the solvent removed in vacuo.

Recrystallization from toluene gave 277 g (59%) of N- triphenylmethyl-5-[2-(4'-bromomethylbiphen-2-yl)]tetrazole as a colorless solid: mp 140-142°C; NMR (CDCI₃) δ 4.39 (s, 2H), 6.85-6.95 (m, 7H), 7.06-7.15 (m, 4H), 7.22-7.43 (m, 9H), 7.45- 7.55 (m, 2H), 7.94-8.01 (m, 1H). NMR indicated that this material was only 85% pure; it contained 7% of corresponding dibromo- compound (8 6.50) and 8% of starting material (8 2.27); however, no further attempts at purification were made and this mixture was used in all subsequent alkylation reactions.

Step 2: Preparation of 5-[4'-[(3,5-dibutyl-1H-1,2,4-triazol-

1-yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole.

Under a static nitrogen atmosphere, 2.77 g (15.0 mmol) of solid 3,5-dibutyl-1H-1,2,4-triazole (from Step 2 of Example 1) was added in small portions to 15 mmol of sodium hydride in 50 ml of dimethyl formamide (DMF) ; stirring was continued until hydrogen evolution had ceased. The anion solution was cooled to -10°C (ice/methanol) and treated with a solution of 8.45 g (15.0 mmol) of N-triphenylmethyl-5-[2-(4'- bromomethylbiphen-2-yl)]tetrazole in 20 ml of dry DMF. The reaction was allowed to warm to ambient temperature and stir overnight. Methanol (10 ml) was added to destroy any

unreacted sodium hydride and the DMF was removed in vacuo.

The residue was dissolved in ethyl acetate, washed with water, and dried (MgSO₄). The crude material (8.61 g ) was

redissolved in 86 ml of toluene and treated with anhydrous HCl to remove the protecting group. Purification by reverse phase chromatography (Waters Delta Prep-3000) using isocratic 40% acetonitrile/water (0.05% TFA) provided 1.72 g (27%) of colorless compound: mp 150.5-152.0°C; NMR (DMSO-d₆) δ 0.84 (t, J = 7 Hz, 3H), 0.88 (t, J = 7 Hz, 3H), 1.22-1.38 (m, 4H), 1.49-1.66 (m, 4H), 2.66 (t, J = 7 Hz, 2H), 2.73 (t, J = 7 Hz, 2H), 5.32 (s, 2H), 7.05-7.15 (m, 4H) , 7.50-7.72 (m, 4H); MS (FAB) m/e (rel intensity) 416 (30), 373 (10), 235 (5), 207 (100), 192 (30); HRMS. Calcd for M+H: 416.2563. Found:

416.2600.

Example 4

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]- 2-carboxylic acid, hydrazide

A 7.10 g (17.5 mmol) sample of the methyl ester product compound of Example 1 was dissolved in 150 ml of methanol and treated with 22 ml (22.2 g 695 mmol) of anhydrous hydrazine under a static nitrogen atmosphere. The reaction was stirred at reflux for 2 days and concentrated in vacuo to give 7.03 g (99%) of compound which was a colorless glass: NMR (CDCI₃) δ 0.88 (t, J = 7 Hz, 3H), 0.94 (t, J = 7 Hz, 3H),

1.28-1.47 (m, 4H), 1.62-1.78 (m, 4H), 2.62-2.73 (m, 4H), 3.5- 4.1 (br s, 2H), 5.26 (s, 2H), 6.53 (s, 1H), 7.13-7.63 (m, 8H).

Example 5

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]- 2-carboxylic acid, 2-[(trifluoromethyl)sulfonyl]hydrazide

A 1.0 g (2.48 mmol) sample of the hydrazide product compound of Example 4 was dissolved in 20 ml of toluene and cooled to 0ºC under a static nitrogen atmosphere. The solution was treated with 1.41 g (5.0 mmol) of

trifluoromethylsulfonyl anhydride. Concentration in vacuo produced 3.91 g of crude material which was a dark oil.

Purification by silica gel chromatography (Waters Prep-500A) using 50% ethyl acetate/hexane gave 1.0 g (75%) of pale yellow compound: mp 345°C (dec); NMR (DMSO-d₆) 8 0.86 (t, J = 7 HZ, 3H), 0.88 (t, J = 7 Hz, 3H), 1.25-1.38 (m, 4H), 1.55-1.65 (m,

4H), 2.50-2.59 (m, 2H), 2.67-2.73 (m, 2H), 5.32 (s, 2H), 7.15-

7.50 (m, 8H); MS (FAB) m/e (rel intensity) 538, (100), 405 (15), 389 (10), 374 (25), 356 (15). Example 6

4'-[(5-butyl-3-chloro-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-carboxylic acid

Step 1 : Preparation of 3-butyl-5-chloro-1H-1,2,4-triazole.

A 10.0 g (80 mmol) sample of 3-butyl-1H-1, 2,4- triazole [H. Paul, G. Hilgetag, and G. Jahnchen, Chem. Ber., 101, 2033 (1968)] was dissolved in 320 mL of water containing 7.0 g (177 mmol) of sodium hydroxide. With stirring, the solution was cooled to 0°C and chlorine was introduced over 3 h. The reaction was purged with nitrogen overnight and the solution extracted with chloroform. The extracts were combined, dried (MgSO₄), and concentrated in vacuo to give

16.8 g of a colorless oil which was placed in 200 mL of water and treated twice with 8.0 g (80 mmol) of sodium

metabisulfite. The pH of the reaction medium was adjusted to 6 with 1M sodium carbonate prior to extraction with

chloroform; the extracts were dried (MgSO₄) and concentrated in vacuo to give 14.9 g of crude product. Purification by silica gel chromatograph (Waters Prep-500A) using

chloroform/methanol (95:5) gave 9.53 g (75%) of a colorless solid: mp 104-105°C; NMR (CDCI₃) 8 0.94 (t, J=7 Hz, 3H), 1.33-1.47 (m, 2H), 1.68-1.83 (m, 2H) , 2.80 (t, J=7 Hz, 2H); MS (FAB) m/e (rel intensity) 162 (28), 160 (100), 158 (10), 130 (5), 126 (10), 117 (5); HRMS. Calcd for M+H: 160.0642.

Found: 160.0651. step 2: Preparation of 4'-[(5-butyl-3-chloro-1H-1,2,4- triazol-1-yl)methyl] [1,1'-biphenyl]-2-carboxylic acid.

Under a static nitrogen atmosphere, 5.0 g (31.3 mmol) of solid 5-butyl-3-chloro-1H-1,2, 4-triazole was added in small portions to 32 mmol of sodium hydride in 50 ml of dimethylformamide (DMF); stirring was continued until hydrogen evolution had ceased. The anion solution was cooled to -10°C (ice/methanol) and treated with a solution of 9.55 g (31.3 mmol) of 4-bromomethyl-2'-methoxycarbonylbiphenyl in 20 ml of dry DMF. The reaction was allowed to warm to ambient

temperature and stir overnight. Methanol (10 ml) was added to destroy any unreacted sodium hydride and the DMF was removed in vacuo. The residue was dissolved in ethyl acetate, washed with water, and dried (MgSO₄) to give 12.2 g of crude material was obtained which was a clear golden oil. A 4.81 g sample of this material was dissolved in 250 ml of methanol and treated with 250 ml of 10% NaOH at ambient temperature for 2 days. A portion of the isomer mixture of acids was separated by reverse phase chromatography (Waters Delta Prep-3000) using isocratic 45% acetronitrile/water (0.05% TFA). The faster moving isomer (250 mg) was identified as the 3-chloro isomer: NMR (DMSO-d₆) 8 0.86 (t, J = 7 Hz, 3H), 1.23-1.36 (m, J = 7

Hz, 2H), 1.54-1.65 (m, J = 7 Hz, 1H), 2.80 (t, J = 7Hz, 2H), 5.40 (s, 2H), 7.23-7.58 (m, 7H), 7.72-7.77 9m, 1H). Example 7

5'-[(5-butyl-3-chloro-1H-1,2,4-triazol-1-yl.methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole Under a static nitrogen atmosphere, 2.00 g (12.4 mmol) of solid 3-butyl-5-chloro-1H-1,2, 4-triazole (from Step 1 of Example 6) was added in small portions to 12.5 mmol of sodium hydride in 50 ml of dimethylformamide (DMF); stirring was continued until hydrogen evolution had ceased. The anion solution was cooled to -10°C (ice/methanol) and treated with a solution of 7.0 g (12.5 mmol) of N-triphenylmethyl-5-[2-(4'- bromomethylbiphen-2-yl)]tetrazole (from Step 1 of Example 3) in 20 ml of dry DMF. The reaction was allowed to warm to ambient temperature and stir overnight. Methanol (10 ml) was added to destroy any unreacted sodium hydride and the DMF was removed in vacuo. The residue was dissolved in ethyl acetate, washed with water; and dried (MgSO₄); 8.0 g of crude material was obtained. A 6.0 g sample of this material was dissolved in 70 ml of toluene and 6 ml of THF. Anhydrous hydrogen chloride was introduced into the solution for 45 min. and the reaction was allowed to stir for an additional 30 min. The solvent was decanted off and the remaining oil washed with toluene to give 3.31 g (89%) of a mixture of isomeric

tetrazoles. A portion of this mixture was purified by reverse phase chromatography (Waters Delta Prep-3000) using isocratic

55% acetonitrile/water (0.05% TFA) . The faster moving isomer (289 mg) was identified as the 3-chloro isomer: NMR (CDCI₃) δ

0.92 (t, J= 7 Hz, 3H), 1.35-1.45 (m, 2H), 1.69-1.77 (m, 2H),

2.77 (t, J = 7 Hz, 2H), 5.27 (s, 2H), 7.20-7.65 (m, 7H), 8.05-

8.10 (m, 1H); MS (FAB) m/e (rel intensity) 394 (70), 235 (65),

207 (100), 192 (40), 178 (45).

Example 8

4'-[(3-butyl-5-chloro-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-carboxylic acid

The slower moving isomer (120 mg) isolated in

Example 6 was identified as the 5-chloro isomer: NMR (DMSO- d₆) 80.88 (t, J = 7 Hz, 3H), 1.25-1.35 (m, J = 7 Hz, 2H),

1.56-1.67 (m, J = 7 Hz, 2H), 2.49 (t, J = 7 Hz, 2H), 5.37 (s,

2H), 7.23-7.58 (m, 7H), 7.72-7.77 (m, 1H).

Example 9

5'-[(3-butyl-5-chloro-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole

The slower moving isomer (250 mg) isolated in Example 7 was identified as the 5-chloro isomer: NMR (CDCI₃) δ 0.88 (t, J = 7 Hz, 3H), 1.35-1.45 (m, 2H), 1.65-1.79 (m, 2H), 2.54 (t, J = 7 Hz, 2H), 5.23 (s, 2H), 7.15-7.65 (m, 7H), 8.00-8.05 (m, 1H).

Example 10

5-[4'-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2 ,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetragole

Step 1: Preparation of 3-butyl-5-(1,1-difluoro)butyl-1H- 1,2,4-triazole.

Under nitrogen, a stirred solution of 56.9 g (0.65 mol) of N-tert-butyl-N-methylamine (Fluka) and 66.1 g (0.65 mol) of triethylamine in 1 L of methylene chloride was cooled to 0°C and treated with neat difluoroacetic anhydride [E.

Sawicki, J. Org. Chem., 21, 376 (1956)] at such a rate as to maintain the reaction temperature below 10°C. The reaction was allowed to warm to ambient temperature and stir overnight. All volitiles were removed in vacuo (bath temperature < 35°C) and the residue redissolved in methylene chloride; the solution was washed with saturated sodium bicarbonate, dried (MgSO₄), and concentrated to give 94 g (89%) of a yellow liquid. Vacuum distillation gave 86 g (81%) of colorless N- tert-butyl-N-methyldifluoroacetamide: bp 87-88°C (22 mm); 'H NMR (CDCI₃) δ 1.37 (s, 9H), 2.93 (t, J=3 Hz, 3H), 5.97 (t,

J=57 Hz, 1H); ¹⁹F NMR (CDCI₃) δ -122.20 (d, J=57 Hz, 2F). A 17.0 g (103 mmol) sample of the amide was dissolved in 50 mL of dry THF and added slowly to a solution of 145 mmol of lithium diisopropylamine (IDA) in 450 mL of dry THF at -78°C. The reaction was allowed to stir for 1 h at -78°C prior to the addition of 17 mL (175 mmol) of 1-iodopropane by syringe.

Stirring at -78°C was continued for 1 hr and then the reaction was allowed to warm to ambient temperature overnight.

Methanol (10 mL) was added and the reaction was concentrated in vacuo; the residue was dissolved in methylene chloride and washed with 1N hydrochloric acid, dried (MgSO₄) and

reconcentrated to give 17.6 g (83%) of crude product.

Purification by vacuum distillation gave 13.3 g (62%) of colorless N-tert-butyl-N-methyl-2,2-difluoro-valeramide: bp 125-130°C (84 mm); 'H NMR (CDCI₃) δ 0.94 (t, J=7 Hz, 3H), 1.37 (S, 9H), 1.40-1.52 (m, 2H), 1.95-2.15 (m, 2H); ¹⁹F NMR (CDCI₃) δ--100.29 (t, J = 20Hz, 2F). The difluorovaleramide was dissolved in 30 mL of trifluoroacetic acid (TFA) and stirred at reflux overnight under nitrogen. The solvent was removed in vacuo and the residue dissolved in methylene chloride; the solution was washed with water, dried (MgSO₄) and concentrated to give 9.7 g (100%) of crude N-methyl-2, 2-difluorovaleramide: 'H NMR (CDCI₃) 8 0.92 (t, J = 7 Hz, 3H), 1.36-1.51 (m, 2H),

1.90-2.11 (m, 2H), 2.84 (d, J = 6 Hz, 3H), 6.60-6.85 (br s, 1H); ¹⁹F NMR (CDCI₃) δ -106.98 (t, J = 19 Hz, 2F). The crude N-methyl amide was dissolved in 40 mL of 6N hydrochloric acid and stirred at reflux for 24 hr. The reaction was cooled to ambient temperature and extracted with methylene chloride; the extracts were combined, dried (MgSO₄), and concentrated to give 8.0 g (56%) of crude 2,2-difluorovaleric acid: 'H NMR (CDCI₃) δ 1.00 (t, J = 7 Hz, 3H), 1.46-1.63 (m, 2H), 1.97-

2.17 (m, 2H); ¹⁹F NMR (CDCI₃) δ -107.16 (t, J = 18 Hz, 2F). A 4.83 g (35 mmol) sample of the crude acid was dissolved in 25 mL (35.2 g, 174 mmol) of phthaloyl chloride in a flask equipped with a reflux condenser and stirred under nitrogen in a 110ºC oil bath for 6 hrs. The condenser was replaced with a distillation head and 3.22 g (60%) of colorless 2,2- difluorovaleryl chloride was collected: bp 96°; 'H NMR

(CDCI₃) δ 1.03 (t, J = 7 Hz, 3H), 1.48-1.65 (m, 2H), 2.03-2.23 (m, 2H); ¹⁹F NMR (CDCI₃) δ -102.41 (t, J = 18 Hz, 2F). The 2,2-difluorovaleryl chloride (20.6 mmol) was dissolved in 10 mL of methylene chloride and dropwise to a solution of 135 g (42 mmol) of anhydrous hydrazine in 20 mL of methylene chloride at 0°C. After the addition was complete, the reaction was stirred at ambient temperature for 1 h, washed with water, dried (MgSO₄), and concentrated to give 3.12 g (91%) of 2,2-difluorovaleric acid hydrazide: NMR (CDCI₃) 8 0.96 (t, J = 7 Hz, 3H), 1.40-1.56 (m, 2H), 1.96-2.17 (m, 2H), 3.93 (br s, 2H), 7.67 (br s, 1H). A 2.84 g (18.7 mmol) sample of the crude hydrazide was dissolved in 50 mL of methanol and treated with 2.41 g (18.7 mmol) of ethyl iminovalerate. Under nitrogen, the reaction was stirred at reflux for 3 days and concentrated in vacuo. Purification by silica gel

chromatography (Waters Prep-500A) using ethyl acetate/hexane (60:40) gave 3.0 g (74%) of 3-butyl-5-(1,1-difluoro)butyl-1H- 1,2,4-triazole as a colorless solid: mp 92-93°C; 'H NMR (CDCI₃) δ 0.97 (t, J = Hz, 3H), 0.92 (t, J = 7 Hz, 3H), 1.30-

1.45 (m, 2H), 1.47-1.62 (m, 2H), 1.66-1.81 (m, 2H), 2.18-2.38 (m, 2H), 2.83 (t, J = 7 Hz, 2H); ¹⁹F NMR (CDCI₃) δ -97.27 (t, J = 18 Hz, 2F); MS (FAB) m/e (rel intensity) 218 (100), 198 (8), 188 (5), 178 (8), 170 (5); HRMS. Calcd for M+H:

218.1469. Found: 218.1461.

Step 2: Preparation of 5-[4'-[[5-butyl-3-(1,1-difluorobutyl)- 1H-1,2,4-triazpl-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H- tetrazole.

Under a static nitrogen atmosphere, 2.0 g (9.2 mmol) of solid 3-butyl-5-(1,1-difluoro)butyl-1H-1,2,4-triazole was added in small portions to 10 mmol of sodium hydride in 50 ml of dimethylformamide (DMF); stirring was continued until hydrogen evolution had ceased. The anion solution was cooled to -10°C (ice/methanol) and treated with a solution of 5.1 g (9.2 mmol) of N-triphenylmethyl-5-[2-(4'-bromomethylbiphen-2- yl)]tetrazole (from Step 1 of Example 3) in 20 ml of dry DMF. The reaction was allowed to warm to ambient temperature and stir overnight. Methanol (10 ml) was added to destroy any unreacted sodium hydride and the DMF was removed in vacuo. the residue was dissolved in ethyl acetate, washed with water, and dried (MgSO₄). Silica gel chromatography using 2.5% ethyl acetate/toluene produced 680 mg (10.7%) of a faster moving isomer and 4.91 g (77.2%) of a slower moving isomer. The slower moving isomer was dissolved in 40 ml 10%

water/acetic acid and stirred at ambient temperature

overnight. The solvent was removed in vacuo; the residue was dissolved in water and the pH adjusted to 9. The water layer was washed with benzene, acidified to pH 4 with 3N HCl, and extracted with ethyl acetate. The ethyl acetate was dried (Mg SO₄) and remove in vacuo. The product was recrystallized from acetonitrile yielding 1.38 g (44%) of the 3-(1,1- difluoro)butyl isomer as colorless solid: mp 165.0-167.5°C; NMR (CDCI₃) 8 d 0.86 (t, J=7 Hz, 3H), 0.94 (t, J=7 Hz, 3H),

1.24-1.38 (m, 2H), 1.40-1.55 (m, 2H), 1.55-1.68 (m, 2H), 2.10- 2.29 (m, 2H), 2.63 (t, J=7 Hz, 2H), 5.27 (s, 2H), 7.00-7.05

(m, 2H), 7.10-7.17 (m, 2H), 7.38-7.43 (m, 1H), 7.48-7.64 (m, 2H), 7.92-7.97 (m, 1H); ¹⁹F NMR (CDCI₃) δ -97.38 (t, J = 18

Hz, 2F); MS (FAB) m/e (rel intensity) 452 (83), 432 (21), 235 (45), 207 (100), 192 (42), 178 (29); HRMS . Calcd for M+H: 452.2374. Found: 452.2398. Example 11

5-[4'-[[3-butyl-5-(1.1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biϋhenyl!-2-yl]-1H-tetrazole

The faster moving isomer isolated in Example 10 was hydrolyzed in an identical manner. Purification by reverse phase chromatography (Waters Delta Prep-3000) using 42% acetonitrile/water (0.05% TFA) for 20 minutes, 45%

acetonitrile/water (0.05% TFA) for 20 minutes, 50%

acetonitrile/water (0.05% TFA) for 20 minutes and then 60% acetonitrile/water (0.05% TFA) . The acetonitrile was removed in vacuo, the pH was adjusted to pH4 with IN NaOH, and the product extracted with ethyl acetate. The ethyl acetate was dried (MgSθ4) and removed in vacuo to give 150 mg (35%) of the 5-(1,1-difluoro)butyl isomer: NMR (CDCI₃) δ d 0.91 (t, J=7 Hz, 3H), 1.01 (t, J=7 Hz, 3H) , 1.27-1.42 (m, 2H), 1.54-1.72 (m, 4H), 2.27-2.43 (m, 2H), 2.61 (t, J=7 Hz, 2H), 5.46 (s, 2H), 7.17-7.22 (m, 2H), 7.25-7.30 (m, 2H), 7.38-7.45 (m, 1H), 7.52-7.65 (m, 2H), 8.15-8.20 (m, 1H); MS (FAB) m/e (rel intensity) 452 (47), 235 (90), 207 (100), 178 (33); HRMS.

Calcd for M+H: 452.2374. Found: 452.2418. Example 12

5-[4'-[(3,5-dipropyl-1H-1,2,4-triazol-1-yl)methyl] [ 1,1'- biphenyl]-2-yl]-1H-tetrazo!e-

Step 1: Preparation of 3,5-dipropyl-1H-1,2,4-triazole.

Under nitrogen, a solution of 375 g (11.8 mol) of anhydrous hydrazine in 1600 mL of methanol was cooled to 0°C and treated with 1.0 kg (9.8 mol) of methyl butyrate. The reaction was allowed to warm to ambient temperature and stir overnight prior to stirring at reflux for 5 h. The reaction was concentrated in vacuo; recrystallization from

toluene/ethyl acetate gave 825.5 g (83%) of butyric acid hydrazide as a colorless solid: mp 44.5-46.0°C; NMR (CDCI₃) δ 0.88 (t, J = 7 Hz, 3H), 1.53-1.68 (m, 2H), 2.09 (t, J = 7 Hz, 2H), 3.89 (br s, 2H), 7.62 (br s, 1H). A 5.0 g (43 mmol) sample of the hydrazide was dissolved in 40 mL of methanol and treated with 4.4 g (43 mmol) of ethyl iminobutyrate [P.

Reynaud and R. C. Moreau, Bull. Soc. Chim. France, 2997

(1964)] under nitrogen. The reaction was stirred at reflux for 3 days and concentrated in vacuo. Purification by silica gel chromatography (Waters Prep-500A) using ethyl

acetate/hexane (60:40) gave 5.37 g (81%) of 3,5-dipropyl-1H- 1,2,4-triazole as a colorless solid: mp 69-70°C; NMR (CDCI₃) 80.92 (t, J = 7 Hz, 6H), 1.64-1.81 (m, 4H), 2.68 (t, J = 7 Hz, 4H); MS (FAB) m/e (rel intensity) 154 (100), 138 (5), 125 (5), 112 (3); HRMS. Calcd for M+H: 154.1344. Found:

154.1390.

Step 2: Preparation of 5-[4'-[(3,5-dipropyl-1H-1,2,4- triazole-1-yl)methyl] [ 1,1'-biphenyl]-2-yl]-1H-tetrazole. Under a static nitrogen atmosphere, 2.00 g (13.1 mmol) of solid 3,5-dipropyl-1H-1,2,4-triazole was added in small portions to 14 mmol of sodium hydride in 50 ml of dimethylformamide (DMF); stirring was continued until hydrogen evolution had ceased. The anion solution was cooled to -10°C (ice/methanol) and treated with a solution of 7.3 g (13.1 mmol) of N-triphenylmethyl-5-[2-(4'-bromomethylbiphen-2- yl)]tetrazole (from Step 1 of Example 3) in 20 ml of dry DMF. The reaction was allowed to warm to ambient temperature and stir overnight. Methanol (10 ml) was added to destroy any unreacted sodium hydride and the DMF was removed in vacuo.

The residue was dissolved in ethyl acetate, washed with water, and dried (MgSO₄). Silica gel chromatography using 33% ethyl acetate/toluene produced 6.5 g (78.6%) of the protected tetrazole which was dissolved in 50 ml of 10% water/acetic acid and stirred at ambient temperature overnight. The solvent was removed in vacuo and the crude product dissolved in water which was made basic with 2.5 N NaOH. The water was extracted with benzene, acidified, and extracted with ethyl acetate. The ethyl acetate was dried (MgSO₄) and removed in vacuo. Recrystallization from acetonitrile gave 2.67 g (67%) of a colorless solid: mp 164.5-167.0°C; NMR (CDCI₃) δ d 0.77 (t, J = 7 Hz, 3H), 0.83 (t, J = 7 Hz, 3H), 1.39-1.59 (m, 4H), 2.21 (t, J = 7 Hz, 2H), 2.38 (t, J = 7 Hz, 2H), 5.16 (s, 2H), 6.80-6.87 (m, 2H), 7.03-7.08 (m, 2H), 7.41-7.44 (m, 1H), 7.50- 7.66 (m, 2H), 7.81-7.87 (m, 1H); MS (FAB) m/e (rel intensity) 388 (29), 207 (100), 192 (38), 178 (28), 165 (20), 154 (37); HRMS. Calcd for M+H: 388.2249. Found: 388.2284.

Example 13

5- [4 '- [ (3, 5-dipentyl-1H-1, 2, 4-triazol-1-yl)methyl] [1, 1 ' - biphenyl] -2-yl] -1H-tetrazole

Step 1: Preparation of 3,5-dipentyl-1H-1,2,4-triazole.

Under nitrogen, a solution of 262 g (8.2 mol) of anhydrous hydrazine in 1300 mL of methanol was cooled to 0°C and treated with 885 g (6.8 mol) of methyl caproate. The reaction was allowed to warm to ambient temperature and stir overnight prior to stirring at reflux for 7 h. The reaction was concentrated in vacuo; recrystallization from toluene gave

707 g (80%) of caproic acid hydrazide as a colorless solid: mp 72.5-73.9°C; NMR (CDCI₃) δ 0.82 (t, J = 7 Hz, 3H), 1.15-

1.33 (m, 4H), 1.51-1.64 (m, 2H), 2.10 (t, J = 7 Hz, 2H), 3.91 (br s, 2H), 7.56 (br s, 1H). A 5.0 g (39 mmol) sample of the hydrazide was dissolved in 40 mL of methanol and treated with 11.2 g (78 mmol) of ethyl iminocaproate [P. Reynaud and R. C. Moreau, Bull. Soc . , Chim . France, 2997 (1964)-which was only about 50% pure by NMR] under nitrogen. The reaction was stirred at reflux for 2 days and concentrated in vacuo.

Purification by silica gel chromatography (Waters Prep-500A) using ethyl acetate/hexane (48:52) gave 7.56 g (92%) of 3,5- dipentyl-1H-1,2, 4-triazole as a colorless solid: mp 66-68°C; NMR (CDCI₃) 8 0.88 (t, J = 7 Hz, 6H), 1.24-1.41 (m, 8H), 1.66-

1.81 (m, 4H), 2.72 (t, J = 7 Hz, 4H); MS (FAB) m/e (rel intensity) 210 (100), 166 (14); HRMS. Calcd for M+H:

210.1970. Found: 210.1964.

Step 2: Preparation of 5-[4'[(3,5-dipentyl-1H-1,2,4-triazol-

1-yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole. Under a static nitrogen atmosphere, 2.0 g (9.6 mmol) of solid 3,5-dipentyl-1H-1,2,4-triazole was added in small portions to 10 mmol of sodium hydride in 50 ml of dimethylformamide (DMF); stirring was continued until hydrogen evolution had ceased. The anion solution was cooled to -10°C (ice/methanol) and treated with a solution of 5.35 g (9.6 mmol) of N-triphenylmethyl-5-[2-(4'-bromo-methylbiphen-2- yl)]tetrazole (from Step 1 of Example 3) in 20 ml of dry DMF. The reaction was allowed to warm to ambient temperature and stir overnight. Methanol (10 ml) was added to destroy any unreacted sodium hydride and the DMF was removed in vacuo.

The residue was dissolved in ethyl acetate, washed with water, and dried (MgSO₄). Silica gel chromatography using 33% ethyl acetate/hexane produced 5.1 g (78%) of the protected tetrazole which was taken up in 40 ml of 10% water in acetic acid and stirred at ambient temperature for 3 days. The solvent was removed in vacuo, the residue dissolved in water, and the pH adjusted to 9. The aqueous layer was washed in benzene, acidified and extracted with ethyl acetate. The solution was dried (MgSθ4) and concentrate in vacuo. Recrystallization from acetonitrile gave 2.1 g (62%) of a colorless solid: mp 116-120°C; NMR (CDCI₃) δ d 0.82 (t, J = 7 Hz, 6H), 1.07-1.31

(m, 8H), 1.40-1.60 (m, 4H), 2.22 (t, J = 7 Hz, 2H), 2.41 (t, J = 7 Hz, 2H), 5.15 (s, 2H), 6.80-6.87 (m, 2H), 7.03-7.10 (m, 2H), 7.41-7.48 (m, 1H), 7.52-7.66 (m, 2H), 7.87-7.93 (m, 1H); MS (FAB) m/e (rel intensity) 444 (100), 207 (72), 178 (13); HRMS. Calcd for M+H: 444.2876. Found: 444.2910.

Example 14

5-[4'-[(5-butyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl]-[1,1'- biphenyl]-2-yl]-1H-tetrazole

Step 1: Preparation of 5-butyl-3-propyl-1H-1,2,4-triazole.

A 3.95 g (38.7 mmol) sample of butyric acid hydrazide (from Step 1 of Example 12) was dissolved in 30 mL of methanol and treated with 5.0 g (38.8 mmol) of ethyl iminovalerate under nitrogen. The reaction was stirred at reflux for 3 days and concentrated in vacuo. Purification by silica gel chromatography (Waters Prep-500A) using ethyl acetate/hexane (80:20) gave 5.51 g (85%) of 5-butyl-3-propyl-1H-1,2,4- triazole as a colorless solid: mp 48.5-50.0°C; NMR (CDCI₃) δ 0.92 (t, J = 7 Hz, 3H), 0.97 (t, J = 7 Hz, 3H), 1.31-1.46 (m, 2H), 1.66-1.84 (m, 4H), 2.72 (t, J = 7 Hz, 2H), 2.75 (t, J = 7 Hz, 2H); MS (FAB) m/e (rel intensity) 168 (100), 166 (4), 152 (3), 138 (3), 125 (3); HRMS . Calcd for M+H: 168.1501.

Found: 168.1534.

Step 2: Preparation of 5-[4'-[(5-bntyl-3-propyl-1H-1,2,4- triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole. Under a static nitrogen atmosphere, 2.0 g (12 mmol) of solid 5-butyl-3-propyl-1H-1,2,4-triazole was added in small portions to 12 mmol of sodium hydride in 50 ml of

dimethylformamide (DMF); stirring was continued until hydrogen evolution had ceased. The anion solution was cooled to -10°C (ice/methanol) and treated with a solution of 6.7 g (12 mmol) of N-triphenylmethyl-5-[2-(4'-bromo-methylbiphen-2- yl)]tetrazole (from Step 1 of Example 3) in 20 ml of dry DMF. The reaction was allowed to warm to ambient temperature and stir overnight. Methanol (10 ml) was added to destroy any unreacted sodium hydride and the DMF was removed in vacuo.

The residue was dissolved in ethyl acetate, washed with water, and dried (MgSO₄). Silica gel chromatography using 15% ethyl acetate/toluene produced 5.96 g (77%) of a mixture of the two isomers which was dissolved in 40 ml of 10% water in acetic acid and stirred at ambient temperture ovenight. The solvent was removed in vacuo and the residue dissolved in 50%

acetonitrile/water. Purification of 1 g sample of the isomeric product mixture by reverse phase chromatography

(Waters Delta Prep-3000) using 25% acetonitrile/water (0.05% TFA) for 50 minutes followed by 28% acetonitrile/water (0.05% TFA) provided two isomers. The faster moving isomer compound was dissolved in the minimal amount of acetonitrile and diluted with water. The pH was adjusted to 8 with 1N NaOH, the acetonitrile removed in vacuo, the pH readjusted to 5 with 1N HCl, and the product extracted with ethyl acetate. The solvent was removed in vacuo and the product lyophylized from acetonitrile/water providing 175 mg (18%) of the 5-butyl-3- propyl isomer as a colorless solid: NMR (CDCI₃) δ d 0.78 (t,

J = 7 Hz, 3H), 0.82 (t, J = 7 Hz, 3H), 1.20-1.33 (m, 2H), 1.41-1.57 (m, 4H), 2.21 (t, J = 7 Hz, 2H), 2.41 (t, J = 7 Hz, 2H), 5.16 (s, 2H), 6.82-6.89 (m, 2H), 7.05-7.11 (m, 2H), 7.42.7.48 (m, 1H), 7.52-7.67 (m, 2H), 7.88-7.94 (m, 1H); MS (FAB) m/e (rel intensity) 402 (50), 207 (100), 192 (25), 168 (39), 152 (8), 125 (5); HRMS. Calcd for M+H: 402.2406. Found: 402.2424.

Example 15

5-[4'-[(3-butyl-5-propyl-1H-1,2,4-triazol-1-yl)methyl]-[1,1'- biphenyl]-2-yl]-1H-tetrazole

The slower moving isomer for Example 14 was isolated in an identical manner and provided 108 mg (11%) of the 3-butyl-5-propyl isomer as a colorless solid: NMR (CDCI₃) δ d 0.86 (t, J = 7 Hz, 3H), 0.89 (t, J = 7 Hz, 3H), 1.19-1.32 (m, 2H), 1.48-1.69 (m, 4H), 2.41 (t, J = 7 Hz, 2H), 2.52 (t, J = 7 Hz, 2H), 5.22 (s, 2H), 6.95-7.02 (m, 2H), 7.11-7.16 (m, 2H), 7.42-7.48 (m, 1H), 7.53-7.68 (m, 2H), 7.97-8.02 (m, 1H); MS (FAB) m/e (rel intensity) 402 (50), 259 (10), 235 (5), 225 (10), 207 (100), 192 (38); HRMS. Calcd for M+H: 402.2406. Found: 402.2435.

Example 16

5-[4'-[(3-butyl-5-isoppntyl-1H-1,2,4-triazol-1-yl)methyl]- [1,1'-biphenyl]-2-yl]-1H-tetrazole

Step 1: Preparation of 3-butyl-5-isopentyl-1H-1,2,4-triazole.

Under nitrogen, a solution of 53.8 g (1.68 mol) of anhydrous hydrazine in 300 mL of methanol was cooled to 0°C and treated with 186 g (1.4 mol) of methyl 4-methylvalerate. The reaction was allowed to warm to ambient temperature and stir overnight prior to stirring at reflux for 4 h. The reaction was concentrated in vacuo giving 166 g (93%) of 4- methyIvaleric acid hydrazide as a colorless solid: 49-51°C; NMR (CDCI₃) δ 0.89 (d, J = 1 Hz, 6H), 1.48-1.64 (m, 3H), 2.15 (t, J = 7 Hz, 2H), 3.91 (br s, 2H), 6.94 (br s, 1H). A 7.86 g (60 mmol) sample of the hydrazide was dissolved in 50 mL of methanol and treated with 7.8 g (60 mmol) of ethyl

iminovalerate under nitrogen. The reaction was stirred at reflux overnight and concentrated in vacuo. Purification by silica gel chromatography (Waters Prep-500A) using ethyl acetate/hexane (40:60) gave 9.6 g (82%) of 3-butyl-5- isopentyl-1H-1,2,4-triazole as a colorless solid which melts close to ambient temperature: NMR (CDCI₃) δ 0.81-0.90 (m, 9H), 1.25-1.40 (m, 2H), 1.47-1.74 (m, 5H), 2.70 (t, J = 7 Hz, 4H); MS (FAB) m/e (rel intensity) 196 (100); HRMS. Calcd for M+H: 196.1814. Found: 196.1832.

Step 2: Preparation of 5- [4 ' - [ (3-butyl-5-isopentyl-1H-1, 2 , 4- triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole.

Under a static nitrogen atmosphere, 2.0 g (10.3 mmol) of solid 3-butyl-5-isopentyl-1H-1,2,4-triazole was added in small portions to 11 mmol of sodium hydride in 50 ml of dimethylformamide (DMF); stirring was continued until hydrogen evolution had ceased. The anion solution was cooled to -10°C (ice/methanol) and treated with a solution of 5.7 g (10.2 mmol) of N-triphenylmethyl-5-[2-(4'-bromo-methylbiphen-2- yl)]tetrazole (from Step 1 of Example 3) in 20 ml of dry DMF. The reaction was allowed to warm to ambient temperature and stir overnight. Methanol (10 ml) was added to destroy any unreacted sodium hydride and the DMF was removed in vacuo. The residue was dissolved in ethyl acetate, washed with water, and dried (MgSO₄). The crude material (8.0 g) was deprotected in 50 ml of 10% water in acetic acid at ambient temperature overnight. Purification of 1.5 g sample by reverse phase chromatography (Waters Delta Prep-3000) using isocratic 30% acetonitrile/water (0.05% TFA) provided two isomers. The faster moving isomer compound was dissolved in the minimal amount of acetonitrile and diluted with water. The pH was adjusted to 9 with 1N NaOH, the acetonitrile removed in vacuo, the pH readjusted to 5 with 1N HCl, and the product extracted with ethyl acetate. The solvent was removed in vacuo and the product lyophylized from acetonitrile/water providing 33.1 mg (2.2%) of the 3-butyl-5-isopentyl isomer as a colorless solid: NMR (CDCI₃) δ d 0.85 (t, J = 7 Hz, 9H), 1.18-1.31 (m,

2H), 1.43-1.59 (m, 4H), 2.38 (t, J = 7 Hz, 2H), 2.54 (t, J = 7 Hz, 2H), 5.19 (s, 2H), 6.93-7.00 (m, 2H), 7.09-7.16 (m, 2H), 7.41-7.47 (m, 1H), 7.52-7.67 (m, 2H), 7.96-8.01 (m, 1H); MS (FAB) m/e (rel intensity) 430 (52), 387 (7), 207 (100), 196 (43), 178 (23), 165 (16), 152 (13); HRMS. Calcd for M+H: 430.2719. Found: 430.2772.

Example 17

5-[4'-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1-yl]methyl)- [1,1'-biphenyl]-2-yl]-1H-tetrazole

The slower moving isomer from Example 16 was isolated in an identical manner and provided 36.5 mg (2.43%) of the 5-butyl-isopentyl isomer as a colorless solid: NMR (CDCl₃) δ d 0.79-0.88 (m, 9H), 1.22-1.36 (m, 2H), 1.38-1.61 (m, 5H), 5.18 (s, 2H), 6.88-6.96 (m, 2H), 7.08-7.14 (m, 2H), 7.41-7.47 (m, 1H), 7.53-7.67 (m, 2H), 7.94-7.99 (m, 1H): MS (FAB) m/e (rel intensity) 430 (38), 387 (8), 207 (100), 196 (37), 178 (27), 165 (15), 152 (12); HRMS. Calcd for M+H: 430.2719. Found: 430.2760.

General Procedure A: The Reaction of Triazoles with

Alkylating Reagents.

Under a static nitrogen atmosphere, 10-50 mmol of the 1H-1,2,4-triazole was added in small portions to

10-50 mmol of sodium hydride in 50 ml of dimethylformamide (DMF); stirring was continued until hydrogen evolution had ceased. The anion solution was cooled to -10 °C

(ice/methanol) and treated with a solution of 10-50 mmol of the alkyling reagent from either step 1 of Example 1 or step 1 of Example 3 in 20 ml of dry DMF. The reaction was allowed to warm to ambient temperature and stir overnight. Methanol (10 ml) was added to destroy any unreacted sodium hydride and the DMF was removed in vacuo. The residue was dissolved in ethyl acetate, washed with water, and dried (MgSO₄). Silica gel chromatography (Waters Prep-500A) using ethyl acetate/hexane gave the pure coupled material as either a mixture of

regioisomers or isomerically pure, depending upon the

individual triazole coupled. A detailed procedure for the hydrolysis, purification, and isolation of the individual regioisomers when the alkylating reagent used was the reagent prepared in step 1 of Example 1 may be found in step 2 of Example 6. Likewise, a detailed procedure for the

deprotection, purification, and isolation of the individual regioisomers, when the alkylating reagent used was the reagent prepared in step 1 of Example 3, may be found in Example 14.

Example 18

4'-[(5-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2- carboxylic acid

Following General Procedure A, 5.0 g (39.9 mmol) of

5-butyl-1H-1,2,4-triazole was coupled with 12.2 g (39.9 mmol) of the alkylating reagent prepared in step 1 of Example 1 to give 3.1 g (22%) of a faster moving isomer: NMR (CDCI₃) δ 0.90 (t, J = 8 Hz, 3H), 1.29-1.45 (m, 2H), 1.63-1.76 (m, 2H), 2.71 (t, J = 8 Hz, 2H), 3.62 (s, 3H), 5.34 (s, 2H), 7.14-7.20 (m, 2H), 7.24-7.33 (m, 3H), 7.40 (dt, J = 8 and 2 Hz, 1H), 7.50 (dt, J = 8 and 2 Hz, 1H), 7.82 (dd, J = 8 and 2 Hz, 1H), 7.85 (s, 1H) and 3.7 g (26%) of a slower moving isomer: NMR (CDCI₃) δ 0.92 (t, J = 8 Hz, 3H), 1.31-1.46 (m, 2H), 1.66- 1.79 (m, 2H), 2.73 (t, J = 8 Hz, 2H), 3.62 (s, 3H), 5.28 (s, 2H), 7.21-7.34 (m, 5H), 7.39 (dt, J = 8 and 2 Hz, 1H), 7.50 (dt, J = 8 and 2 Hz, 1H), 7.83 (dd, J = 8 and 2 Hz, 1H), 7.94 (s, 1H). The faster moving isomer was hydrolyzed to give 2.75 g (92%) of 4'-[(5-butyl-1H-1,2,4-triazol-1-yl)methyl]-[1,1'- biphenyl]-2-carboxylie acid as a colorless solid: NMR (DMSO- d₆) 8 0.85 (t, J = 8 Hz, 3H), 1.23-1.38 (m, 2H), 1.52-1.65 (m, 2H), 2.76 (t, J = 7 Hz, 2H), 5.41 (s, 2H), 7.16-7.24 (m, H), 7.27-7.37 (m, 3H), 7.44 (dt, J = 8 and 2 Hz, 1H), 7.56 (dt, J. = 8 and 2 Hz, 1H), 7.72 (dd, J = 8 and 2 Hz, 1H), 7.86 (s, 1H); MS (FAB) m/e (rel intensity) 336 (100), 307 (7), 289 (7), 224 (8), 211 (100), 193 (9).

Example 19

4'-[(3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2- carboxylic acid

The slower moving isomer from Example 18 was hydrolyzed to give 2.3 g (67%) of 4'-[(3-butyl-1H-1,2,4- triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylic acid as a colorless solid: NMR (DMSO-d₆) δ 0.87 (t, J = 8 Hz, 3H), 1.23-1.38 (m, 2H), 1.54-1.67 (m, 2H), 2.58 (t, J = 8 Hz, 2H), 5.36 (s, 2H), 7.23-7.38 (m, 5H), 7.44 (dt, J = 8 and 2 Hz, 1H), 7.56 (dt, J = 8 and 2 Hz, 1H), 7.72 (dd, J = 8 and 2 Hz, 1H), 8.51 (s, 1H) ; MS (FAB) m/e (rel intensity) 336 (85), 211 (100), 165 (24), 126 (52).

Example 20

4'-[(3,5-di-perfluoropropyl-1H-1, 2 ,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid

Following General Procedure A, 11.0 g (27.2 mmol) of 3,5-bis(perfluoropropyl)-1H-1,2,4-triazole was coupled with 8.30 g (27.2 mmol) of the alkylating reagent prepared in step 1 of Example 1 to give 8.7 g (51%) of a colorless oil: NMR (CDCl₃) 83.62 (s, 3H), 5.63 (s, 2H), 7.25-7.37 (m, 5H), 7.44 (dt, J = 8 and 2 Hz, 1H), 7.54 (dt, J = 8 and 2 Hz, 1H), 7.87 (dd, J = 8 and 2 Hz, 1H). A 8.5 g (13.5 mmol) sample of this material was hydrolyzed to give 6.91 g (81%) of 4'-[(3,5- bis (1,1,2,2,3,3,3-heptafluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxlic acid as a colorless solid: NMR (CDCI₃) δ 5.62 (s, 2H), 7.27-7.37 (m, 5H), 7.44 (dt, J = 8 and 2 Hz, 1H), 7.58 (dt, J = 8 and 2 Hz, 1H), 7.98 (dd, J = 8 and 2 Hz, 1H); MS (TSP) M+NH₄ (rel intensity) 633

(100), 211 (12); HRMS. Calc'd for M+Li: 622.0788. Found:

622.0759. Example 21

5-[4'-[(3-phenyl-5-butyl-1H-1,2,4-triazol-1-yl)methyl] (1,1'- biphenyl)-2-yl]-1H-tetrazole

Following General Procedure A, 2.0 g (9.9 mmol) of 5-butyl-3-phenyl-1H-1,2,4 triazole was coupled with 5.5 g (9.9 mmol) of the alkylating reagent prepared in step 1 of Example 3 to give 5.2 g (77%) of a faster moving isomer: NMR (CDCI₃) δ0.90 (t, J = 8 Hz), 1.30-1.44 (m, 2H), 1.63-1.77 (m, 2H), 2.67 (t, J = 8 Hz, 2H), 5.24 (s, 2H), 6.88-7.01 (m, 8H), 7.08- 7.53 (m, 17H), 7.95 (dd, J = 8 and 2 Hz,1H) , 8.12 (dd, J = 8 and 2 Hz, 2H) and 420 mg (6.3%) of a slower moving isomer: NMR (CDCI₃) δ 0.96 (t, J = 8 Hz, 3H), 1.38-1.52 (m, 2H), 1.75- 1.89 (m, 2H), 2.84 (t, J = 8 Hz, 2H), 5.27 (s, 2H), 6.88-6.97 (m, 8H), 7.13 (d, J = 8 Hz, 2H), 7.17-7.54 (m, 15H), 7.57 (d, J = 8 Hz, 2H), 7.93 (dd, J = 8 and 2 Hz, 1H) . A 4.8 g (7.1 mmol) sample of the faster moving isomer was deportected to give 1.64 g (53%) of 5-[4'-[(3-phenyl-5-butyl-1H-1,2,4- triazol-1-yl)methyl] (1,1'-biphenyl-2-yl]-1H-tetrazole as a colorless solid: mp 113 °C (dec); NMR (CDCI₃) δ 0.87 (t, J = 8 Hz, 3H), 1.24-1.39 (m, 2H), 1.55-1.69 (m, 2H), 2.60 (t, J = 8 2Hz, 5.19 (s, 2H), 7.04 (d, J = 8 Hz, 2H), 7.11 (d, J = 8 Hz, 2H), 7.27-7.39 (m, 4H), 7.47-7.60 (m, 2H), 7.87 (dd , J = 8 and 2 Hz, 2H), 7.95 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 436 (100), 393 (8), 207 (60), 192 (20), 178 (13), 165 (8); HRMS. Calc'd for M+H: 436.2249. Found:

436.2240.

Example 22

5-[4'-[(3-butyl-5-phenyl-1H-1,2,4-triazol-1-yl)methyl](1,1'- biphenyl)-2-yl]-1H-tetrazole

The slower moving isomer from Example 21 was deprotected to give 251 mg (60%) of 5-[41-[(3-butyl-5-phenyl- 1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H- tetrazole as a colorless solid: mp 205 °C (dec); NMR (CDCI₃) δ 0.88 (t, J = 8 Hz, 3H), 1.23-1.38 (m, 2H), 1.55-1.68 (m, 2H), 2.52 (t, J = 8 Hz, 2H), 5.32 (s, 2H), 6.99 (d, J = 8 Hz, 2H), 7.08 (d, J = 8 Hz, 2H), 7.31-7.61 (m, 8H), 7.90 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 436 (100), 393 (9), 374 (7), 277 (7), 247 (15), 207 (45); HRMS. Calc'd for M+H: 436.2249. Found: 436.2201.

Example 23

5-[4'-[[3-butyl-5-(dimethoxymethy!)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole

Following General Procedure A, 2.0 g (10 mmol) of

5-butyl-3-(dimethoxymethyl)-1H-1,2,4-triazole was coupled with 5.6 g (10 mmol) of the alkylating regagent prepared in step 1 of Example 3 to give 1.65 g (24%) of a faster moving isomer: NMR (CDCI₃) δ 0.92 (t, J = 8 Hz, 3H), 1.31-1.45 (m, 2H), 1.66- 1.78 (m, 2H), 2.69 (t, J = 8 Hz, 2H), 3.33 (s, 6H), 5.30 (s,

2H), 5.42 (s, 1H), 6.90-6.96 (m, 5H), 7.02-7.12 (m, 4H), 7.21- 7.38 (m, 11H), 7.41-7.52 (m, 2H), 7.86-7.92 (m, 1H) and 3.65 g (54.0%) of a slower moving isomer. NMR (CDCI₃) 8 0.85 (t, J = 8 Hz, 3H), 1.22-1.36 (m, 2H), 1.57-1.70 (m, 2H), 2.59 (t, J = 8 Hz, 2H), 3.45 (s, 6H), 5.20 (s, 2H), 5.55 (s, 1H), 6.89-6.97 (m, 5H), 7.08-7.19 (m, 4H), 7.21-7.37 (m, 11H), 7.41-7.52 (m, 2H), 7.90-7.95 (m, 1H). The faster moving isomer was

deprotected to give 737 mg (70%) of 5-[4'-[[3-butyl-5- (dimethoxymethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole as a colorless solid: mp 152.5- 153.5 °C; NMR (CDCI₃) 8 0.87 (t, J = 8 Hz, 3H), 1.20-1.30 (m, 2H), 1.53-1.65 (m, 2H), 2.46 (t, J = 8 Hz, 2H), 3.30 (s, 6H), 5.37 (s, 2H), 5.40 (s, 1H), 7.05-8.05 (m, 4H), 7.45 (dd, J = 8 and 2 Hz, 1H), 7.51-7.65 (m, 2H), 8.02 (d, J = 8 Hz, 1H); MS (FAB) m/e (rel intensity) 434 (65), 402 (40), 370 (11), 342 (46), 249 (85), 235 (18), 207 (100), 192 (89), 168 (70); HRMS. Calc'd for M+H: 434.2304. Found: 434.2332.

Example 24

5- [4 ' - [ (5-butyl-3-dimethoxymethyl-1H-1 , 2 , 4-triazol -1 - yl)methyl](1,1'-biphenyl-2-yl]-1H-tetrazole

A 3.65 g (5.4 mmol) sample of the slower moving isomer from Example 23 was deprotected to give 108 mg of colorless 5-[4'-[[5-butyl-3-(dimethoxymethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole after lyophilization: NMR (CDCI₃) δ 0.86 (t, J = 8 Hz, 3H), 1.24- 1.39 (m, 2H), 1.56-1.70 (m, 2H), 2.66 (t, J = 8 Hz, 2H), 3.30 (s, 6H), 5.23 (s, 2H), 5.35 (s, 1H), 7.02 (d, J = 8 Hz, 2H), 7.10 (d, J = 8 Hz, 2H), 7.40 (dd, J = 8 and 2 Hz, 1H), 7.51 (dt, J = 8 and 2 Hz, 1H), 7.59 (dt, J = 8 and 2 Hz, 1H), 7.89 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 434 (10), 402 (40), 249 (100), 207 (36), 192 (54), 168 (12); HRMS, Calc'd for M+H: 434.2304. Found: 434.2271. Example 25

5-[4'-[(3-butyl-5-phenylethyl-1H-1,2,4-triazol-1- yl)methyl] (1,1'-biphenyl-2-yl]-1H-tetrazole

Following General Procedure A, 2.3 g (10 mmol) of

3-butyl-5-phenethyl-1H-1,2,4-triazole was coupled with 6.6 g (10 mmol) of the alkylating reagent prepared in step 1 of Example 3 to give 2.67 g (38%) of a faster moving isomer: NMR (CDCI₃) 80.97 (t, J = 8 Hz, 3H), 1.36-1.50 (m, 2H), 1.71-1.84 (m, 2H), 2.73 (t, J = 8 Hz, 2H), 2.78-2.88 (m, 2H), 2.92-3.01 (m, 2H), 4.82 (s, 2H), 6.80-6.95 (m, 9H), 7.02-7.11 (m, 5H), 7.16-7.36 (m, 11H), 7.41-7.52 (m, 2H), 7.91-7.97 (m,1H) and 2.94 g (42%) of a slower moving isomer: NMR (CDCI₃) δ 0.88 (t, J = 8 Hz, 3H), 1.23-1.38 (m, 2H), 1.57-1.70 (m, 2H), 2.58 (t, J = 8 Hz, 2H), 2.97-3.13 (m, 4H), 5.11 (s, 2H), 6.86 (d, J = 8 Hz, 2H), 6.89-6.96 (m, 6H), 7.10 (d, J = 8 Hz, 2H), 7.14- 7.39 (m, 15H), 7.42-7.54 (m, 2H), 7.93 (dd, J = 8 and 2 Hz, 1H) . The faster moving isomer was deprotected to give 1.6 g (88%) of 5-[4'-[[3-butyl-5-(2-phenylethyl)-1H-1,2,4-triazol-1- yl)methyl] [1,1'-biphenyl-2-yl]-1H-tetrazole a colorless solid: NMR (CDCI₃) δ 0.86 (t, J = 8 Hz, 3H), 1.17-1.31 (m, 2H), 1.48- 1.51 (m, 2H), 2.42 (t, J = 8 Hz, 2H), 2.76 (t, J = 8 Hz, 2H), 2.92 (t, J = 8 Hz, 2H), 4.80 (s, 2H), 6.83 (d, J. = 8, 2H), 6.92-7.00 (m, 2H), 7.08 (d, J = 8 Hz, 2H), 7.17-7.32 (m, 3H), 7.42 (dd, J = 8 and 2 Hz, 1H), 7.51-7.65 (m, 2H), 7.96 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 464 (37), 230 (25), 207 (100), 178 (17); HRMS. Calc'd for M+H: 464.2563. Found: 464.2532.

Example 26

5-[4' [(5-butyl-3-phenylethyl-1H-1,2,4-triazol-1- yl)methyl] (1,1'-biphenyl-2-yl]-1H-tetrazole

The slower moving isomer from Example 25 was deprotected to give 1.5 g (77%) of 5-[4'-[[5-buty1-3-(2- phenylethyl)-1H-1,2,4-triazol-1-yl]methyl] [1,1'-biphenyl-2- yl]-1H-tetrazole as a colorless solid: mp 156.0-157.2°C; NMR (CDCI₃) δ 0.84 (t, J = 8 Hz, 3H), 1.19-1.34 (m, 2H), 1.47-1.61 (m, 2H), 2.52 (t, J = 8 Hz, 2H), 2.66-2.77 (m, 2H), 2.85- 2.95(m, 2H), 5.15 (s, 2H), 6.88 (d, J = 8 Hz, 2H), 7.05-

7.11 (m, 4H), 7.12-7.28 (m, 5H), 7.41 (dd, J = 8 and 2 Hz, 1H) , 7.50 (dt, J = 8 and 2 Hz, 1H) , 7.59 (dt, J = 8 and 2 Hz, 1H) , 7.92 (dd, J = 8 and 2 Hz, 1H) ; MS (FAB) m/e (rel intensity) 464 (83), 230 (22), 207 (92); HRMS. Calc'd for M+H:

464.2563. Found: 464.2560. Example 27

5-butyl-1-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl] - 1H-1, 2 ,4-triazole-3-methanamine

A 1.5 g (3.5 mmol) sample of the diacetal compound of Example 24 was dissolved in 40 ml of ethanol and 40 ml of 3N HCl. The reaction was stirred at ambient temperature overnight and then at reflux for 50 min, the course of the reaction was followed by analytical reverse phase HPLC. The solvent was removed in vacuo. The residue was dissolved in ethyl acetate and extracted with saturated sodium bicarbonate solution until the water layer stayed basic. The water layer was acidified and extracted with an ethyl acetate/methylene chloride mixture. The organic layer was dried (MgSO₄) and removed in vacuo yielding 0.96 g of crude aldehyde: NMR (CDCl₃) δ 0.66 (t, J = 8 Hz, 3H), 1.06-1.20 (m, 2H), 1.42-1.54

(m, 2H), 2.53 (t, J = 8 Hz, 2H), 5.17 (s, 2H), 6.80-6.95 (m,

4H), 7.17-7.38 (m, 3H), 7.42-7.48 (m, 1H), 9.70 (s, 1H).

Under a static nitrogen atmosphere, 0.91 g (2.3 mmol) of this material was dissolved in 10 ml of methanol and 1.77 g (23 mmol) ammonium acetate was added followed by 0.10 g (1.61 mmol) sodium cyanoborate. After stirring at ambient temperature for 3 days, analytical reverse phase HPLC

indicated that the reaction was complete. Purification was accomplished by reverse phase chromatography (Waters Delta Prep 3000) using 25% acetonitrile/water (0.05% TFA). The solvent from the pure fractions was removed in vacuo and the residue dissolved in methanol and 3N HCl. After stirring for 30 min, the solvent was removed in vacuo and the residue lyophilized from acetonitrile/water providing 100 mg (10%) of 5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]- 1H-1,2,4-triazole-3-methanamine as the colorless hydrochloride salt: NMR (DMSO-d₆) δ 0.85 (t, J = 8 Hz, 3H), 1.22-1.38 (m, 2H), 1.51-1.64 (m, 2H), 2.77 (t, J = 8 Hz, 2H), 4.00-4.09 (m, 2H), 5.40 (s, 2H), 7.01-7.25 (m, 4H), 7.39 (s, 1H), 7.48-7.73 (m, 3H); MS (FAB) m/e (rel intensity) 389 (100), 207 (65), 192 (17); HRMS. Calc'd for M+H: 389.2202. Found: 389.2170.

Example 28

5-[4'-[ (3-butyl-5-octyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole Following General Procedure A, 2.0 g (8.4 mmol) of

3-butyl-5-octyl-1H-1,2,4-triazole was coupled with 5.5 g (8.4 mmol) of the alkylating reagent prepared in step 1 of Example 3. Silica gel chromatography (Waters Prep 500-A) using 25% ethyl acetate/hexane produced 4.5 g (75.4%) of a mixture of the two isomers which was dissolved in 40 ml of 10%

water/acetic acid and stirred at ambient temperature

overnight. The solvent was removed in vacuo. Purification of a sample of the isomeric product mix by reverse phase

chromatography (Waters Delta Prep-3000) using 45%

acetonitrile/water (0.05% TFA) for 30 minutes followed by 50% acetonitrile/water (0.05% TFA) provided two isomers. The faster moving isomer compound was dissolved in dilute base, the water was acidified (pH 4-5) with IN HCl, and the product extracted with ethyl acetate. The ethyl acetate was dried (MgSO₄) and removed in vacuo yielding a solid which was recrystallized from acetonitrile providing 92 mg of 5-[4'-[(3- butyl-5-octyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2- yl]-1H-tetrazole as a colorless solid: mp 136.5-138.0°C; NMR

(CDCI₃) δ 0.82 (t, J = 8 Hz, 3H), 0.86 (t, J = 8 Hz, 3H), 1.11-1.33 (m, 12H), 1.40-1.60 (m, 4H), 2.27 (t, J = 8 Hz, 2H), 2.44 (t, J = 8 Hz, 2H), 5.16 (s, 2H), 6.87 (d, J = 8 Hz, 2H), 7.07 (d, J = 8 Hz, 2H), 7.44 (dd, J = 8 and 2 Hz, 1H), 7.50- 7.66 (m, 2H), 7.90 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e

(rel intensity) 472 (5), 207 (7); HRMS. Calc'd for M+H:

472.3189. Found: 472.3180.

Example 29

5-[4'-[(5-hutyl-3-octyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole

The slower moving isomer from Example 28 was isolated in an identical manner and the product lyophilized from acetonitrile/water providing 53 mg of 5-[4'-[(5-butyl-3- octyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H- tetrazole as a colorless solid: NMR (CDCI₃) δ 0.83 (t, J = 8

Hz, 3H), 0.86 (t, J = 8 Hz, 3H) 1.12-1.37 (m, 12H), 1.46-1.63

(m, 4H), 2.35 (t, J = 8 Hz, 2H) 2.51 (t, J = 8 Hz, 2H), 5.19

(s, 2H), 6.92 (d, J = 8 Hz, 2H) 7.09 (d, J = 8 Hz, 2H), 7.40-

7.48 (m, 1H), 7.51-7.66 (m, 2H) 7.91 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 472 (6), 207 (8); HRMS

Calc'd for M+H: 472.3189. Found: 472.3230.

Example 30

1-[[5-butyl-1-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4- ylmethyl]-1H-1,2,4-triazol-3-yl]methyl]-1-butanone Under a static nitrogen atmosphare, 30.0 g (150 mmol) 5-butyl-3-dimethoxy-1H-1,2,4-triazole (from Step 1 of Example 23 was added in small portions to 165 mmol of sodium hydride in 300 ml anhydrous THF; stirring was continued for 1 h. The anion solution was cooled to -10 °C (methanol/ice) and treated with Sem-Cl dropwise. The reaction was allowed to warm to ambient temperature and stir overnight. The solvent was removed in vacuo. The residue was dissolved in methylene chloride, washed with water, dried (MgSO₄), and the solvent removed again in vacuo. Silica gel chromatography using 20% ethyl acetate/hexane followed by ethyl acetate provided 13.6 g of the faster movfing isomer as an oil: NMR (CDCI₃) δ -0.07 (s, 9H), 0.82-0.92 (m, 5H), 1.26-1.40 (m, 2H), 1.62-1.74 (m, 2H), 2.67 (t, J = 8 Hz, 2H), 3.38 (s, 6H), 3.53-3.62 (m, 2H), 5.47 (s, 2H), 5.55 (s, 1H). Under a static nitrogen

atmosphere, 12.6 g (38.2 mmol) of the faster moving Semprotected triazole isomer from above was dissolved in 630 ml of anhydrous THF, cooled to -78 °C, and 45.8 mmol of sec-butyl lithium was added dropwise. The solution was stirred for 1 h and then the anion was quenched with 4.5 ml (45.8 mmol) of n- propyl iodide. The solution was stirred at -78 °C for 5 h and then allowed to warm to ambient temperature overnight. The solvent was removed in vacuo. The residue was dissolved in methylene chloride, washed with water, dried (MgSO₄) and the solvent removed providing 12.4 g of crude

Sem-protected 5-butyl-3-(1,1-dimethoxybutane)-1H-1,2,4- triazole: NMR (CDCI₃) δ -0.04 (s, 9H), 0.75-0.93 (m, 8H),

0.98-1.11 (m, 2H), 1.25-1.41 (m, 2H), 1.62-1.74 (m, 2H), 1.99- 2.08 (m, 2H), 2.68 (t, J = 8 Hz, 2H), 3.20 (s, 6H), 3.62 (t, J = 8 Hz, 2H), 5.56 (s, 2H). A 1.0 g (2.7 mmol) sample of the crude dimethoxybutyl compound was dissolved in 5 ml of ethanol and 5 ml of 3M HCl and stirred at reflux for 2.5 h. The solvent was removed in vacuo providing 560 mg of the crude HCl salt of 5-butyl-3-(1-butanone)-1H-1,2,4-triazole: NMR (DMSO- d₆) 8 0.83-0.94 (m, 6H), 1.21-1.36 (m, 2H), 1.55-1.75 (m, 4H),

2.83 (t, J = 8 Hz, 2H), 2.97 (t, J = 8 Hz, 2H). The crude HCl salt of the triazole was dissolved in 20 ml of fresh methanol,

3A molecular sieves were added, and the mixture stirred at reflux under nitrogen overnight . The solution was filtered through celite and the solvent removed in vacuo. The residue was dissolved in ethyl acetate and washed with saturated sodium bicarbonate solution. The solvent was dried (MgSO₄) and removed in vacuo providing 390 mg of crude 5-butyl-3-(1,1- dimethoxybutyl)-1H-1,2,4-triazole: NMR (CDCI₃) 80.90 (t, J = 8 Hz, 3H), 0.99 (t, J = 8 Hz, 3H), 1.29-1.46 (m, 2H), 1.66-

1.84 (m, 4H), 2.80 (t, J = 8 Hz, 2H), 3.06 (t, J = 8 Hz, 2H), 3.18 (s, 6H). Under a static nitrogen atmosphere, 380 mg (1.6 mmol) of this material in 5 ml of anhydrous dimethylformamide (DMF) was added to 1.9 mmol sodium hydride in 5 ml of DMF; stirring was continued for 1 h. The anion solution was cooled to 0 °C and 890 mg (1.6 mmol) of the alkylating reagent prepared in from step 1 of Example 3 was added as a solid. The reaction was allowed to warm to ambient temperature and stir overnight. Methanol (1 ml) was added to destroy any unreacted sodium hydride and the DMF was removed in vacuo. The residue was dissolved in ethyl acetate, washed with water, and dried (MgSO₄). The solvent was removed in vacuo providing

1.2 g of crude material which was dissolved in 10 ml ethanol and 10 ml 3N HCl and stirred at reflux for 2 h. The solvent was removed in vacuo. Purification by reverse phase

chromatography (Water Delta Prep 3000) using isocratic 37% acetonitrile/water (0.05% TFA) for 40 minutes followed by 50% acetonitrile/water (0.05% TFA) provided the TFA salt. The salt was dissolved in basic water (pH 9-10), the water was acidified to pH 4 with 3N HCl, and the product extracted with ethyl acetate. The ethyl acetate was dried (MgSO₄) and removed in vacuo yielding a solid which was recrystallized from acetonitrile providing 146 mg (21%) of 1-[[5-butyl-1-[2'- (1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-1H-1,2,4- triazol-3-yl]methyl]-1-butanone mp 150.5-152.5°C; NMR (CDCI₃) δ 0.85 (t, J = 8 Hz, 3H), 0.96 (t, J = 8 Hz, 3H), 1.23-1.39

(m, 2H), 1.54-1.77 (m, 4H), 2.67 (t, J = 8 Hz, 2H), 2.97 (t, J = 8 Hz, 2H), 5.28 (s, 2H), 7.02 (d, J = 8 Hz, 2H), 7.10 (d, J = 8 Hz, 2H) , 7 .37 (d, J = 8 Hz, 1H) , 7 .43-7 . 62 (m, 2H) , 7. 86 (d, J = 8 Hz, 1H); MS (FAB) m/e (rel intensity) 430 (6), 207 (12); HRMS. Calc'd for M+H: 430.2355. Found: 430.2404.

Example 31

N-[[5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biohenyl]-4- ylmethyl]-1H-1,2,4-triazol-3-yl]methyl]acetamide

A 92.9 mg (0.22 mmol) sample of 5-[4'-[(5-butyl-3- methylamine-1H-1,2,4-triazol-1-yl)methyl]-(1,1'-biphenyl-2- yl]-1H-tetrazole hydrochloride from Example 27 was dissolved in 5 ml of water and the pH was adjusted to 9 with 1M

potassium carbonate (K₂CO₃) . The solution was cooled to 0 °C and 0.22 ml of 1M K₂CO₃ was added followed by 0.22 mmol of acetic anhydride. Additional K₂CO₃ was added as needed to maintain a pH of 9. At 30 min intervals, this addition was repeated until analytical reverse phase chromatography showed that all starting material has been consumed. The pH was adjusted to three with 1N HCl and extracted with ethyl acetate. The ethyl acetate was removed in vacuo and the product lyophilized from acetonitrile/water providing 36 mg (39%) of N-[[5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]- 4-ylmethyl]-1H-1,2,4-triazol-3-yl]methyl]acetamide as a colorless solid: NMR (CDCI₃) δ 0.80 (t, J = 8 Hz, 3H), 1.18- 1.37 (m, 2H), 1.47-1.64 (m, 2H), 1.94 (s, 3H), 2.63 (t, J = 8 Hz, 2H), 4.22 (d, J = 8 Hz, 2H), 5.18 (s, 2H), 6.95 (d, J = 8 Hz, 2H), 7.04-7.21 (m, 2H), 7.44 (d, J = 8 Hz, 1H), 7.50-7.66 (m, 2H), 7.90 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 431 (42), 207 (100); HRMS. Calc'd for M+H:

431.2308. Found: 431.2271.

Example 32

5-[4'-[(5-butyl-3-methyl-1H-1,2,4-triazol-1-yl)methyl]-[1,1'- biphenyl]-2-yl]-1H-tetrazole

Following General Procedure A, 700 mg (5.0 mmol) of 5-butyl-3-methyl-1H-1,2, 4-triazole was coupled with 2.8 g (5.0 mmol) of the aklylating reagent prepared in step 1 of Example 3. Silica gel chromatography using ethyl acetate/toluene

(35:65) produced 2.75 g (90%) of a mixture of the two isomers which was dissolved in 30 ml 10% water/acetic acid and sitrred at ambient temperature for 3 days. The solvent was removed in vacuo and the residue dissolved in dilute base, washed with toleune, acidified to pH 4 with 1N HCl and the product extracted with ethyl acetate. Purification of the isomeric product mixture by reverse phase chromatography (Water Delta Prep-3000) using isocratic acetonitrile/water (23:77) (0.05% TFA) provided two isomers. The faster moving isomer compound was dissolved in dilute base, acidified to pH 3-4 and

extracted with ethyl acetate. The solvent was removed in vacuo; recrystallization from acetonitrile gave 199 mg (12%) of 5-[4'-[(5-butyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl]- [1,1'-biphenyl]-2-yl]-1H-tetrazole as a colorless solid: mp 170.0-170.5°C; NMR (CDCI₃) δ 0.79 (t, J = 8 Hz, 3H), 1.18-1.32 (m, 2H), 1.44-1.56 (m, 2H), 1.99 (s, 3H), 2.49 (t, J = 8 Hz, 2H), 5.15 (s, 2H), 6.87 (d, J = 8 Hz, 2H), 7.08 (d, J = 8 Hz, 2H),7.44 (dd, J = 8 and 2 Hz, 1H), 7.51-7.65 (m, 2H), 7.90 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 374 (100), 235 (13), 207 (100), 140 (29); HRMS. Calc'd for M+H: 374.2093. Found: 374.2062.

Example 33

5-[4'-[ (-3butyl-5-methyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole

The slower moving isomer from Example 32 was dissolved in dilute base, acidified to pH 3-4, and extraced with ethyl acetate. The solvent was removed in vacuo and the product lyophilized from acetonitrile/water which gave 536 mg (33 %) of 5-[4'-[(3-butyl-5-methyl-1H-1,2,4-triazol-1- yl)methyl]-[1,1'-biphenyl]-1-yl]-1H-tetrazole as a colorless solid: NMR (CDCI₃) δ 0.82 (t, J = 8 Hz, 3H), 1.21-1.35 (m,

2H), 1.53-1.66 (m, 2H), 2.35 (s, 3H), 2.56 (t, J = 8 Hz, 2H), 5.23 (s, 2H), 7.03 (d, J = 8 Hz, 2H), 7.11 (d, J = 8 Hz, 2H), 7.42 (dd, J = 8 and 2 Hz, 1H), 7.47-7.63 (m, 2H), 7.88 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 374 (65), 331 (12), 235 (13), 207 (100), 192 (38), 140 (56); HRMS. Calc'd for M+H: 374.2093. Found: 374.2071.

Example 34

1,1-dimethylethyl [3-butyl-[1-2'-(1H-tetrazol-5-yl) [1,1'- biphenyl]-4-ylmethyl]-1H-1,2,4-triazol-5-yl]methylcarbamate

Following General Procedure A, 6.0 g (25 mmol) of

[(5-butyl-1H-1,2,4-triazol-3-yl)methyl]carbamate was coupled with 16.4 g (25 mmol) of the alkylating reagent prepared in step 1 of Example 3. Silica gel chromatography (Waters Prep 500A) using ethyl acetate/hexane (2:3) gave 4.29 g (24%) of a faster moving isomer: NMR (CDCI₃) δ 0.94 (t, J = 8 Hz, 3H),

1.33-1 .46 (m, 2H) , 1 .43 (s, 9H) , 1 .66-1 .78 (m, 2H) , 2 . 69 (t, J = 8 Hz, 2H), 4.26 (d, J = 8 Hz, 2H), 5.24 (s, 2H), 6.87-6.93 (m, 7H), 7.01 (d, J = 8 Hz, 2H), 7.11 (d, J = 8 Hz, 2H), 7.21- 7.28 (m, 5H), 7.30-7.37 (m, 4H), 7.42-7.52 (m, 2H), 7.94 (dd, J = 8 and 2 Hz, 1H) and 9.74 g (54%) of a slower moving isomer: NMR (CDCI₃) δ 0.87 (t, J = 8 Hz, 3H), 1.24-1.36 (m, 2H) , 1.44 (s, 9H), 1.57-1.69 (m, 2H), 2.58 (t, J = 8 Hz, 2H), 4.38 (d, J = 8 Hz, 2H), 5.12 (s, 2H), 6.91 (d, J = 8 Hz, 8H), 7.11 (d, J = 8 Hz, 2H), 7.21-7.28 (m, 6H), 7.30-7.37 (m, 4H), 7.42-7.52 (m, 2H), 7.91-7.96 (m, 1H). The faster moving isomer was dissolved in 30 ml of water/acetic acid (1:4) and stirred at ambient temperature overnight. The solvent was removed in vacuo; the residue dissolved in dilute base and washed with toluene. The water layer was acidified to pH 3-4 and extracted with ethyl acetate. Recrystallization from acetonitrile gave 2.53 g (88%) of 1,1-dimethylethyl[3-butyl- [1-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-1H-1,2,4- triazol-5-yl]methylcarbamate as a colorless solid: mp 144- 147°C; NMR (CDCI₃) δ 0.88 (t, J = 8 Hz, 3H), 1.22-1.45 (m, 2H), 1.36 (s, 9H), 1.54-1.66 (m, 2H), 2.56 (t, J = 8 Hz, 2H), 4.05 (d, J = 8 Hz, 2H), 5.38 (s, 2H), 5.50 (s, 1H), 7.06 (d, J = 8 Hz, 2H), 7.12 (d, J = 8 Hz, 2H), 7.45 (dd, J = 8 and 2 Hz, 1H), 7.50-7.63 (m, 2H), 7.99 (d, J = 8 Hz, 1H) ; MS (FAB) m/e (rel intensity) 495 (12), 395 (38), 367 (15), 207 (100), 178 (42); HRMS. Calc'd for M+Li : 495.2808. Found: 495.2771.

Example 35

Λ

1,1-dimethylethyl [5-bntyl-[1-[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-ylmethyl]-1H-1,2,4-triazol-3-yl]methylcarbamate

The slower moving isomer from Example 34 was dissolved in 70 ml of water/acetic acid (1:4) and stirred at ambient temperature overnight. The solvent was removed in vacuo; the residue dissolved in dilute base and washed with toluene. The water layer was acidified to pH 4 with 1N HCl and extracted with ethyl acetate. The ethyl acetate was dried (MgSO₄) and removed in vacuo. Lyophilization from

acetonitrile/water gave 5.0 g (76%) of 1,1-dimethylethyl[5- butyl-[1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-1H- 1,2,4-triazol-3-yl]methylcarbamate as a colorless solid: NMR (CDCI₃) δ 0.77 (t, J = 8 Hz, 3H), 1.16-1.30 (m, 2H), 1.40 (s, 9H), 1.42-1.56 (m, 2H), 2.57 (t, J = 8 Hz, 2H), 4.12 (d, J = 8 Hz, 2H), 5.19 (s, 2H), 5.59 (s, 1H), 6.94 (d, J = 8 Hz, 2H), 7.08 (d, J = 8 Hz, 2H), 7.43 (dd, J = 8 and 2 Hz, 1H), 7.50- 7.63 (m, 2H), 7.92 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 495 (29), 367 (38), 338 (21), 207 (100), 178 (48); HRMS. Calc'd for M+Li: 495.2808. Found: 495.2800. Example 36

3-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]- 1H-1,2,4-triazole-5-methanamine

Under nitrogen, 219 mg (0.45 mmol) of 1,1- dimethylethyl [3-butyl-[1-[2'-(1H-tetrazol-5-yl) [1,1'- biphenyl]-4-ylmethyl]-1H-1,2,4-triazol-5-yl] methylcarbamate from Example 34 was suspended in 10 ml of 4N HCl in dioxane. After 30 minutes, 10 ml of methylene chloride was added. The mixture was stirred at ambient temperature overnight. The solvent was removed in vacuo. Lyophilization from

acetonitrile/water gave 201 mg (100%) of 3-butyl-1-[2'-(1H- tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-1H-1,2,4-triazole-5- methanamine as the colorless hydrochloride salt: NMR (CDCI₃) 8 0.82 (t, J = 8 Hz, 3H), 1.21-1.35 (m, 2H), 1.59-1.72 (m, 2H), 2.72 (t, J = 8 Hz, 2H), 4.97 (s, 2H), 5.69 (s, 2H), 6.93 (d, J = 8 Hz, 2H), 7.23 (d, J = 8 Hz, 2H), 7.32 ((d, J = 8 Hz, 1H), 7.39 (dt, J = 8 and 2 Hz, 1H), 7.51 (dt, J = 8 and 2 Hz, 1H), 7.74 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel

intensity) 389 (55), 207 (100), 192 (39), 178 (26); HRMS.

Calc'd for M+H: 389.2202. Found: 389.2170. Example 37

5-[4'-[[3-bntyl-5-(2,2-dlethyoxyethyl)-1H-1,2,4-trjazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole

Following General Procedure A, 4.7 g (19.5 mmol) of

5-butyl-3-(2,2-diethoxyethyl)-1H-1,2,4-triazole was coupled with 19.5 mmol of the alkylating reagent prepared in step 1 of Example 3. Silica gel chromatography (Waters Prep 500A) using ethyl acetate/hexane (2:3) gave 5.98 g (43%) of a faster moving isomer: NMR (CDCI₃) 8 0.94 (t, J = 8 Hz, 3H), 1.13 (t, J = 8 Hz, 6H), 1.33-1.48 (m, 2H), 1.67-1.79 (m, 2H), 2.70 (t, J = 8 Hz, 2H), 2.94 (d, J = 8 Hz, 2H), 3.39-3.51 (m, 2H), 3.63-3.75 (m, 2H), 4.81 (t, J = 7 Hz, 1H), 5.22 (s, 2H), 6.87- 6.98 (m, 8H), 7.09 (d, J = 8 Hz, 2H), 7.21-7.29 (m, 6H), 7.30- 7.37 (m, 4H), 7.41-7.52 (m, 2H), 7.91-7.96 (m, 1H) and 6.3 g (45%) of a slower moving isomer: NMR (CDCI₃) δ 0.88 (t, J = 8 Hz, 3H), 1.15 (t, J = 1 Hz, 6H), 1.24-1.37 (m, 2H), 1.56-1.68 (m, 2H), 2.57 (t, J = 8 Hz, 2H), 3.06 (d, J = 7 Hz, 2H), 3.46- 3.60 (m, 2H), 3.66-3.78 (m, 2H), 5.05 (t, J = 7 Hz, 1H) , 5.14 (s, 2H), 6.87-6.95 (m, 8H), 7.10 (d, J = 8 Hz, 2H), 7.21-7.29 (m, 6H), 7.31-7.37 (m, 4H), 7.42-7.53 (m, 2H), 7.90-7.96 (m, 1H). The faster moving isomer was dissolved in 50 ml of acetic acid/water (4:1) and stirred at ambient temperature for 3 days. The solvent was removed in vacuo; the residue dissolve in dilute base and washed with toluene. The water layer was cooled to 0 °C, acidified to pH 4-5 and extracted with ethyl acetate. Lyophilization from acetonitrile/water gave 3.8 g (98%) of 5-[4'-[[3-butyl-5-(2,2-diethyoxyethyl)- 1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H- tetrazole as a colorless solid: NMR (CDCI₃) δ 0.80 (t, J = 8 Hz, 3H), 1.10 (t, J = 8 Hz, 6H), 1.10-1.24 (m, 2H), 1.37-1.49 (m, 2H), 2.31 (t, J = 8 Hz, 2H), 2.66 (d, J = 7 Hz, 2H), 3.34- 3.47 (m, 2H), 3.59-3.71 (m, 2H), 4.75 (t, J = 7 Hz, 1H), 5.28 (s, 2H), 6.88 (d, J = 8 Hz, 2H), 7.06 (d, J = 8 Hz, 2H), 7.46 (dd, J = 8 and 2 Hz, 1H), 7.55 (dt, J = 8 and 2 Hz, 1H), 7.62 (dt, J = 8 and 2 Hz, 1H), 7.91 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 476 (20), 430 (28), 356 (13), 235 (15), 207 (100), 192 (67); HRMS. Calc'd for M+H: 476.2773. Found: 476.2723.

Example 38

5-[4'-[[5-butyl-3-(2,2-diethyoxyethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole

The 6.2 g (8.6 mmol) of the slower moving isomer from Example 37 was dissolved in 50 ml of acetic acid/water (4:1) and stirred at ambient temperature for 3 days. The solvent was removed in vacuo; the residue dissolved in dilute base, and washed with toluene. The water layer was cooled to 0 °C, acidified with 1N HCl to pH 4-5, and extracted with ethyl acetate. Lyophilization from acetonitrile/water gave 3.7 g (92%) of 5-[4'-[[5-butyl-3-(2,2-diethyoxyethyl)-1H- 1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole as colorless solid: NMR (CDCI₃) δ 0.85 (t, J = 8 Hz, 3H), 1.09 (t, J = 8 Hz, 6H), 1.24-1.38 (m, 2H), 1.51-1.63 (m, 2H), 2.55 (t, J = 8 Hz, 2H), 2.75 (d, J = 7 Hz, 2H), 3.38-3.50 (m, 2H), 3.54-3.66 (m, 2H), 4.87 (t, J = 7 Hz, 1H), 5.19 (s, 2H), 6.99 (d, J = 8 Hz, 2H), 7.12 (d, J = 8 Hz, 2H), 7.42 (dd, J = 8 and 2 Hz, 1H), 7.50-7.65 (m, 2H), 7.97 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 476 (3), 430 (28), 235 (10), 207 (100), 192 (61); HRMS. Calc'd for M+H: 476.2773. Found:

476.2760. Example 39

5-[4'-[(5-butyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole

Following General Procedure A, 770 mg (5 mmol) of 5-butyl-3-ethyl-1H-1,2,4-triazole was coupled with 2.8 g (5 mmol) of the alkylating reagent prepared in step 1 of Example 3. Silica gel chromatography (Waters Prep-500A) using ethyl acetate/hexane (2:3) gave 2.24 g (72%) of a mixture of the two isomers which was dissolved in 30 ml of acetic acid/water (9:1) and stirred at ambient temperature for 4 days. The solvent was removed in vacuo; the residue dissolved in dilute base, and washed with toluene. The water layer was acidified to pH 4 and extracted with ethyl acetate. The extracts were combined, dried (MgSO₄) and concentrated in vacuo.

Purification of a 600 mg sample of the isomeric product mixture by reverse phase chromatography (Waters Delta Prep- 3000) using isocratic acetonitrile/water (25:75) (0.05% TFA) provided two isomers. The faster moving isomer was dissolved in dilute base, acidified, extracted with ethyl acetate, dried (MgSO₄) and the ethyl acetate removed in vacuo.

Lyophilization from acetonitrile/water gave 209 mg of 5-[4'- [(5-butyl-3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole as a colorless solid: NMR (CDCI₃) δ 0.88 (t, J = 8 Hz, 3H), 1.33-1.40 (m, 2H), 1.38 (t, J = 8 Hz, 3H), 1.58-1.70 (m, 2H), 2.67-2.85 (m, 4H), 5.26 (s,

2H), 7.10 (s, 4H), 7.41 (dd, J = 8 and 2 Hz, 1H), 7.74-7.62 (m, 2H), 7.86 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 388 (58), 207 (100), 192 (35); HRMS. Calc'd for M+H: 388.2249. Found: 388.2218.

Example 40

5-[4'-[(3-butyl-5-ethyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole

The slower moving isomer from Example 39 was dissolved in dilute base, acidified to pH 3-4, extracted with ethyl acetate, dried (MgSO₄), and the ethyl acetate removed in vacuo. Lyophilization from acetonitrile/water gave 188 mg of

5-[4'-[(3-butyl-5-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetaazole as a colorless solid: NMR

(CDCI₃) δ 0.87 (t, J = 8 Hz, 3H), 1.16 (t, J = 8 Hz, 3H),

1.21-1.35 (m, 2H), 1.52-1.65 (m, 2H), 2.50 (t, J = 8 Hz, 2H), 2.67 (q, J = 8 Hz, 2H), 5.23 (s, 2H), 7.02 (d, J = 8 Hz, 2H), 7.12 (d, J = 8 Hz, 2H), 7.43 (dd, J = 8 and 2 Hz, 1H), 7.50- 7.65 (m, 2H), 7.89 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 388 (35), 207 (100), 192 (47); HRMS. Calc'd for M+H: 388.2249. Found: 388.2222. Example 41

N2-acetyl-N-[[5-butyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl]-1H-1,2,4-triazol-3-yl]methyl]-L- glutamine, 1 ,1-dimethylethyl ester Under nitrogen, 30 ml of TFA was added dropwise to a solution of 4.9 g (10 mmol) of 1,ldimethylethyl [5-butyl-[1- [2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-1H-1,2,4- triazol-3-yl]methyl]carbamate from Example 35 in 30 ml of methylene chloride at -10°C (methanol/ice). The mixture was allowed to warm to ambient temperature and stir overnight. The solvent was removed in vacuo giving the TFA salt of the free amine. The TFA salt was dissolved in 35 ml of anhydrous DMF along with 8.7 ml (50 mmol) of anhydrous diisopropyl ethyl amine and treated with 20 mmol of the symmetrical anhydride of N-Boc-γ-glutamic acid t-butyl ester in 55 ml of anhydrous DMF. The reaction was stirred at ambient temperature overnight. The DMF was removed in vacuo; the residue dissolved in ethyl acetate, washed with cold 1M K₂CO₃ and water. The ethyl acetate was dried (MgSO₄) and the solvent removed in vacuo. Under nitrogen, 30 ml of TFA was added dropwise to a solution of this material in 30 ml of methylene chloride at -10 °C

(methanol/ice). The reaction was allowed to warm to ambient temperature and stir overnight. The solvent was removed in vacuo giving the TFA salt of the free amine. The TFA salt was dissolved in 30 ml of water and cooled to 0 °C. The pH was adjusted to nine with 1M K₂CO₃ . The solution was cooled to 0º C, 0.94 ml (10 mmol) of acetic anhydride was added followed by 5 ml of 1M K₂CO₃, and the pH was adjusted to 9 with

additional 1M K₂CO₃. At 30 minute intervals, this addition was repeated until 5 additions had been made. The pH was adjusted to 4 with 6N HCl and the solution extracted with ethyl acetate. The ethyl acetate was dried (MgSO₄) and removed in vacuo. Purification by silica gel chromatography (Waters

Prep 500A) using isopropanol/acetic acid/chloroform (20:5:75) followed by lyophilization from acetonitrile/water gave 2.5 g (41%) of N2-acetyl-N-[[5-butyl-1-[[2'-(1H-tetrazol-5-yl) [1,1'- biphenyl]-4-yl]methyl]-1H-1,2,4-triazol-3-yl]methyl]-L- glutamine, 1,1-dimethylethyl ester as a colorless solid: NMR (CDCI₃) δ 0.89 (t, J = 8 Hz, 3H), 1.27-1.41 (m, 2H), 1.52-1.71 (m, 2H), 1.56 (s, 9H), 2.00 (s, 3H), 2.05-2.29 (m, 2H), 2.31- 2.55 (m, 2H), 2.73 (t, J = 8 Hz, 2H), 4.48-4.58 (m, 3H), 5.24 (s, 2H), 7.09 (d, J = 8 Hz, 2H), 7.17 (d, J = 8 Hz, 2H), 7.36- 7.42 (m, 1H), 7.44-7.55 (m, 2H), 7.90 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 616 (20), 263 (23), 235 (26), 207 (100); HRMS. Calc'd for M+H: 616.3360. Found:

616.3353.

Example 42

5-[4'-[[3-bυtyl-5-(2-cyclohexylethyl)-1H-1,2,4-tr azol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole

Following General Procedure A, 1.2 g (5 mmol) of 5- butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazole was coupled with 5 mmol of the alkylating reagent prepared in step 1 of Example 3. Silica gel chromatography (Waters Prep 500A) using ethyl acetate/hexane (1:3) gave 3.6 g (100%) of a mixture of the two isomers which was dissolved in 50 ml of acetic acid/water (9:1) and stirred at ambient temperature overnight. The solvent was removed in vacuo; the residue dissolved in dilute base, acidified and washed with ethyl acetate. The ethyl acetate was removed in vacuo. Purification of a small sample of the isomer product mixture by reverse phase chromatography (Water Delta Prep-3000) using isocratic acetonitrile/water

(41:59) (0.05% TFA) provided two isomers. The faster moving isomer was dissolved in dilute base, acidified to pH 3-4, extracted with ethyl acetate, dried (MgSO₄) and the ethyl acetate removed in vacuo. Lyophilization from

acetonitrile/water gave 58 mg of 5-[4'-[[3-butyl-5-(2- cyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]- 2-yl]-1H-tetrazole as a colorless solid: NMR (CDCI₃) δ 0.78- 0.95 (m, 5H), 1.07-1.40 (m, 6H), 1.48-1.74 (m, 9H), 2.66 (t, J = 8 Hz, 2H), 2.78 (t, J = 8 Hz, 2H), 5.24 (s, 2H), 7.10 (q, J = 8 Hz, 4H), 7.41 (dd, J = 8 and 2 Hz, 1H), 7.48-7.63 (m, 2H), 7.89 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 470 (45), 236 (35), 207 (100), 192 (33); HRMS. Calc'd for M+H: 470.3032. Found: 470.2990.

Example 43

5-[4'-[[5-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole

The slower moving isomer from Example 42 was dissolved in dilute base, acidified to pH 3-4, extracted with ethyl acetate, dried (MgSO₄), and the ethyl acetate removed in vacuo. Lyophilization from acetonitrile/water gave 29 mg of 5-[4'-[[5-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole as a colorless solid: NMR (CDCI₃) δ 0.95-1.00 (m, 5H), 1.10-1.43 (m, 6H),

1.59-1.77 (m, 9H), 2.83 (t, J = 8 Hz, 2H), 2.92 (t, J = 8 Hz, 2H), 5.31 (s, 2H), 7.10-7.18 (m, 4H), 7.40 (dd, J = 8 and 2 Hz, 1H), 7.47-7.61 (m, 2H), 7.89 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 470 (35), 236 (33), 207 (100), 192 (33); HRMS. Calc'd for M+H: 470.3032. Found: 470.2994. Example 44

5-[4'-[[5-butyl-3-(Phenylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole

Under nitrogen, 0.74 g (2.2 mmol) of N2-[4-[(2- cyanophenyl) phenyl]methyl] phenyl acetic acid hydrazide was dissolved in 5 ml of absolute ethanol and treated with 0.28 g (2.2 mmol) of ethyl iminovalerate. The reaction was stirred at relux for 3 days. The solvent was removed in vacuo, 5 ml of xylene was added and the reaction stirred at reflux under nitrogen for an additional 3 days. The solvent was removed in vacuo. Purification by silica gel chromatography

(Chromatatron, 4 mm plate) using a step gradient of ethyl acetate/chloroform gave 410 g (31%) of 5-[4'-[[5-butyl-3- (phenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl-2- yl]nitrile : NMR (CDCI₃) δ 0.88 (t, J = 8 Hz, 3H) , 1.27-1.41 (m, 2H), 1.59-1.72 (m, 2H), 2.67 (t, J = 8 Hz, 2H), 4.06 (s, 2H), 5.30 (s, 2H), 7.14-7.37 (m, 8H), 7.39-7.50 (m, 3H), 7.53 (dt, J = 8 and 2 Hz, 1H), 7.75 (dd, J = 8 and 2 Hz, 1H).

Under nitrogen, 230 mg (1.13 mmol) of trimethyl tin azide was added to a solution of the nitrile in 5 ml of xylene. The reaction was stirred at reflux for 3 days. The solvent was removed in vacuo and the residue dissolved in 10 ml of acetic acid/water (9:1) and stirred at ambient temperature overnight. The solvent was removed in vacuo. Reverse phase

chromatography (Delta Prep 3000) using acetonitrile/water (35- 45:65-55) gave the TFA salt. The salt was dissolved in dilute base, acidified to pH 3-4, extracted with ethyl acetate, dried (MgSO₄) and the ethyl acetate removed in vacuo.

Lyophilization from acetonitrile/water gave 182 mg (45%) of 5- [4'-[[5-butyl-3-(phenylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole as a colorless solid: NMR (CDCI₃) δ 0.84 (t, J = 8 Hz, 3H), 1.22-1.36 (m, 2H), 1.51-1.64 (m, 2H), 2.59 (t, J = 8 Hz, 2H), 3.85 (s, 2H), 5.20 (s, 2H), 7.02 (d, J = 8 Hz, 2H), 7.14 (d, J = 8 Hz, 2H), 7.17-7.28 (m, 5H), 7.43 (dd, J = 8 and 2 Hz, 1H), 7.51-7.65 (m, 2H), 7.96 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 450 (56), 207 (100), 192 (30), 178 (22); HRMS.

Calc'd for M+H: 450.2406. Found: 450.2434.

Example 45

5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]- 1H-1,2,4-triazole-3-propanol

Following General Procedure A, 920 mg (5.0 mmol) of 5-butyl-1H-1,2,4-triazole-3-propanol was coupled with 5.0 mmol of the alkylating reagent prepared in step 1 of Example 3. Silica gel chromatography (Waters Prep 500A) using

isopropanol/chloroform (5:95) gave a mixture of the two pure isomers which was dissolved in 40 ml acetic acid/water (9:1) and stirred at ambient temperature for 3 days. The solvent was removed in vacuo. Purification of an aliquot by reverse phase chromatography (Waters Delta Prep 3000) using

acetonitrile/water (26:74) (0.05% TFA) provided two isomers. Lyophilization of the faster moving isomer from acetonitrile/ water gave 124 mg of 5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-ylmethyl]-1H-1,2,4-triazole-3-propanol as the colorless FTA salt: NMR (CDCI₃) δ 0.71 (t, J = 8 Hz, 3H), 1.10-1.24 (m, 2H), 1.42-1.54 (m, 2H), 1.70-1.81 (m, 2H), 2.49 (t, J = 8 Hz, 2H), 2.60 (t, J = 8 Hz, 2H), 3.46 (t, J = 6 Hz, 2H), 5.02 (s, 2H), 6.92 (q, J = 8 Hz, 4H), 7.24-7.34 (m, 2H), 7.40 (dt, J = 8 and 2 Hz, 1H), 7.52 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 418 (100), 207 (48), 184 (10); HRMS. Calc'd for M+H: 418.2355. Found: 418.2370.

Example 46

3-butyl-1- [2 ' - (1H-tetrazol-5-yl) [1 , 1 ' -biphenyl] -lylmethyl] -1H-

1,2,4-triazole-5-propanol

Lyophilization of the slower moving isomer from Example 45 gave 114 mg of 3-butyl-1-[2'-(1H-tetrazol-5- yl)[1,1'-biphenyl]-Iylmethyl]-1H-1,2,4-triazole-5-propanol as the colorless TFA salt: NMR (CDCI₃) δ 0.75 (t, J = 8 Hz, 3H), 1.13-1.27 (m, 2H), 1.48-1.60 (m, 2H), 1.64-1.75 (m, 2H), 2.52 (t, J = 8 Hz, 2H), 2.66 (t, J = 8 Hz, 2H), 3.39 (t, J = 6 Hz, 2H), 5.12 (s, 2H), 6.94 (s, 4H), 7.25-7.35 (m, 2H), 7.40 (dt, J = 8 and 2 Hz, 1H), 7.52 (d, J = 8 Hz, 1H); MS (FAB) m/e (rel intensity) 418 (100), 207 (30); HRMS. Calc'd for M+H:

418.2355. Found: 418.2344.

Example 47

5-[4'-[[5-butyl-3-(difluoromethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole Following General Procedure A, 470 mg (2.7 mmol) of

5-butyl-3-(difluoromethyl)-1H-1,2,4-triazole was coupled with 2.7 mmol of the alkylating reagent prepared in step 1 of Example 3. Purification by reverse phase chromatography (Waters Delta Prep 3000) using acetonitrile/water (36:64) (0.05% TFA) gave two isomers. The faster moving isomer was dissolved in dilute base, acidified to pH 3-4, extracted with ethyl acetate, dried (MgSO₄), and the ethyl acetate removed in vacuo. Lyophilization from acetonitrile/water gave 471 mg (27%) of 5-[4'-[[5-butyl-3-(difluoromethyl)-1H-1,2,4-triazol- 1-yl]methyl][1.1'-biphenyl]-2-yl]-1H-tetrazole as a colorless solid: NMR (CDCI₃) δ 0.88 (t, 2 = 8 Hz, 3H), 1.28-1.43 (m, 2H), 1.60-1.73 (m, 2H), 2.72 (t, J = 8 Hz, 2H), 5.32 (s, 2H), 6.61 (t, J = 54 Hz, 1H), 7.12 (d, J = 8 Hz, 2H), 7.18 (d, J = 8 Hz, 2H), 7.42 (dd, J = 8 and 2 Hz, 1H), 7.51-7.65 (m, 2H), 8.00 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 410 (45), 235 (55), 207 (100), 192 (57); HRMS. Calc'd for M+H: 410.1905. Found: 410.1903.

Example 48

5-[4'-[[3-butyl-5-(difluoromethyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole

The slower moving isomer from Example 47 was dissolved in dilute base, acidified, extracted with ethyl acetate, dried (MgSO₄), and the ethyl acetate removed in vacuo. Lyophilization from acetonitrile/water gave 104 mg

(6%) of 5-[4'-[[3-butyl-5-(difluoromethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole as a colorless solid: NMR (CDCI₃) δ 0.91 (t, J = 8 Hz, 3H), 1.25-1.41 (m,

2H), 1.60-1.73 (m, 2H), 2.64 (t, J = 8 Hz, 2H), 5.43 (s, 2H), 6.81 (t, J = 52 Hz, 1H), 7.20 (d, J = 8 Hz, 2H), 7.28 (d, J = 8 Hz, 2H), 7.43 (dd, J = 8 and 2 Hz, 1H), 7.52-7.65 (m, 2H), 8.10 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 410 (87), 235 (100), 207 (83); HRMS. Calc'd for M+H:

410.1905. Found: 410.1903. Example 49

5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]- 1H-1,2,4-triazole-3-carboxaldehyde

A 92 mg sample of 5-[4'-[[5-butyl-3- (dimethoxymethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole from Example 24 was dissolved in 20 ml of ethanol and 2 ml of 3N HCl. The reaction was stirred at ambient temperature for 3 days. The solvent was removed in vacuo. Lyophilization from acetonitrile/water gave 70 mg (81%) of 5-butyl-1-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4- ylmethyl]-1H-1,2,4-triazole-3-carboxaldehyde as the colorless hydrochloride salt: NMR (CDCI₃) 8 0.89 (t, J = 8 Hz, 3H), 1.30-1.44 (m, 2H), 1.66-1.78 (m, 2H), 2.78 (t, J = 8 Hz, 2H), 5.38 (s, 2H), 7.17 (q, J = 8 Hz, 4H), 7.40 (d, J = 8 Hz, 1H), 7.50-7.64 (m, 2H), 8.02 (d, J = 8 Hz, 1H); MS (FAB) m/e (rel intensity) 388 (36), 235 (42), 207 (100), 192 (50); HRMS.

Calc'd for M+Li: 395.2046. Found: 395.2049. Example 50

5-[4'-[[5-butyl-3-(phenylacetyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole

Under nitrogen, 7.3 mmol of sec-butyl lithium was added dropwise to 2.0 g (6.1 mmol) of the Sem-protected 5- butyl-3-(dimethoxymethyl)-1H-1,2,4-triazole from Example 30 in

100 ml of anhydrous THF at -78 °C. The reaction was stirred for 1 h and then quenched with 0.87 ml (7.3 mmol) of benzyl bromide. The reaction was allowed to warm to ambient

temperature and stir overnight. The THF was removed in vacuo; the residue dissolved in methylene chloride, washed with water and dried (MgSO₄). The methylene chloride was removed in vacuo. The residue was dissolved in 10 ml of ethanol and 10 ml of 3M HCl and stirred at reflux for 2.5 h. The solvents were removed in vacuo. The residue was dissolved in ethyl acetate, washed with saturated sodium bicarbonate solution, and dried (MgSO₄). Silica gel chromatography (Waters Prep

500A) using ethyl acetate/hexane (35:65) gave 460 mg (31%) of 5-butyl-3-(phenylacetyl)-1H-1,2,4-triazole: NMR (CDCI₃) δ 0.92 (t, J = 8 Hz, 3H), 1.31-1.55 (m, 2H), 1.70-1.83 (m, 2H), 2.88 (t, J = 8 Hz, 2H), 4.39 (s, 2H), 7.21-7.38 (m, 5H).

Following General Procedure A, 440 mg (1.8 mmol) of this material was reacted with 1.8 mmol of the alkylating reagent prepared in step 1 of Example 3. The crude product was dissolved in 10 ml of acetic acid/water (9:1) and stirred at ambient temperature for 4 days. The solvent was removed in vacuo; the residue dissolved in dilute base and washed with toluene. The water was acidified and extracted with ethyl acetate. Purification by reverse phase chromatography (Waters Delta Prep 3000) using acetonitrile/water (45:55) gave 50 mg (5%) of 5-[4'-[[5-butyl-3-(phenylacetyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole as the colorless TFA salt: NMR (DMSO-d₆) δ 0.86 (t, J = 8 Hz, 3H), 1.23-1.38 (m, 2H), 1.52-1.65 (m, 2H), 2.80 (t, J = 8 Hz, 2H), 4.32 (s, 2H), 5.52 (s, 2H), 7.11 (d, J = 8 Hz, 2H), 7.19 (d, J = 8 Hz, 2H), 7.23-7.35 (m, 5H), 7.52-7.63 (m, 2H), 7.65-7.74 (m, 2H); MS (FAB) m/e (rel intensity) 478 (100), 244 (8), 235 (8), 207 (34), 192 (12); HRMS. Calc'd for M+H: 478.2355. Found:

478.2414.

Example 51

5-[4'-[[5-butyl-3-(1,1-difluoro-2-phenylethyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-1-yl]-1H-tetrazole

Under nitrogen, 8.5 g (48 mmol) of 5-butyl-3-

(difluoromethyl)-1H-1,2,4-triazole from Example 47 was added in portions to 53 mmol of sodium hydride in 85 ml of anhydrous THF; stirring was continued for 1 h. The anion solution was cooled to 0 °C and treated dropwise with 8.9 ml (50 mmol) of Sem-Cl. The reaction was allowed to warm to ambient

temperature and stir overnight. The THF was removed in vacuo; the residue dissolved in methylene chloride, washed with water, and dried (MgSO₄). Purification by silica gel

chromatography (Waters Prep 500A) using ethyl acetate/hexane (1:9) gave 4.9 g 34% of the Sem-protected triazole as an oil: NMR (CDCI₃) δ -0.04 (s, 9H), 0.86-0.95 (m, 5H), 1.39-1.43 (m, 2H), 1.65-1.76 (m, 2H), 2.71 (t, J = 8 Hz, 2H), 3.62 (t, J = 8 Hz, 2H), 5.53 (s, 2H), 6.82 (t, J = 52 Hz, 1H). Under nitrogen, 14.2 mmol of sec-butyllithium was added dropwise to 3.6 g (11.8 mmol) of the Sem-protected triazole in 200 ml of anhydrous THF at -78 °C. The reaction was allowed to stir for 1 h prior to the addition of 1.7 ml (14.2 mmol) of benzyl bromide. After stirring at -78 °C for 2 h, the reaction was allowed to warm to ambient temperature and stir overnight.

The solvent was removed in vacuo; the residue dissolved in methylene chloride, washed with water, and dried (MgSO₄).

Silica gel chromatography (Waters Prep 500A) using ethyl acetate/hexane (5:95) gave 600 mg (10%) of the Sem protected 5-butyl-3-(1,1-difluoro-2-phenylethyl)-1H-1,2,4-triazole: NMR (CDCI₃) 8 -0.04 (s, 9H), 0.85 (t, J = 8Hz, 2H), 0.94 (t, J = 8 Hz, 3H), 1.30-1.44 (m, 2H), 1.67-1.79 (m, 2H), 2.73 (t, J = 8 Hz, 2H), 3.54 (t, J = 8 Hz, 2H), 3.70 (t, J = 16 Hz, 2H), 5.34 (s, 2H), 7.21-7.31 (m, 5H). The Sem protected triazole was dissolved in 5 ml of ethanol and 5 ml of 3M HCl and allowed to stir at reflux for 3 h. The ethanol was removed in vacuo and the pH adjusted to nine with dilute sodium hydroxide. The resulting solution was extracted with methylene chloride; the extracts were combined, dried (MgSO₄), and concentrated in vacuo to provide 5-butyl-3-(1,1-difluoro-2-phenethyl-1H-1,2,4- triazole. Following General Procedure A, 1.4 mmol of this material was coupled with 1.4 mmol of the alkylating reagent prepared in step 1 of Example 3. The crude product was dissolved in 10 mL of acetic acid/water (9:1) and stirred at ambient temperature for 3 days. The solvent was removed in vacuo; the residue dissolved in dilute base and washed with toluene. The water was acidified to pH 3-4, extracted with ethyl acetate, and dried (MgSO₄). Purification by reverse phase chromatography (Waters Delta Prep 3000) using

acetonitrile/water (47:53) (0.05% TFA) gave the TFA salt. The salt was dissolved in dilute base, acidified to pH 3-4, extracted with ethyl acetate, and dried (MgSO₄).

Lyophilization from acetonitrile/water gave 290 mg (42%) of 5- [4'-[[5-butyl-3-(1,1-difluoro-2-phenylethyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-1-yl]-1H-tetrazole: NMR (CDCI₃) δ 0.86 (t, J = 8 Hz, 3H), 1.21-1.36 (m, 2H), 1.54-1.68 (m, 2H), 2.64 (t, J = 8 Hz, 2H), 3.57 (t, J = 16 Hz, 2H), 5.23 (s, 2H), 6.92 (d, J = 8 Hz, 2H), 7.10 (d, J = 8 Hz, 2H), 7.16-7.25 (m, 5H), 7.39 (dd, J = 8 and 2 Hz, 1H), 7.50-7.65 (m, 2H), 7.99 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity)

500(100), 266 (6), 235 (8), 207 (25), 192 (8); HRMS. Calc'd for M+H: 500.2374. Found: 500.2358.

Example 52

5-butyl-1-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]- 1H-1,2,4-triazole-3-carboxylie acid

A 3.36 g (7.1 mmol) sample of 5-[4'-[[5-butyl-3- (2,2-diethyoxyethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole from Example 38 was dissolved in 15 ml of ethanol and 15 ml of 3M HCl. The reaction was stirred at ambient temperature overnight and then at reflux for 2 h. The solvent was removed in vacuo, the residue dissolved in 15 ml of THF and 15 ml of 3M HCl and stirred for 3 days at ambient temperature. The solvent was removed in vacuo; the residue dissolved in dilute base, acidified and extracted with ethyl acetate and methylene chloride. The solvents were combined and dried (MgSO₄). The solvents were removed in vacuo. The residue was dissolved in 70 ml of acetone and 35 ml of water. Potassium permanganate was added in 4 equal portions of 190 mg after each preceeding portion had reacted. The mixture was filtered through celite and the solvent removed in vacuo. Purification by reverse phase

chromatography (Waters Delta Prep 3000) gave 88 mg (7%) of 5- butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-1H- 1,2,4-triazole-3-carboxylic acid as the colorless TFA salt after lyophilization from acetonitrile/water: NMR (DMSO-d₆) δ 0.85 (t, J = 8 Hz, 3H), 1.23-1.38 (m, 2H), 1.52-1.62 (m, 2H), 2.78 (t, J = 8 Hz, 2H), 5.46 (s, 2H), 7.13 (q, J = 8 Hz, 4H), 7.51-7.62 (m, 2H), 7.64-7.73 (m, 2H); MS (FAB) m/e (rel intensity) 404 (100), 235 (20), 207 (91), 192 (24); HRMS.

Calc'd for M+H: 404.1835. Found: 404.1882.

Example 53

5-[4'-[(5-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1 '-biphenyl]- 2-yl]-1H-tetrazole

Following general procedure A , 630 mg (5 mmol) of

3-butyl-1H-1,2, 4-triazole was reacted with 5 mmol of the alkylating reagent prepared in step 1 of Example 3 to give 2.3 g (76%) of a mixture of the two isomers. Deprotection of the faster isomer provided 5-[4'-[(5-butyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]1H-tetrazole: NMR (CDCI₃) δ

0.87 (t, J = 8 Hz, 3H), 1.35-1.41 (m, 2H), 1.59-1.72 (m, 2H), 2.72 (t, J = 8 Hz, 2H), 5.30 (s, 2H), 7.09 (d, J = 8 Hz, 2H), 7.17 (d, J = 8 Hz, 2H), 7.44 (dd, J = 8 and 2 Hz, 1H), 7.52- 7.66 (m, 2H), 7.72 (s, 1H), 8.01 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 360 (88), 235 (20), 207 (100), 192 (31), 178 (22); HRMS. Calc'd for M+H: 360.1936. Found:

360.1938. Example 54

5-[4'-[(3-butyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'-biphenyl]- 2-yl]-1H-tetrazole The slower moving isomer from Example 53 was deprotected to provide 5-[4'-[(3-butyl-1H-1,2,4-triazol-1- yl)methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole: NMR (CDCI₃) δ 0.74 (t, J = 8 Hz, 3H), 1.19-1.33 (m, 2H), 1.51-1.63 (m, 2H), 2.55 (t, J = 8 Hz, 2H), 5.23 (s, 2H), 7.10 (q, 2 = 8 Hz, 4H), 7.44 (dd, 2 = 8 and 2 Hz, 1H) , 7.50-7.64 (m, 2H), 7.92 (dd, J = 8 and 2 Hz, 1H) , 8.02 (s, 1H) ; MS (FAB) m/e (rel intensity) 360 (84), 135 (18), 207 (100), 192 (26), 178 (16), 126 (22); HRMS. Calc'd for M+H: 360.1936. Found: 360.1971.

Example 55

5-[4'-[[3-butyl-5-(tricyclo[3.3.1^{3. 7}]dec-1-yl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole

Following general procedure A, 1.3 g (5.0 mmol) of

5-butyl-3-adamantyl-1H-1,2,4-triazole was reacted with 5.0 mmol of the alkylating reagent prepared in step 1 of Example 3 to give 2.94 g (72%) of a mixture of the two isomers.

Deprotection of the faster moving isomer provided 5-[4'-[[3- butyl-5- (tricyclo [3.3.1^3.7]dec-1-yl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole: NMR (CDCI₃) δ 0.90 (t, J = 8 Hz, 3H), 1.27-1.41 (m, 2H), 1.42-1.55 (m, 3H), 1.58-1.73 (m, 5H), 1.76-1.91 (m, 9H), 2.28-2.43 (m, 2H), 5.42 (s, 2H), 6.72-6.83 (m, 2H), 7.07 (d, J = 8 Hz, 2H), 7.45-7.66 (m, 3H), 7.88 (t, J = 8 Hz, 1H) ;MS (FAB) m/e (rel intensity)

494 (100), 260 (37), 207 (74), 178 (22); HRMS. Calc'd for M+H: 494.3032. Found: 494.3014. Example 56

5-[4'-[[5-butyl-3-(tricyclo[3.3.1.1^3.7]dec-1-yl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole The slower moving isomer from Example 55 was deprotected to provide 5-[4'-[[5-buty1-3- (tricyclo[3.3.1.1^3.7]dec-1-yl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole: NMR (CDCI₃) δ 0.87 (t, J = 8 Hz, 3H), 1.31-1.47 (m, 2H), 1.52-1.71 (m, 9H), 1.78 (s, 7H), 1.88 (s, 3H), 2.20-2.35 (m, 2H), 5.22 (s, 2H), 6.87 (d, J = 8 Hz, 2H), 7.13 (d, J = 8 Hz, 2H), 7.42 (dd, J = 8 and 2 Hz, 1H) , 7.49-7.63 (m, 2H), 7.93 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 494 (73), 451 (10), 260 (24), 207 (66), 178 (21); HRMS. Calc'd f or M+H : 494.3032. Found: 494.3026. Example 57

5-[4'-[[3-butyl-5-(3-cyclohexylpropyl)-1H-1,2,4-triazo!-1- yl]methyl][1,1'-biphenyl1-2-yl]-1H-tetrazole

Following general procedure A, 1.25 g (5 mmol) of 5- butyl-3-(3-cyclohexylpropyl)-1H-1,2,4-triazole was reacted with 5 mmol of the alkylating reagent prepared in step 1 of Example 3 to give 3.1 g (85%) of a mixture of the two isomers. Deprotection of the faster moving isomer provided 5-[4'-[[3- butyl-5-(3-cyclohexylpropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole: NMR (CDCI₃) δ 0.73-0.92 (m, 2H), 0.87 (t, J = 8 Hz, 3H), 1.06-1.21 (m, 6H), 1.22-1.36 (m, 2H), 1.53-1.71 (m, 9H), 2.51 (t, J = 8 Hz, 2H), 2.61 (t, J = 8 Hz, 2H), 5.22 (s, 2H), 7.01 (d, J = 8 Hz, 2H), 7.12 (d, J = 8 Hz, 2H), 7.42 (dd, J = 8 and 2 Hz, 1H), 7.51- 7.64 (m, 2H), 7.94 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 484 (83), 250 (38), 207 (100), 178 (25); HRMS.

Calc'd for M+H: 484.3189. Found: 484.3223. Example 58

5-[4'-[[5-butyl-3-(3-cyclohexylpropyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl.-2-yl]-1H-tetrazole The slower moving isomer from Example 57 was deprotected to provide 5-[4'-[[5-butyl-3-(3-cyclohexylpropyl)- 1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H- tetrazole: NMR (CDCI₃) δ 0.74-0.90 (m, 2H), 0.83 (t, J = 8 Hz, 3H), 1.05-1.22 (m, 6H), 1.23-1.35 (m, 2H), 1.50-1.70 (m, 9H), 2.40 (t, J = 8 Hz, 2H), 2.57 (t, J = 8 Hz, 2H), 5.20 (s, 2H), 6.96 (d, J = 8 Hz, 2H), 7.10 (d, J = 8 Hz, 2H), 7.43 (dd, J = 8 and 2 Hz, 2H), 7.50-7.64 (m, 2H), 7.92 (dd, J = 8 and 2 Hz, 2H); MS (FAB) m/e (rel intensity) 484 (65), 250 (26), 207 (100), 178 (18); HRMS. Calc'd for M+H: 484.3189. Found: 484.3181. Example 59

5-[4'-[[5-butyl-3-(fluoromethyl)-1H-1,2,4-triazol-1- yl]methyl] [ 1 , 1'-biphenyl]-2-yl]-1H-tetrazole

Following general procedure A, 790 mg (5.0 mmol) of

5-butyl-3-(fluoromethyl)-1H-1,2,4-triazole was reacted with 5 mmol of the alkylating reagent prepared in step 1 of Example 3 to give 1.3 g (42%) of a mixture of the two isomers.

Deprotection of the faster moving isomer provided 5-[4'-[[5- butyl-3-(fluoromethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole: NMR (CDCI₃) δ 0.86 (t, J = 8 Hz, 3H), 1.26-1.40 (m, 2H), 1.56-1.69 (m, 2H), 2.67 (t, J = 8 Hz, 2H), 5.16 (s, 1H), 5.27 (s, 2H), 5.32 (s, 1H), 7.06 (d, J = 8 Hz, 2H), 7.16 (d, J = 8 Hz, 2H), 7.43 (dd, 2 = 8 and 2 Hz, 1H), 7.52-7.65 (m, 2H), 7.99 (dd, J = 8 and 2 Hz, 1H); MS

(FAB) m/e (rel intensity) 392 (100), 235 (22) , 207 (66), 192 (18), 178 (14); HRMS. Calc'd for M+H: 392.1999. Found:

392.1932. Example 60

5-[4'-[[3-butyl-5-(fluoromethyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole

The slower moving isomer from Example 59 was deprotected to provide 5-[4'-[[3-butyl-5-(fluoromethyl)-1H- 1,2,4-triazol-1-yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole: NMR (CDCI₃) δ 0.89 (t, J = 8 Hz, 3H), 1.24-1.40 (m, 2H), 1.59 (m, 2H), 2.65 (t, J = 8 Hz, 2H), 5.38 (s, 3H), 5.55 (s, 1H) , 7.21 (s, 4H), 7.43 (d, J = 8 Hz, 1H) , 7.51-7.65 (m, 2H), 8.05 (d, J = 8 Hz, 1H) ; MS (FAB) m/e (rel intensity) 392 (90), 235 (56), 207 (100), 192 (51), 178 (24); HRMS. Calc'd for M+H: 392.1999. Found: 392.1944.

Example 61

5-[4'-[[3-butyl-5-(tricyclo[3.3.1.1^3.7]dec-1-ylmethyl]-1H- 1,2,4-triazole-1-yl]methyl] [1,1'-biphenyl1-2-yl]-1H-tetrazole

Following general procedure A, 1.4 g (5.0 mmol) of

5-butyl-3-adamantyl-1H-1,2,4-triazole was reacted with 5.0 mmol of the alkylating reagent prepared in step 1 of Example 3 to give a mixture of the two isomers. Deprotection of the faster moving isomer provided 5-[4'-[[3-butyl-5- (tricyclo[3.3.1.1^3.7]dec-1-ylmethyl]-1H-1,2,4-triazole-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole: NMR (CDCI₃) δ 0.84 (t, J = 8 Hz, 3H), 1.16-1.30 (m, 2H), 1.41 (s, 6H), 1.44- 1.56 (m, 5H), 1.65 (d, J = 12 Hz, 3H), 1.92 (s, 3H), 2.18 (s, 2H), 2.30 (t, J = 8 Hz, 2H), 5.18 (s, 2H), 6.79 (d, J = 8 Hz, 2H), 7.01 (d, J = 8 Hz, 2H), 7.46 (d, J = 8 Hz, 1H), 7.52 (m, 2H), 7.85 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel

intensity) 508 (45), 274 (25), 207 (100), 192 (31); HRMS.

Calc'd for M+H: 508.3189. Found: 508.3162. Example 62

5-[4'-[[.5-butyl-3-(tricyclo[3.3.1.1^3.7]dec-1-ylmethyl]-1H-

1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole The slower moving isomer from Example 61 was deprotected to provide 5-[4'-[[5-butyl-3- (tricyclo[3.3.1.1^3.7]dec-1-ylmethyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole: NMR (CDCI₃) δ 0.85 (t, J = 8 Hz, 3H), 1.21-1.37 (m, 8H), 1.44-1.58 (m, 5H), 1.62 (d, J = 10 Hz, 3H), 1.86 (s, 3H), 2.07 (s, 2H), 2.49 (t, J = 8 Hz, 2H), 5.21 (s, 2H),6.89 (d, J = 8 Hz, 2H), 7.07 (d, 2 = 8 Hz, 2H), 7.53 (dd, J = 8 and 2 Hz, 1H), 7.52-7.65 (m, 2H), 7.91 (dd, J = 8 and 2 Hz, 1H), MS (FAB) m/e (rel intensity) 508 (42), 274 (22), 207 (100), 192 (34); HRMS. Calc'd for M+H: 508.3189. Found: 508.3142. Example 63

5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]- 1H-1,2,4-triazole-3-propanoic acid A 2.18 g sample of the mixture of the two isomers from Example 45 was oxidized to the corresponding aldehydes with oxalyl chloride/dimethyl sulfoxide and subsequently oxidized to the acids with potassium permanganate to give 1.8 g of a mixture of the two propanoic isomers. Deprotection of the faster moving isomer provided 5-butyl-1-[2'-(1H-tetrazol- 5-yl) [1,1'-biphenyl]-4-ylmethyl]-1H-1,2,4-triazole-3-propanoic acid: NMR (CDCI₃) δ 0.99 (t, J = 8 Hz, 3H), 1.28-1.43 (m, 2H), 1.61-1.74 (m, 2H), 2.67-2.80 (m, 4H), 2.94 (t, J = 6 Hz, 2H), 5.18 (s, 2H), 7.04-7.14 (m, 4H), 7.42 (dd, J = 8 and 2 Hz, 1H), 7.50 (dt, J = 8 and 2 Hz, 1H), 7.59 (dt, J = 8 and 2 Hz, 1H), 7.90 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 432 (89), 389 (15), 237 (36), 198 (100); HRMS.

Calc'd for M+H: 432.2148. Found: 432.2216. Example 64

3-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]- 1H-1,2,4-triazole-5-propanoic acid

The slower moving isomer from Example 63 was deprotected to give 3-butyl-1-[2'-(1H-tetrazol-5-yl) [1,1'- biphenyl]-4-ylmethyl]-1H-1,2,4-triazole-5-propanoic acid: NMR (CDCI₃) δ 0.92 (t, J= 8 Hz, 3H), 1.30-1.40 (m, 2H), 1.65-1.78 (m, 2H), 2.70 (t, J = 8 Hz, 2H), 2.84-2.91 (m, 2H), 2.93-3.00 (m, 2H), 5.40 (s, 2H), 7.20 (d, J = 8 Hz, 2H), 7.34 (d, J = 8 Hz, 2H), 7.37-7.42 (m, 1H), 7.51-7.62 (m, 2H), 8.30-8.36 (m, 1H); MS (FAB) m/e (rel intensity) 432 (100) 198 (45); HRMS. Calc'd for M+H: 432.2148. Found: 432.2214.

Example 65

5-[4'-[(3-butyl-5-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole

Following General Procedure A, 2.07 g (10 mmol) of 3-butyl-5-cyclohexyl-1H-1,2,4-triazole was reacted with 6.5 g (11.8 mmol) of the alkylating reagent prepared in step 1 of Example 3 to give 6.3 g (9.2 mmol) of a mixture of the two isomers. Deprotection of the faster moving isomer provided 33 mg of 5-[4'-[(3-butyl-5-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-1,2,4-triazole as a colorless solid: mp 157.5-159.5 °C; NMR (CDCI₃) δ 0.87 (t, J = 7 Hz, 3H), 1.11-1.36 (m, 6H), 1.45-1.70 (m, 6H), 1.70-1.80 (m, 2H), 2.50 (t, J = 7 Hz, 2H), 2.64-2.78 (m, 1H), 5.23 (s, 2H), 6.98 (d, J = 8 Hz, 2H), 7.08 (d, J = 8 Hz, 2H), 7.41 (dd, J = 5 and 1 Hz, 1H), 7.49 (dt, J = 5 and 1 Hz, 1H), 7.57 (dt, J = 5 and 1 Hz, 1H), 7.80 (dd, J = 5 and 1 Hz, 1H): MS (FAB) m/e (rel intensity), 442 (100), 414 (10), 399 (20), 235 (8), 207 (65), 192 (18). Example 66

5-[4'-[(5-butyl-3-cyclohexyl-1H-1,2,4-triazol-1

yl)methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole

The slower moving isomer from Example 65 was deprotected to provide 135 mg of 5-[4'-[(5-butyl-3-cyclohexyl- 1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H- tetrazole as a colorless solid: mp 125-127 °C; NMR (CDCI₃) δ 0.85 (t, J = 7 Hz, 3H), 1.12-1.40 (m, J = 8 Hz, 8H), 1.52-1.75 (m, J = 8 Hz, 4H), 1.81 (d, J = 8 Hz, 2H), 2.50 (t, J = 8 Hz, 3H), 5.20 (s, 2H), 6.94 (d, J = 8 Hz, 2H), 7.09 (d, J = 8 Hz, 2H), 7.42 (dd, J= 8 and 2 Hz, 1H) , 7.50-7.64 (m, J= 8 Hz, 2H), 7.88 (dd, J= 8 and 2 Hz, 1H) ; MS (FAB) m/e (rel

intensity) 442 (100), 414 (10), 399 (20), 235 (10), 207 (75), 192 (17) .

Example 67

1,1-dimethylethyl 3-butyl-[1-[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-ylmethyl]-1H-1,2,4-triazol-5-yl]propylcarbamate

Following General Procedure A, 6.0 g (20 mmol) of 3-butyl-5-(N-Boc-3-aminopropyl)-1H-1,2,4-triazole was reacted with 13.1 g (24 mmol) of the alkylating reagent prepared in step 1 of Example 3. Deprotection of the faster moving isomer gave 3.52 g (33%) of 1,1-dimethylethyl 3-butyl-[1-[2'-(1H- tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-1H-1,2,4-triazol-5- yl]propylcarbamate as a colorless solid: NMR (DMSO-d₆) δ 0.88 (t, J = 8 Hz, 3H), 1.22-1.34 (m, J= 8 Hz, 2H), 1.36 (s, 9H), 1.54-1.66 (m, J = 7 Hz, 2H), 1.66-1.78 (m, J = 7 Hz, 2H), 2.5 (t, J= 8 Hz, 2H), 2.67 (t, J = 8 Hz, 2H), 2.96 (q, J = 8 Hz, 2H), 5.26 (s, 2H), 7.08 (s, 4H), 7.55 (q, J= 8 Hz, 2H), 7.65 (d, J = 8 Hz, 2H); MS (FAB) m/e (rel intensity) 517 (60), 489 (10), 461 (10), 439 (10), 417 (23), 389 (18), 357 (8), 323 (8), 305 (15), 283 (80), 227 (70), 207 (100), 183 (65); HRMS. Calc'd for M+H: 517.3039. Found 517.3001. Example 68

1,1-dimethylethyl 5-butyl-[1-[2'-(1H-tetrazol-5yl)[1,1'- biphenyl]-4-ylmethyl]-1H-1,2,4-triazol-3-yl]propylcarbamate The slower moving isomer from Example 67 was deprotected to give 3.43 g (33%) of 1,1-dimethylethyl 5-butyl- [1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-1H-1,2,4- triazol-3-yl]propylcarbamate as a colorless solid: NMR (DMSO- d₆) 8 0.84 (t, J= 7 Hz, 3H), 1.29 (q, J = 8 Hz, 2H), 1.38 (s, 9H), 1.48-1.59 (m, J = 8 Hz, 2H), 1.72 (t, J = 8 Hz, 2H), 2.53 (t, J= 7 Hz, 2H), 2.67 (t, J = 8 Hz, 2H), 2.97 (q, J = 8 Hz, 2H), 5.28 (s, 2H), 7.08 (s, 4H), 7.50 (d, J = 8 Hz, 1H) 7.55 (d, J = 8 Hz, 1H), 7.61-7.68 (m, J= 7 Hz, 2H); MS (FAB) m/e (rel intensity) 517 (40), 439 (10) 417 (40), 390 (20), 357 (10), 207 (100), 192 (40); HRMS. Calc'd for M+H : 517.3039. Found: 517.3014. Example 69

5-[4'-[[3-(1,1,2,2,2,-pentafluoroethyl)-5-butyl-1H-1,2,4- triazol-1-yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazol

Following General Procedure A, 1.21 g (5.0 mmol) of 3-perfluoroethyl-5-butyl-1H-1,2,4-triazole was reacted with 3.2 g (5.7 mmol) of the alkylating reagent prepared in step 1 of Example 3. Deprotection provided 409 mg of 5-[4'-[[3- (1,1,2,2,2-pentafluoroethyl)-5-butyl-1H-1,2,4-triazol-1- yl]methyl[1,1-biphenyl]-2-yl]-1H-tetrazole as a colorless oil: NMR (CDCI₃) δ 0.90 (t, J = 7 Hz, 3H), 1.36 (q, J = 1 Hz, 2H), 1.67 (t, J= 7 Hz, 2H), 2.78 (t, J = 7 Hz, 2H), 5.38 (s, 2H), 7.18 (s, 4H), 7.42 (d, J = 8 Hz, 1H) , 7.51-7.67 (m, J = 8 Hz, 2H), 7.98 (d, J = 8 Hz, 1H) ; MS (FAB) m/e (rel intensity) 478 (40), 452 (15), 235 (90), 207 (100), 178 (40), 152 (35); HRMS. Calc'd. for M+H: 478.1778. Found: 478.1807.

5-[4'-[[3-(1,1,2,2,3,3,3-heptafluoropropyl)-5-bυtyl-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole

Following General Procedure A, 1.46 g (5.0 mmol) of 5-butyl-3-perfluoropropyl-1H-1,2,4-triazole was reacted with 3.20 g (5.7 mmol) of the alkylating reagent prepared in step 1 of Example 3. Deprotection provided 210 mg of 5-[4'-[[3- (1,1,2,2,3,3,3-heptafluoropropyl)-5-butyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole as a colorless oil: NMR (CDCI₃) δ 0.90 (t, J = 7 Hz, 3H), 1.36 (q, J= 8 Hz, 2H), 1.63-1.75 (m, J = 8 Hz, 2H), 2.78 (t, J = 8 Hz, 2H), 5.40 (s, 2H), 7.20 (q, J= 1 Hz, 4H), 7.42 (dd, J = 8 and 2 Hz, 1H), 7.52-7.65 (m, J = 8 Hz, 2H), 8.04 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 528 (35), 502 (15), 294 (12), 235 (90), 207 (100), 136 (15); HRMS. Calc'd for M+H: 528.1747. Found: 528.1701. Example 71

5-[4'-[[3-butyl-5-(3-aminopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole

Under a static nitrogen atmosphere 2.40 g (4.7 mmol) of 5-[4'-[[3-butyl-5-(N-Boc-3-aminopropyl)-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole from Example 67 was dissolved in 30 mL of 4N HCl in dioxane at ambient temperature and allowed to stir overnight. The solvents were removed in vacuo; the residue was triturated with diethyl ether and filtered providing 2.08 g (98%) of 5- [4'-[[3-butyl-5-(3-aminopropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole as the

hydrochloride salt: NMR (DMSO-d₆) δ 0.88 (t, J = 1 Hz, 3H), 1.25-1.39 (m, 2H), 1.57-1.69 (m, 2H), 1.92-2.40 (m, 2H), 2.62 (t, J = 7 Hz, 2H), 2.89 (q, J = 8 Hz, 2H), 2.98 (t, J = 8 Hz, 2H), 5.38 (s, 2H), 7.10 (d, J = 8 Hz, 2H), 7.19 (d, J = 8 Hz, 2H), 7.54 (d, J = 8 Hz, 1H), 7.59 (dd, J= 8 and 2 Hz, 1H), 7.66 (s, 1H), 7.70 (dd, J= 8 and 2 Hz, 1H), 8.10 (br s, 2H); MS (FAB) m/e (rel intensity) 417 (38), 389 (10), 357 (10), 207 (100), 166 (50), 139 (10) 115 (10); HRMS. Calc'd for M+H: 417.2515. Found: 417.2563. Example 72

5-[4'-[[3-(3-aminopropyl)-5-butyl-1H-1,2,4-triazol-1- yl)methyl](1,1'-biphenyl)-2-yl]-1H-tetrazole

Under a static nitrogen atmosphere 2.30 g (4.5 mmol) of 5-[4'-[[3-(N-Boc-3-aminopropyl)-5-butyl-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole from Example 68 was dissolved in 30 mL of 4N HCl in dioxane at ambient temperature and allowed to stir overnight. The solvents were removed in vacuo; the residue was triturated with diethyl ether and filtered providing 1.99 g (98%) of 5- [4'-[[3-(3-aminopropyl)-5-butyl-1H-1,2,4-triazol-1- yl]methyl] (1,1'-biphenyl)-2-yl]-1H-tetrazole as the

hydrochloride salt: NMR (DMSO-d₆) δ 0.85 (t, J = 1 Hz, 3H), 1.22-1.38 (m, 2H), 1.59 (t, J = 8 Hz, 2H), 1.96 (t, J = 8 Hz, 2H), 2.71-2.79 (m, 2H) 2.80-2.92 (m, 4H), 5.40 (s, 2H) 7.10 (d, J= 8 Hz, 2H), 7.18 (d, J = 8 Hz, 2H) 7.52 (d, J = 8 Hz, 1H), 7.59 (d, J = 8 Hz, 1H), 7.68 (d, J = 8 Hz, 2H); MS (FAB) m/e (rel intensity) 417 (60), 389 (10), 357 (10), 263 (5), 235 (10), 207 (100), 166 (40), 136 (15); HRMS. Calc'd for M+H: 417.2515. Found: 417.2510. Example 73

5-[4'-[(3-butyl-5-cyclohexylmethyl-1H-1,2,4-triazol-1- yl)methyl] [1 ,1'-biphenyl]-2-yl]-1H-tetrazole

Following General Procedure A, 2.21 g (10.0 mmol) of 3-butyl-5-cyclohexylmethyl-1H-1,2,4-triazole was reacted with 6.55 g (11.8 mmol) of the alkylating reagent prepared in step 1 of Example 3 to give 5.90 g (85%) of a mixture of the two isomers. The faster moving isomer was deprotected to provide 64 mg of 5-[4'-[(3-butyl-5-cyclohexylmethyl-1H-1,2,4- triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole as a colorless solid: NMR (CDCI₃) δ 0.92 (t, J = 1 Hz, 3H) 0.94- 1.05 (m, 2H) 1.08-1.25 (m, 3H), 1.25-1.41 (m, 2H), 1.55-1.80 (m, 8H), 2.65 (d, J = 1 Hz, 2H), 2.68 (t, J = 1 Hz, 2H), 5.27 (s, 2H), 7.11 (q, J = 8 Hz, 4H), 7.42 (dd, J = 8 and 2 Hz, 1H), 7.49-7.63 (m, 2H), 7.94 (dd, J = 8 and 2 Hz, 1H); MS

(FAB) m/e (rel intensity) 456 (100), 428 (10), 413 (20), 280 (10), 235 (10), 222 (25), 207 (80), 192 (30); HRMS. Calc'd for M+H: 456.2876. Found: 456.2839. Example 74.

5-[4'-[(3-cyclohexylmethyl-5-butyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole

The slower moving isomer from Example 73 was deprotected to provide 51 mg of 5-[4'-[(3-cyclohexylmethyl-5- butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H- tetrazole as a colorless solid: NMR (CDCI₃) δ 0.84 (t, J = 8 Hz, 3H), 0.92 (q, J = 8 Hz, 2H), 1.05-1.22 (m, 3H), 1.22-1.36 (m, 2H), 1.52-1.69 (m, 8H), 2.50 (d, J = 1 Hz, 2H), 2.63 (t, J = 8 Hz, 2H), 5.18 (s, 2H), 7.05 (q, J = 8 Hz, 4H), 7.35-7.55 (m, 3H), 7.68 (dd, J = 8 and 2 Hz, 1H); MS (FAB) m/e (rel intensity) 456 (90), 413 (10), 281 (10), 243 (10), 222 (35), 207 (100), 192 (35); HRMS. Calc'd for M+H: 456.2876. Found: 456.2849.

Example 75

4'-[(3-ethyl-5-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylie acid

Following General Procedure A, 1.0 g (6.0 mmol) of 3-ethyl-5-butyl-1H-1,2,4-triazole was reacted with 2.41 g (7.9 mmol) of the alkylating reagent prepared in step 1 of Example 1. Hydrolysis of the faster moving isomer provided 220 mg of 4'-[(3-ethyl-5-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid as a colorless solid: NMR (DMSO- dδ) δ 0.85 (t, J = 1 Hz, 3H), 1.19 (t, J = 1 Hz, 3H), 1.27-

1.38 (m, 2H), 1.52-1.63 (m, 2H), 2.59 (q, J = 1 Hz, 2H), 2.74 (t, J = 1 Hz, 2H), 5.35 (s, 2H), 7.21 (d, J = 8 Hz, 2H), 7.31 (d, J = 8 Hz, 2H), 7.35 (dd, J = 8 and 2 Hz, 1H), 7.48 (dt, J = 8 and 2 Hz, 1H), 7.57 (dt, J = 8 and 2 Hz, 1H), 7.72 (dd, J = 8 and 2 Hz, 1H).

Example 76

4'-[(3-butyl-5-ethyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-carboxylic acid

The slower moving isomer from Example 75 was hydrolyzed to provide 174 mg of 4'-[(3-butyl-5-ethyl-1H-1,2,4- triazol-1-yl)methyl] [1,1'-biphenyl]-2-carboxylic acid as a colorless solid: NMR (DMSO-d₆) δ 0.89 (t, J = 1 Hz, 3H), 1.17 (t, J = 1 Hz, 3H), 1.27-1.40 (m, 2H), 1.56-1.68 (m, 2H), 2.58 (t, J = 8 Hz, 2H), 2.77 (q, J = 8 Hz, 2H), 5.35 s, 2H), 7.21 (d, J = 8 Hz, 2H), 7.32 (d, J = 8 Hz, 2H), 7.36 (dd, J = 8 and 2 Hz, 1H), 7.46 (dt, J = 8 and 2 Hz, 1H) , 7.57 (dt, J = 8 and 2 Hz, 1H), 7.73 (dd, J = 8 and 2 Hz, 1H) .

Example 77

4'-[(3-butyl-5-methyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid

Following General Procedure A, 1.0 g (7.2 mmol) of 3-butyl-5-methyl-1H-1,2,4-triazole was reacted with 2.89 g (9.5 mmol) of the alkylating reagent prepared in step 1 of Example 1. Hydrolysis of the slower moving isomer provided 220 mg of 4'-[(3-butyl-5-methyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-carboxylic acid as a colorless solid: NMR (DMSO-d₆) δ 0.88 (t, J = 1 Hz, 3H), 1.25-1.38 (m, 2H), 1.54-1.67 (m, 2H), 2.39 (s, 3H), 2.54 (t, J = 8 Hz, 2H), 5.32 (s, 2H), 7.21 (d, J = 8 Hz, 2H), 7.32 (d, J = 8 Hz, 2H), 7.36 (dd, J = 8 and 2 Hz, 1H), 7.46 (dt, J = 8 and 2 Hz, 1H), 7.56 (dt, J = 8 and 2 Hz, 1H), 7.72 (dd, J = 8 and 2 Hz, 1H).

Exampel 78

4'-[(3-methyl-5-butyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-carboxylic acid

The faster moving isomer from Example 77 was hydrolyzed to provide 19 mg of 4'-[(3-methyl-5-butyl-1H-1,2,4- triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylic acid as a colorless solid: NMR (DMSO-d₆) δ 0.86 (t, J = 1 Hz, 3H), 1.25-1.38 (m, 2H), 1.52-1.64 (m, 2H), 2.21 (s, 3H), 2.72 (t, J = 1 Hz, 2H), 5.32 (s, 2H), 7.21 (d, J = 8 Hz, 2H), 7.32 (d, J = 8 Hz, 2H), 7.35 (dd, J = 8 and 2 Hz, 1H), 7.45 (dt, J = 8 and 2 Hz, 1H), 7.57 (dt, J = 8 and 2 Hz, 1H), 7.72 (dd, J = 8 and 2 Hz, 1H).

BIOLOGICAL EVALUATION

Assay A: Angiotensin Il Binding Activity

Compounds of the invention were tested for ability to bind to the smooth muscle angiotensin II receptor using a rat uterine membrane preparation. Angiotensin II (All) was purchased from Peninsula Labs. ¹²⁵l-angiotensin ll (specific activity of 2200 Ci/mmol) was purchased from Du Pont-New

England Nuclear. Other chemicals were obtained from Sigma Chemical Co. This assay was carried out according to the method of Douglas et al [Endocrinology, 1 06 , 120-124 (1980)]. Rat uterine membranes were prepared from fresh tissue. All procedures were carried out at 4°C. Uteri were stripped of fat and homogenized in phosphate-buffered saline at pH 7.4 containing 5 mM EDTA. The homogenate was centrifuged at 1500 x g for 20 min., and the supernatant was recentrifuged at

100,000 x g for 60 min. The pellet was resuspended in buffer consisting of 2 mM EGTA and 50 mM Tris-HCl (pH 7.5) to a final protein concentration of 4 mg/ml. Assay tubes were charged with 0.25 ml of a solution containing 5 mM MgCl₂, 2 mM EDTA,

0.5% bovine serum albumin, 50 mM Tris-HCl, pH 7.5 and ¹²⁵I-AII (approximately 10⁵ cpm) in the absence or in the presence of unlabelled ligand. The reaction was initiated by the addition of membrane protein and the mixture was incubated at 25°C for 60 min. The incubation was terminated with ice-cold 50 mM Tris-HCl (pH 7.5) and the mixture was filtered to separate membrane-bound labelled peptide from the free ligand. The incubation tube and filter were washed with ice-cold buffer. Filters were assayed for radioactivity in a Micromedic gamma counter. Nonspecific binding was defined as binding in the presence of 10 μM of unlabelled All. Specific binding was calculated as total binding minus nonspecific binding. The receptor binding affinity of an All antagonist compound was indicated by the concentration (IC₅₀) of the tested All antagonist which gives 50% displacement of the total

specifically bound ¹²⁵I-AII from the high affinity ("Type 1") All receptor. Binding data were analyzed by a nonlinear least-squares curve fitting program. Results are reported in Table I.

Assay B: ln Vitro Vascular Smooth Muscle-Response for All

The compounds of the invention were tested for antagonist activity in rabbit aortic rings. Male New Zealand white rabbits (2-2.5 kg) were sacrificed using an overdose of pentobarbital and exsanguinated via the carotid arteries. The thoracic aorta was removed, cleaned of adherent fat and connective tissue and then cut into 3-mm ring segments. The endothelium was removed from the rings by gently sliding a rolled-up piece of filter paper into the vessel lumen. The rings were then mounted in a water-jacketed tissue bath, maintained at 37°C, between moveable and fixed ends of a stainless steel wire with the moveable end attached to an FT03 Grass transducer coupled to a Model 8 Grass Polygraph for recording isometric force responses. The bath was filled with 20 ml of oxygenated (95% oxygen/5% carbon dioxide) Krebs solution of the following composition (mM) : 130 NaCl, 15

NaHCO₃, 15 KCl, 1.2 NaH₂PO₄, 1.2 MgSO₄, 2.5 CaCl₂, and 11.4 glucose. The preparations were equilibrated for one hour before approximately one gram of passive tension was placed on the rings. Angiotensin II concentration-response curves were then recorded (3 X 10^-10 to 1 X 10^-5 M). Each concentration of All was allowed to elicit its maximal contraction, and then All was washed out repeatedly for 30 minutes before

rechallenging with a higher concentration of All. Aorta rings were exposed to the test antagonist at 10^-5 M for 5 minutes before challenging with All. Adjacent segments of the same aorta ring were used for all concentration-response curves in the presence or absence of the test antagonist. The

effectiveness of the test compound was expressed in terms of pA₂ values and were calculated according to H.O. Schild [Br. J. Pharmacol. Chemother., 2, 189-206 (1947)]. The pA₂ value is the concentration of the antagonist which increases the EC₅₀ value for All by a factor of 2. Each test antagonist was evaluated in aorta rings from two rabbits. Results are reported in Table I.

Assay C: In Vivo Intraduodenal Pressor Assay Response for AlI Antagonists Male Sprague-Dawley rats weighing 225-300 grams were anesthetized with Inactin (100 mg/kg, i.p.) and catheters were implanted into the trachea, femoral artery, femoral vein and duodenum. Arterial pressure was recorded from the femoral artery catheter on a Gould chart recorder (Gould, Cleveland, OH). The femoral vein catheter was used for injections of angiotensin II, mecamylamine and atropine. The tracheal catheter allow for airway patency, and the duodenal catheter was used for intraduodenal (i.d.) administration of test compounds. After surgery, the rats were allowed to

equilibrate for 30 minutes. Mecamylamine (3 mg/kg, 0.3 ml/kg) and atropine (400 ug/kg, 0.3 ml/kg) were then given i.v. to produce ganglion blockade. These compounds were administered every 90 minutes throughout the test procedure. Angiotensin II was given in bolus does i.v. (30 ng/kg in saline with 0.5% bovine serum albumin, 0.1 ml/kg) every 10 minutes three times or until the increase in arterial pressure produced was within 3 mmHg for two consecutive All injections. The last two All injections were averaged and were taken as the control All pressor response. Ten minutes after the final control All injection, the test compound (dissolved in sodium bicarbonate) was administered i.d. at a dose of 3, 10, 30 or 100 mg/kg in a volume of 0.2 ml. Angiotensin II injections were then given 5, 10, 20, 30, 45, 60, 75, 90, and 120 minutes after

administration of the test compound and response of arterial pressure was monitored. The response to All was calculated as percent of the control response and then the percent

inhibition is calculated as 100 minus the percent control response. Duration of action of a test compound was defined as the time from peak percent inhibition to 50% of peak. One compound at one dose was tested in each rat . Each test compound was tested in two rats and the values for the two rats were averaged. Results are reported in Table I. Assay D: In Vivo Tntragastric Pressor Assay Response for All Antagonists

Male Sprague-Dawley rats weighing 225-300 grams were anesthetized with methohexital (30 mg/kg, i.p.) and catheters were implanted into the femoral artery and vein. The

catheters were tunneled subcutaneously to exit dorsally, posterior to the head and between the scapulae. The catheters were filled with heparin (1000 units/ml of saline). The rats were returned to their cage and allowed regular rat chow and water ad libitum. After full recovery from surgery (3-4 days), rats were placed in Lucite holders and the arterial line was connected to a pressure transducer. Arterial pressure was recorded on a Gould polygraph (mmHg). After 1-2 hours of stable baseline recording, the intravenous infusion of angiotensin II (50 ng/kg/min) was given at a rate of 0.0096 ml/min. After allowing one hour for pressure to stabilize, the test compound (suspended in 0.5% methylcellulose in water) was administered by gavage. The volume administered was 2 ml/kg body weight. Arterial pressure was monitored for 5 hours post-dosing. The angiotensin II infusion was then discontinued and pressure was allowed to reach a stable recovery level. Percent inhibition (%I) of the angiotensin II pressor response was calculated from the difference in pressure at a given timepoint post-dosing with the test compound and the angiotensin Il-infused pressure, divided by the difference in pressure with and without the angiotensin II infusion; this value was multiplied by 100. Duration of action of a test compound was defined as the time taken for pressure to return to angiotensin Il-infused baseline levels after compound administration. A compound at one dose was tested in two rats. Results are reported in Table I.

NT = NOT TESTED

*Antagonist activity not observed up to 10 μM of test compound. 1Assay A: Angiotensin II Binding Activity

2Assay B: In Vitro Vascular Smooth Muscle Response 3Assays C/D: In Vivo Pressor Response (test compounds administered intraduodenally, except for compounds of Examples #3, #26 and #30 which were given intragastrically).

Also embraced within this invention is a class of pharmaceutical compositions comprising one or more compounds of Formula I in association with one or more non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds of the present invention required to prevent or arrest the progress of the medical condition are readily ascertained by one of ordinary skill in the art. The compounds and composition may, for example, be administered intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically.

For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. These may with advantage contain an amount of active ingredient from about 1 to 250 mg, preferably from about 25 to 150 mg. A suitable daily dose for a mammal may vary widely depending on the condition of the patient and other factors. However, a dose of from about 0.1 to 3000 mg/kg body weight, particularly from about 1 to 100 mg/kg body weight, may be appropriate.

The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier. A suitable daily dose is from about 0.1 to 100 mg/kg body weight injected per day in multiple doses depending on the disease being treated. A preferred daily dose would be from about 1 to 30 mg/kg body weight. Compounds indicated for prophylactic therapy will preferably be administered in a daily dose generally in a range from about 0.1 mg to about 100 mg per kilogram of body weight per day. A more preferred dosage will be a range from about 1 mg to about 100 mg per kilogram of body weight. Most preferred is a dosage in a range from about 1 to about 50 mg per kilogram of body weight per day. A suitable dose can be administered, in multiple sub-doses per day. These sub-doses may be administered in unit dosage forms. Typically, a dose or sub-dose may contain from about 1 mg to about 100 mg of active compound per unit dosage form. A more preferred dosage will contain from about 2 mg to about 50 mg of active compound per unit dosage form. Most preferred is a dosage form containing from about 3 mg to about 25 mg of active compound per unit dose.

The dosage regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex and medical condition of the patient, the severity of the disease, the route of

administration, and the particular compound employed, and thus may vary widely.

For therapeutic purposes, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or

suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Although this invention has been described with respect to specific embodiments, the details of these

embodiments are not to be construed as limitations.

Claims

What Is Claimed Is:

1. Compound of Formula I

alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl,

polycycloalkylalkyl, thienylalkyl, phenylacyl,

phenylhaloalkyl, aminoalkyl, acylaminoalkyl,

alkoxycarbonylaminoalkyl, alkylcarbonyloxy, mercaptocarbonyl, mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio,

alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl,

aralkylthiocarbonyloxy, aralkylthiocarbonylthio,

alkylthiocarbonyl, aralkylthiocarbonylthio, mercapto,

alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R¹² and R¹³ taken together, R¹⁴ and R¹⁵ taken together and R¹⁶ and R¹⁷ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R¹² and R¹³ taken together and each of R¹⁴ and R¹⁵ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and wherein each of R³ through R¹¹ may be further

-Y_nA wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms;

wherein B is a single bond connecting the phenyl rings to form a biphenyl moiety or B is a group selected from

and -CH=CH-, wherein p is a number selected from one

through three, inclusive; wherein R¹⁸ is selected from

aralkoxycarbonyl; and wherein any of the foregoing R¹ through R¹⁸, Y, A and B groups having a substitutable position may be substituted by one or more groups selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl,

trifluoromethyl, halo, oxo, difluoroalkyl, alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl, cycloalkyl,

cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, carboxyl, mercapto,

wherein X is selected from oxygen atom and sulfur atom;

wherein R^{1 9} is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, DR²⁴ and

wherein D is selected from oxygen atom and sulfur atom and R²⁴ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁰, R²¹, R²², R²³, R²⁵ and R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁰' R²¹, R²², R²³ R²⁵ and R²⁶ is further independently selected from amino and amido radicals of the formula

wherein each of R²⁷, R²⁸, R²⁹, R³⁰ R³¹ and R³² is

cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl,

haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁰ and R²¹ taken together and each of R²² and R²³ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R²⁰ and R²¹ taken together and each of R²⁵ and R²⁶ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; or a tautomer thereof or a pharmaceutically- acceptable salt thereof.

2. Compound of Claim 1 wherein m is one; wherein each of R¹ through R^{1 1} is independently selected from hydrido, formyl, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, polycycloalkyl, polycycloalkylalkyl, thienylalkyl, phenylacyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl, alkoxycarbonylaminoalkyl, alkylcarbonyloxy, mercaptocarbonyl, mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio, alkylthiocarbonyl, alkylcarbonylthio,

alkylthiocarbonyloxy, alkylthioarbonylthio,

alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl,

aralkylthiocarbonylthio, aralkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto,

alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

-Y_nA wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; wherein B is a single bond or is a group selected from

wherein X is selected from oxygen atom and sulfur atom;

wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and R³² is

cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl,

3. Compound of Claim 2 wherein m is one; wherein each of R¹ through R¹¹ is independently selected from hydrido, hydroxy, formyl, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, polycycloalkyl, polycycloalkylalkyl, haloalkyl, thienylalkyl, phenylacyl, phenylhaloalkyl,

aminoalkyl, acylaminoalkyl, alkoxycarbonylaminoalkyl,

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from hydrido and haloalkyl, and from acidic moieties of the formula -Y_nA wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

wherein each of R³⁸ and R³⁹ is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R³⁸ and R³⁹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R³⁸ and R³⁹ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R³⁴ and R³⁵ may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially

and -CH=CH-, wherein p is a number selected from one

wherein X is selected from oxygen atom and sulfur atom;

independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

4. Compound of Claim 3 wherein m is one; wherein each of R ¹ and R² is independently selected from hydrido, hydroxy, formyl, alkyl, carboxyalkyl, phenyl, phenylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl,

polycycloalkylalkyl, alkylcarbonyl, alkoxyalkyl, hydroxyalkyl, halo, haloalkyl, thienylalkyl, phenylacyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl and alkoxycarbonylaminoalkyl; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties of the formula

-Y_nA

and -CH=CH-, wherein p is one or two; wherein R¹⁸ is

selected from hydrido, alkyl, aryl, formyl, alkylcarbonyl, arylcarbonyl, carboxyl, alkoxycarbonyl, aryloxycarbonyl and aralkoxycarbonyl; wherein each of R¹ through R¹¹, Y, A and B independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl,

haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and

aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

5. Compound of Claim 4 wherein m is one; wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, alkyl, carboxyalkyl, phenyl, phenylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl,

polycycloalkylalkyl, alkylcarbonyl, dialkoxyalkyl,

hydroxyalkyl, halo, haloalkyl, thienylalkyl, phenylacetyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl and

alkoxycarbonylaminoalky; wherein each of R³ through R ¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio, mercapto and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties of the formula

-Y_nA wherein n is a number selected from zero through two,

independently selected from amino radical of the formula

and -CH=CH-, wherein p is one; wherein R¹⁸ is selected from hydrido, alkyl, aryl, formyl, alkylcarbonyl, arylcarbonyl, carboxyl, alkoxycarbonyl, aryloxycarbonyl and aralkoxycarbonyl; wherein each of R¹ through R¹⁸, Y, A and B and independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

6. Compound of Claim 5 wherein m is one; wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl,

cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, adamantyl, adamantylmethyl, 1-oxoethyl, oxobutyl, 1-oxopentyl, dimethoxymethyl, diethoxymethyl, 1,1- dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxypropyl, halo, monofluoromethyl, difluoromethyl, 1,1- difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1- difluoropentyl, pentafluoroethyl, heptafluoropropyl,

thienylmethyl, 2-(2-thienyl)ethyl, 2-(3-thienyl)ethyl, phenylacetyl, phenyldifluoroethyl, aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, acetyl,

alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties consisting of CO₂H, CO₂CH_3, SH, CH₂SH, C₂H₄SH, PO₃H₂, NHSO₂CF₃,

NHSO₂C₆F_5, SO₃H, CONHNH_2, CONHNHSO₂CF₃, CONHOCH₃, CONHOC₂H_5, CONHCF₃, OH, CH₂OH, C₂H₄OH, OPO₃H_2, OSO₃H and heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein B is a single bond or is one or more groups selected from

wherein p is one; wherein R¹⁸ is selected from

7. Compound of Claim 6 wherein m is one; wherein R¹ is selected from hydrido, hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n- octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, adamantyl, adamantylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl,

dimethoxymethyl, diethoxymethyl, 1,1-dimethoxypropyl,

1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, pentafluoroethyl, heptafluoropropyl, thienylmethyl, 2- (2-thienyl) ethyl, phenylacetyl, phenyldifluoroethyl,

aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl and t-butoxycarbonylaminoethyl; wherein R² is selected from hydrido, carboxyethyl, cyclohexyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n- pentyl and neopentyl; with the proviso that both R¹ and R² cannot be hydrido simultaneously; wherein each of R³, R⁴, R⁷,

R⁹, R¹⁰ and R¹¹ is hydrido; wherein at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic moiety selected from CO₂H, SH, PO₃H₂ SO₃H, CONHNH_2, CONHNHSO₂CF₃, OH,

wherein each of R⁴⁰ and R⁴¹ is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃; and the amide, ester and salt derivatives of said acidic moieties; wherein B is a single bond or is a group selected from O O O

ll

-(CH₂)

-C-, -CN- , -NC- , -O- , -S- and -N- ,

H H R¹⁸ wherein p is one; wherein R¹⁸ is selected from

8. Compound of Claim 7 wherein m is one; wherein R¹ is selected from hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4- methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclohexylmethyl,

dimethoxymethyl, diethoxymethyl, 1,1-dimethoxypropyl,

phenyldifluoroethyl, aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl and t-butoxycarbonylaminoethyl; wherein R² is selected from carboxyethyl, cyclohexyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl and neopentyl; wherein each of R³, R⁴, R⁷, R⁹, R¹⁰ and R¹¹ is hydrido; wherein at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic moiety selected from CO₂H, SH, PO₃H₂ SO₃H, CONHNH_2, CONHNHSO₂CF₃, OH,

wherein p is one; wherein R¹⁸ is selected from

9. Compound of Claim 8 wherein at least one of R⁵ and R⁹ is an acidic moiety selected from CO₂H, SH, PO₃H_2, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

wherein each of R⁴⁰ and R⁴¹ is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃; and the amide, ester and salt derivatives of said acidic moieties; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

10. Compound of Claim 9 selected from compounds, and their pharmaceutically-acceptable salts, of the group of compounds consisting of

2-[[4-[(3,5-dibutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid; 2-[[4-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-dipropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-isopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-disecbutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-dipentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid; 2- [ [4- [ (3, 5-diisopentyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-(1-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-(2-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-(3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[[5-(3-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-diethoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-dipropoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[(3,5-dibutoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

2-[[4-[[3,5-di(2-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid; 2- [ [4- [ [3, 5-di (3-butenyl) -1H-1, 2, 4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

5-[2-[[4-[(3-butyy-5-chloro-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl-1H-tetrazole;

5-[2-[[4-[(5-butyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-dibutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-butyl-3-(1,1 dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-dipropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5- [2- [ [4- [ (3, 5-isopropyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-secbutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-secbutyl-3-butyl-1H-1,2,4-triazol-1- yl) methyl]phenyl] methyl ]phenyl] -1H-tetrazole;

5- [2- [ [4- [ (3, 5-disecbutyl-1H-1, 2, 4-triazol-1 - yl)methyl]phenyl] methyl]phenyl] -1H-tetrazole;

5- [2- [ [4- [ (5-secbutyl-3-isopentyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-secbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-secbutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-secbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]1H-tetrazole; 5-[2-[[4-[[5-secbutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-isobutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-isobutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-isobutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-isobutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-tertbutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-tertbutyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-tertbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-tertbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-tertbutyl-3-(1,1-difluoropentyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5- [2- [ [4- [ (5-pentyl-3-propyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-isopentyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(5-isopentyl-3-butyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-isopentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-(1-butenyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5- [2- [ [4- [ [5- (1-butenyl) -3-butyl-1H-1, 2, 4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5-[2-[[4-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-dipropoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[(3,5-diisopropoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[3,5-di(2-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5- [2- [ [4- [ [3, 5-di (3-butenyl) -1H-1, 2, 4-triazol-1 - yl]methyl]phenyl] methyl]phenyl] -1H-tetrazole;

5- [2- [ [4- [ [3, 5-di (1-butynyl) -1H-1, 2, 4-triazol-1- yl]methyl]phenyl]methyl]phenyl][-1H-tetrazole;

5-[2-[[4-[[3,5-di(2-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[2-[[4-[[3,5-di(3-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

3-[[4-[(3,5-dibutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid; 3-[[4-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-dipropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-isopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-propyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

3-[[4-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-dipentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid; 3- [ [4- [ (3, 5-diisopentyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-(1-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-(2-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-(3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[[5-(3-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-diethoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-dipropoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-dibutoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-dithiopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[(3,5-dithioisopropyl-1H-1,2,4-triazol-1-yl)methyl]phenyl]methyl]benzoic acid;

3-[[4-[[3,5-di(2-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid; 3-[[4-[[3,5-di(3-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]benzoic acid;

5-[3-[[4-[(3,5-dibutyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-buty1-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3,5-dipropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5- [3- [ [4- [ (3, 5-isopropyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-propyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-2-yl]-1H-tetrazole;

5-[3-[[4-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-secbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-secbutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-secbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]1H-tetrazole; 5-[3-[[4-[[5-secbutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-isobutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl] -1H-tetrazole;

5-[3-[[4-[[5-isobutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-isobutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-isobutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5- [3- [ [4- [ (5-tertbutyl-3-propyl-1H-1, 2, 4-triazol-1- y l)methyl]phenyl]methyl]phenyl] -1H-tetrazole;

5- [3- [ [4- [ (5-tertbutyl-3-butyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-tertbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-tertbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-tertbutyl-3-(1,1-difluoropentyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5- [3- [ [4- [ (5-pentyl-3-propyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-isopentyl-3-ethyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(5-isopentyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-isopentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-

1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-isopentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-(1-butenyl)-3-propyl-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5- [3- [ [4- [ [5- (1-butenyl) -3-butyl-1H-1, 2, 4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5-[3-[[4-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[5-(3-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4- triazol-1-yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3,5-dipropoxy-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3,5-dithioethyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[(3,5-dithiopropyl-1H-1,2,4-triazol-1- yl)methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5- [3- [ [4- [ (3, 5-dithioisopropyl-1H-1, 2, 4-triazol-1- yl)methyl]phenyl]methyl]phenyl] -1H-tetrazole;

5- [3- [ [4- [ [3, 5-di (1-butenyl) -1H-1, 2, 4-triazol-1 - yl] methyl]phenyl]methyl]phenyl] -1H-tetrazole;

5- [3- [ [4- [ [3, 5-di (2-butenyl) -1H-1, 2, 4-triazol-1 - yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole; 5-[3-[[4-[[3,5-di(3-butenyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole;

5-[3-[[4-[[3,5-di(3-butynyl)-1H-1,2,4-triazol-1- yl]methyl]phenyl]methyl]phenyl]-1H-tetrazole.

11. Compound of Claim 1 of Formula II

wherein m is a number selected from one to four, inclusive; wherein each of R¹ through R^{1 1} is independently selected from hydrido, formyl, hydroxy, alkyl, hydroxyalkyl, halo,

haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl,

polycycloalkylalkyl, thienylalkyl, phenylacyl,

phenylhaloalkyl, aminoalkyl, acylaminoalkyl,

alkoxycarbonylaminoalkyl, glutamic acid alkyl ester,

alkylcarbonylthio, alkylthiocarbonyloxy,

alkylthiocarbonylthio, alkylthiothiocarbonyl,

aralkylthiocarbonyloxy, aralkylthiocarbonylthio,

alkylthiocarbonyl, aralkylthiocarbonylthio, mercapto,

alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein

R¹² and R¹³ taken together, R¹⁴ and R¹⁵ taken together and R¹⁶ and R¹⁷ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R¹² and R¹³ taken together and each of R¹⁴ and R¹⁵ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino or amido radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and wherein each of R³ through R¹¹ may be further

independently selected from hydrido and haloalkyl, and from acidic moieties of the formula -Y_nA wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties;

wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R¹ through R¹⁷, Y and A groups having a substitutable position may be substituted by one or more groups selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, halo, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, carboxyl, mercapto,

wherein X is selected from oxygen atom and sulfur atom;

wherein D is selected from oxygen atom and sulfur atom and R²⁴ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁰, R²¹, R²², R²³, R²⁵ and R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁰, R²¹, R²², R²³, R²⁵ and R²⁶ is further independently selected from amino and amido radicals of the formula

wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and R³² is

cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl,

12. Compound of Claim 11 wherein m is one; wherein each of R¹ through R¹¹ is independently selected from hydrido, formyl, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, polycycloalkyl, polycycloalkylalkyl, thienylalkyl, phenylacyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl, alkoxycarbonylaminoalkyl, glutamic acid alkyl ester, alkylcarbonyloxy, mercaptocarbonyl,

mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio,

alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthioarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio,

arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio,

aralkylthiocarbonyloxy, aralkylthiocarbonylthio,

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

independently selected from hydrido and haloalkyl, and from acidic moieties of the formula -Y_nA wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R¹ through R¹⁷, Y and A groups having a substitutable position may be substituted by one or more groups selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl,

carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom;

wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and R³² is

cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl,

13. Compound of Claim 12 wherein m is one; wherein each of R¹ through R¹¹ is independently selected from hydrido, hydroxy, formyl, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, polycycloalkyl, polycycloalkylalkyl, haloalkyl, thienylalkyl, phenylacyl, phenylhaloalkyl,

aminoalkyl, acylaminoalkyl, alkoxycarbonylaminoalkyl, glutamic acid alkyl ester, alkylcarbonyloxy, mercaptocarbonyl,

alkoxycarbonyloxy, alkylthio, arylthio, aralkylthio,

aralkylthiocarbonylthio, mercapto, alkylsulfinyl,

alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and amino and amido radicals of the formula

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

H W W W W

-OH, -SH, -NR³³, -C-WH, -S-WH, -S-WH, -P-WH, -P-NH and -P-WH

W R³⁴ R³⁵ WR³⁶ wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁷; wherein each of R³³, R³⁴, R³⁵, R³⁶ and R³⁷ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,

alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl,

wherein X is selected from oxygen atom and sulfur atom;

14. Compound of Claim 13 wherein m is one; wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, alkyl, carboxyalkyl, phenyl, phenylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl,

polycycloalkylalkyl, alkylcarbonyl, alkoxyalkyl, hydroxyalkyl, halo, haloalkyl, thienylalkyl, phenylacyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl, alkoxycarbonylaminoalkyl and glutamic acid alkyl ester; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties of the formula

H W W W

-OH, -SH, -NR³³, -C-WH, -S-WH, -S-WH and -P-WH

W WR³⁶ wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁷; wherein each of R³³, R³⁶ and R³⁷ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,

-

wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R^{1 1} so as to form a fused-ring system with one of the phenyl rings of Formula I; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; wherein each of R¹ through R¹¹, Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

15. Compound of Claim 14 wherein m is one; wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, alkyl, carboxyalkyl, phenyl, phenylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl,

polycycloalkylalkyl, alkylcarbonyl, dialkoxyalkyl,

hydroxyalkyl, halo, haloalkyl, thienylalkyl, phenylacetyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl,

alkoxycarbonylaminoalkyl and glutamic acid alkyl ester; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio, mercapto and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties of the formula

-Y_nA wherein n is a number selected from zero through two,

H W W W

-OH, -SH, -NR^{3 3}, -C-WH, -S-WH, -S-WH and -P-WH

W I

WR³⁶ wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁷; wherein each of R³³, R³⁶ and R³⁷ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R³³ and R³⁶ may be further

independently selected from amino radical of the formula

alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula II; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl; wherein each of R¹ through R¹¹, Y and A and independently may be substituted at any substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, oxo, trifluoromethyl, difluoroalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

16. Compound of Claim 15 wherein m is one; wherein each of R¹ arid R² is independently selected from hydrido, hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl,

cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl,

cyclohexylpropyl, adamantyl, adamantylmethyl, 1-oxoethyl, oxobutyl, 1-oxopentyl, dimethoxymethyl, diethoxymethyl,

1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxypropyl, halo, monofluoromethyl, difluoromethyl,

1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1- difluoropentyl, pentafluoroethyl, heptafluoropropyl,

thienylmethyl, 2(2-thienyl) ethyl, 2(3-thienyl)ethyl,

phenylacetyl, phenyldifluoroethyl, aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, acetyl,

alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties consisting of CO₂H, CO₂CH₃, SH, CH₂SH, C₂H₄SH, PO₃H₂, NHSO₂CF₃ ,

NHSO ₂C₆F_5, SO ₃H, CONHNH_2, CONHNHSO₂CF₃ , CONHOCH₃ , CONHOC₂H_5, CONHCF ₃, OH, CH₂OH, C₂H₄OH, OPO ₃H_{2 ,} OSO ₃H ,

wherein each of R⁴⁰, R⁴¹ and R⁴² is independently selected from H, Cl, CN, NO₂, CF₃, C₂F₅, C₃F₇, CHF₂, CH₂F, CO₂CH₃, CO₂C₂H₅, SO₂CH_3, SO₂CF₃ and SO₂C₆F₅; wherein Z is selected from O, S, NR⁴³ and CH₂; wherein R⁴³ is selected from hydrido, CH₃ and CH₂C₆H_5; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R³ through R¹¹ so as to form a fused ring system with one of the biphenyl rings of the biphenyl moiety of

Formula II, said fused ring system selected from

and the esters, amides and salts of said acidic moieties.

17. Compound of Claim 16 wherein m is one; wherein R¹ is selected from hydrido, hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n- octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, adamantyl, adamantylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl,

dimethoxymethyl, diethoxymethyl, 1,1-dimethoxypropyl,

2(2-thienyl)ethyl, phenylacetyl, phenyldifluoroethyl,

CONHNHSO₂CF₃, OH,

wherein each of R⁴⁰ and R⁴¹ is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H_2, SO₃H, CONHNH_2, CONHNHSO₂CF₃, OH,

wherein each of R⁴⁰ and R⁴¹ is independently selected from Cl, CN, NO₂, CF₃, CO₂CH₃ and SO₂CF₃; and the esters, amides and salt derivatives of said acidic moieties; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

18. Compound of Claim 17 wherein m is one; wherein

R¹ is selected from hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4- methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclohexylmethyl,

dimethoxymethyl, diethoxymethyl, 1,1-dimethoxypropyl, 1,1- dimethoxybutyl, 1,1-dimethoxypentyl, hydroxypropyl, halo, monofluoromethyl, difluoromethyl, 1,1-difluoroethyl, 1,1- difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl,

pentafluoroethyl, heptafluoropropyl, phenylacetyl,

phenyldifluoroethyl, aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein R² is selected from carboxyethyl, cyclohexyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert- butyl, n-pentyl and neopentyl; wherein at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂ SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

19. Compound of Claim 18 wherein at least one of R⁵ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H_2, SO₃H, CONHNH_2, CONHNHSO₂CF₃, OH,

20. Compound of Claim 17 selected from compounds, and their pharmaceutically-acceptable salts, of the group of compounds consisting of

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-carboxylic acid, 2-[(trifluoromethyl)sulfonyl]hydrazide;

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-carboxylic acid;

4 '-[[5-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-propyl-3-(1,1-difluoroethyl) 1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4'-[[5-isobutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylie acid;

4'-[[5-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid; 4 ' - [ (3, 5-diisopentyl-1H-1, 2, 4-triazol-1-yl) methyl] [1, 1 ' - biphenyl]-2-carboxylic acid;

4'-[[5-(3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-carboxylic acid;

4 '- [ [3, 5-di (2-butenyl) -1H-1, 2, 4-triazol-1-yl] methyl] [1, 1 ' - biphenyl]-2-carboxylic acid; 4'-[[3,5-di(3-butenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-carboxylic acid;

5-[4'-[(5-butyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1,1 dimethoxybutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dipropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(3,5-isopropyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-[iphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yljmethyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(5-isobutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isobutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[(5-pentyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dipentyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-isopentyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl] [1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-diisopentyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-butyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-(1-butenyl)-3-isopentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yljmethyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dipropoxy-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3,5-di(2-butenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5- [4 ' - [ [3, 5-di (3-butenyl) -1H-1, 2, 4-triazol-1-yl]methyl] [1, 1 ' - biphenyl] -2-yl] -1H-tetrazole; 5-[4'-[[3,5-di(1-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

21. Compound of Claim 17 selected from compounds, and their pharmaceutically-acceptable salts, of the group of compounds consisting of

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

3-carboxylic acid, hydrazide;

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

3-carboxylic acid, 2-[(trifluoromethyl)sulfonyl]hydrazide; 4'-[(5-butyl-3-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

3-carboxylic acid;

4'-[[5-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-butyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid; 4'-[[5-butyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[(3,5-dipropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[5-propyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-ethyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[[5-secbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yljmethyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[(3,5-ditertbutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid; 4'-[[5-tertbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[(3,5-diisopentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[5-isopentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-carboxylic acid;

4'-[(3,5-dithiopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid; 4'-[(3,5-dithioisopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[3,5-di(1-butenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[3,5-di(3-butenyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-carboxylic acid;

4'-[[3,5-di(1-butynyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-3-carboxylic acid;

5-[4'-[[5-buty1-3-(1,1 dimethoxybutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole; 5-[4'-[[3-butyl-5-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-isopropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-propyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yljmethyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5- [4 ' - [ [5-propyl-3- (1, 1-difluorobutyl) -1H-1, 2, 4-triazol-1- yl]methyl] [1, 1 ' -biphenyl] -3-yl] -1H-tetrazole;

5-[4'-[[5-propyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-secbutyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole; 5-[4'-[[5-secbutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-propyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-isobutyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-tertbutyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole; 5-[4'-[[5-tertbutyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-dipentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(5-pentyl-3-isopentyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(1,1-difluoropropyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluoroethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-isopentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole; 5-[4'-[[5-isopentyl-3-(1,1-difluoropentyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-isopentyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(1-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(2-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(3-butenyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(1-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(2-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[5-(3-butynyl)-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[(3,5-dithihisopropyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-3-yl]-1H-tetrazole; 5-[4'-[[3,5-di(1-butenyl)-1H-1,2,4-triazol-1-yl]methyl] [1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[3,5-di(2-butenyl)-1H-1,2,4-triazol-1-yl]methyl] [1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[3,5-di(3-butenyl)-1H-1,2,4-triazol-1-yl]methyl] [1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[3,5-di(1-butynyl)-1H-1,2,4-triazol-1-yl]methyl] [1,1'- biphenyl]-3-yl]-1H-tetrazole;

5-[4'-[[3,5-di(2-butynyl)-1H-1,2,4-triazol-1-yl]methyl] [1,1'- biphenyl]-3-yl]-1H-tetrazole; and

5-[4'-[[3,5-di(3-butynyl)-1H-1,2,4-triazol-1-yl]methyl] [1,1'- biphenyl]-3-yl]-1H-tetrazole.

22. Compound of Claim 17 selected from compounds, and their pharmaceutically-acceptable salts, of the group of compounds consisting of

methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-carboxylate;

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-carboxylic acid, hydrazide;

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-carboxylic acid, 2-[(trifluoromethyl)sulfonyl]hydrazide;

5'-[(3-butyl-5-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-buty1-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3,5-dipropyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

5.-[4'-[(5-butyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl]-[1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-5-prσpyl-1H-1,2,4-triazol-1-yl)methyl]-[1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-5-isopentyl-1H-1,2,4-triazol-1-yl)methyl]-

[1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1-yl]methyl)-

[1,1'-biphenyl]-2-yl]-1H-tetrazole;

4'-[(5-butyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'-biphenyl]-2- carboxylic acid;

4'-[(3-butyl-1H-1,2,4-triazol-1-yl)methyl][1.1'-biphenyl]-2- carboxylic acid;

5-[4'-[(3-butyl-5-phenyl-1H-1,2,4-triazol-1-yl)methyl](1,1'- biphenyl)-2-yl]-1H-tetrazole;

5-[4'-[[3-butyl-5-(dimethoxymethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-dimethoxymethyl-1H-1,2,4-triazol-1- yl)methyl] (1,1'-biphenyl-2-yl]-1H-tetrazole;

5-[4'[(5-butyl-3-phenylethyl-1H-1,2,4-triazol-1- yl)methyl](1,1'-biphenyl-2-yl]-1H-tetrazole; 5-[4'-[(3-butyl-5-octyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-octyl-1H-1,2,4-triazol-1-yl)methyl] [1,1'- biphenyl]-2-yl]-1H-tetrazole;

1-[[5-butyl-1-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4- ylmethyl]-1H-1,2,4-triazol-3-yl]methyl]-1-butanone;

N-[[5-butyl-1-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4- ylmethyl]-1H-1,2,4-triazol-3-yl]methyl] acetamide;

5-[4'-[(5-butyl-3-methyl-1H-1,2,4-triazol-1-yl)methyl]-[1,1'- biphenyl]-2-yl]-1H-tetrazole;

glutamine, 1,1-dimethylethyl ester;

5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-

1H-1,2,4-triazole-3-propanol;

3-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-lylmethyl]-1H-

1,2,4-triazole-5-propanol;

5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-

1H-1,2,4-triazole-3-carboxylic acid;

5-[4'-[(5-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]- 2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-yl]-1H-tetrazole;

5-[4'-[[3-butyl-5-(tricyclo[3.3.1.1^3.7]dec-1-ylmethyl]-1H-

1,2,4-triazole-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(tricyclo[3.3.1.1^3.7]dec-1-ylmethyl]-1H-

1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

3-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]- 1H-1,2,4-triazole-5-propanoic acid;

5-[4'-[(3-butyl-5-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-cyclohexyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[3-(1,1,2,2,2-pentafluoroethyl)-5-butyl-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[3-(1,1,2,2,3,3,3-heptafluoropropyl)-5-butyl-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3-cyclohexylmethyl-5-butyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

4'-[(3-ethyl-5-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-carboxylic acid;

5-[4'-[[5-propyl-3-(2-thienylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5- [4'-[[5-propyl-3-(3-thienylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-(2-thieniophencarbonyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-propyl-3-(3-thieniophencarbonyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-propyl-3-[1-oxo-(2-thienyl)propyl-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(2-thienylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(3-thienylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-[2-(2-thienyl)ethyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-buty1-3-(3-thieniophencarbonyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-butyl-3-[1,1-difluoro-2-(2-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-[1-oxo-2-(2-thienyl)ethyl]-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-[1-oxo-2-(3-thienyl)ethyl]-1H-1,2,4-triazol-

1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-[1-oxo-2-(2-thienyl)propyl-1H-1,2,4-triazol- 1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-(2-thienylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-[2-(2-thienyl)ethyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-[2-(3-thienyl)ethyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-[1,1-difluoro-2-(2-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-pentyl-3-[1,1-difluoro-2-(3-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-[1-oxo-2-(3-thienyl)ethyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-pentyl-3-[1-oxo-3-(2-thienyl)propyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; and 5-[4'-[[5-pentyl-3-[1-oxo-3-(3-thienyl)propyl]-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole.

23. Compound of Claim 22 which is 4'[(3,5-dibutyl- 1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylie acid or a pharmaceutically-acceptable salt thereof.

24. Compound of Claim 22 which is 5-[4'-[(3,5- dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H- tetrazole or a pharmaceutically-acceptable salt thereof.

25. Compound of Claim 22 which is 5'-[(5-butyl-3- chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H- tetrazole or a pharmaceutically-acceptable salt thereof.

26. Compound of Claim 22 which is 5-[4'-[[5-butyl- 3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole or a pharmaceutically-acceptable salt thereof.

27. Compound of Claim 22 which is 5-[4'-[(3,5- dipropyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-

1H-tetrazole or a pharmaceutically-acceptable salt thereof.

28. Compound of Claim 22 which is 5-[4'-[(3,5- dipentyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]- 1H-tetrazole or a pharmaceutically-acceptable salt thereof.

29. Compound of Claim 22 which is 5-[4'-[(5-butyl-

3-propyl-1H-1,2,4-triazol-1-yl)methyl]-[1,1'-biphenyl]-2-yl]- 1H-tetrazole or a pharmaceutically-acceptable salt thereof.

30. Compound of Claim 22 which is 5-[4'-[(3-butyl- 5-propyl-1H-1,2,4-triazol-1-yl)methyl]-[1,1'-biphenyl]-2-yl]-

1H-tetrazole or a pharmaceutically-acceptable salt thereof.

31. Compound of Claim 22 which is 5-[4'-[(3-butyl- 5-isopentyl-1H-1,2,4-triazol-1-yl)methyl]-[1,1'-biphenyl]-2 - yl]-1H-tetrazole or a pharmaceutically-acceptable salt thereof.

32. Compound of Claim 22 which is 5-[4'-[(5-butyl- 3-isopentyl-1H-1,2,4-triazol-1-yl]methyl)-[1,1'-biphenyl]-2- yl]-1H-tetrazole or a pharmaceutically-acceptable salt thereof.

33. Compound of Claim 22 which is 5- [4 '-[(3- phenyl-5-butyl-1H-1,2,4-triazol-1-yl)methyl](1,1'-biphenyl)-2- yl]-1H-tetrazole or a pharmaceutically-acceptable salt thereof.

34. Compound of Claim 22 which is 5-[4'-[(5-butyl- 3-dimethoxymethyl-1H-1,2,4-triazol-1-yl)methyl](1,1'-biphenyl- 2-yl]-1H-tetrazole or a pharmaceutically-acceptable salt thereof.

35. Compound of Claim 22 which is 5-[4'[(5-butyl- 3-phenylethyl-1H-1,2,4-triazol-1-yl)methyl](1,1'-biphenyl-2- yl]-1H-tetrazole or a pharmaceuticaily-acceptable salt

thereof.

36. Compound of Claim 22 which is 1-[[5-butyl-1- [2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-1H-1,2,4- triazol-3-yl]methyl]-1-butanone or a pharmaceutically- acceptable salt thereof.

37. Compound of Claim 22 which is 5-[4'-[(5-butyl- 3-methyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-

1H-tetrazole or a pharmaceutically-acceptable salt thereof.

38. Compound of Claim 22 which is 5-[4'-[[5-butyl- 3-(2,2-diethyoxyethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole or a pharmaceutically-acceptable salt thereof.

39. Compound of Claim 22 which is 5-[4'-[(5-butyl- 3-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H- tetrazole or a pharmaceutically-acceptable salt thereof.

40. Compound of Claim 22 which is 5-[4'-[(3-butyl- 5-ethyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H- tetrazole or a pharmaceutically-acceptable salt thereof.

41. Compound of Claim 22 which is 5-[4'-[[5-butyl- 3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole or a pharmaceutically-acceptable salt thereof.

42. Compound of Claim 22 which is 5-[4'-[[5-butyl- 3-(phenylmethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]- 2-yl]-1H-tetrazole or a pharmaceutically-acceptable salt thereof.

43. Compound of Claim 22 which is 5-butyl-1-[2'- (1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-1H-1,2,4- triazole-3-propanol or a pharmaceutically-acceptable salt thereof.

44. Compound of Claim 22 which is 5-[4'-[[5-butyl- 3- (difluoromethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole or a pharmaceutically-acceptable salt thereof.

45. Compound of Claim 22 which is 5-[4'-[[5-butyl- 3-(difluoromethyl)-1H-1,2,4-triazol-1-yl]methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole or a pharmaceutically-acceptable salt thereof.

46. Compound of Claim 22 which is 5-[4'-[[5-butyl- 3-(1,1-difluoro-2-phenylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-1-yl]-1H-tetrazole or a

pharmaceutically-acceptable salt thereof.

47. Compound of Claim 22 which is 5-butyl-1-[2'- (1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-1H-1,2,4- triazole-3-carboxylic acid or a pharmaceutically-acceptable salt thereof.

48. Compound of Claim 22 which is 5-[4'-[(5-butyl- 1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-1H- tetrazole or a pharmaceutically-acceptable salt thereof.

49. Compound of Claim 22 which is 5-[4'-[[3-butyl' 5-(tricyclo[3.3.1³-⁷]dec-1-yl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole or a

pharmaceutically-acceptable salt thereof.

50. Compound of Claim 22 which is 5-[4'-[[5-butyl- 3-(tricyclo[3.3.1.1^3.7]dec-1-yl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole or a

pharmaceutically-acceptable salt thereof.

51. Compound of Claim 22 which is 5-[4'-[[5-butyl- 3-(tricyclo[3.3.1.1^3.7]dec-1-ylmethyl]-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole or a

pharmaceutically-acceptable salt thereof.

52. Compound of Claim 22 which is 5-butyl-1-[2'- (1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-1H-1,2,4- triazole-3-propanoic acid or a pharmaceutically-acceptable salt thereof.

53. Compound of Claim 22 which is 5-[4'-[(3-butyl- 5-cyclohexyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2- yl]-1H-tetrazole or a pharmaceutically-acceptable salt thereof.

54. Compound of Claim 22 which is 5-[4'-[(5-butyl- 3-cyclohexyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2- yl]-1H-tetrazole or a pharmaceutically-acceptable salt thereof.

55. Compound of Claim 22 which is 5-[4'-[[3- (1,1,2,2,2-pentafluoroethyl)-5-butyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazol or a

pharmaceutically-acceptable salt thereof.

56. Compound of Claim 22 which is 5-[4'-[[3-

(1,1,2,2,3,3,3-heptafluoropropyl)-5-butyl-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole or a

pharmaceutically-acceptable salt thereof.

57. Compound of Claim 22 which is 5-[4'-[(3- cyclohexylmethyl-5-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole or a pharmaceutically-acceptable salt thereof.

58. A pharmaceutical composition comprising a therapeutically-effective amount of an angiotensin II

antagonist compound and a pharmaceutically-acceptable carrier or diluent, said antagonist compound selected from a family of compounds of Formula II:

alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl,

polycycloalkylalkyl, thienylalkyl, phenylacyl,

phenylhaloalkyl, aminoalkyl, acylaminoalkyl,

alkoxycarbonylaminoalkyl, glutamic acid alkyl ester,

alkylcarbonylthio, alkylthiocarbonyloxy,

alkylthiocarbonylthio, alkylthiothiocarbonyl,

aralkyIthiocarbonyloxy, aralkylthiocarbonylthio,

alkylthiocarbonyl, aralkylthiocarbonylthio, mercapto,

alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein

-Y_nA wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties;

aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula ^x

wherein X is selected from oxygen atom and sulfur atom;

wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and R³² is

cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl,

59. The composition of Claim 58 wherein m is one; wherein each of R¹ through R¹¹ is independently selected from hydrido, formyl, hydroxy, alkyl, hydroxyalkyl, halo,

haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,

polycycloalkylalkyl, thienylalkyl, phenylacyl,

phenylhaloalkyl, aminoalkyl, acylaminoalkyl,

alkoxycarbonylaminoalkyl, glutamic acid alkyl ester,

arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkyIthiocarbonyloxy,

aralkylthiocarbonylthio, aralkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto,

alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

independently selected from hydrido and haloalkyl, and from acidic moieties of the formula -Y_nA wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R¹ through R¹⁷, Y and A groups having a substitutable position may be substituted by one or more groups selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom;

cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁰, R²¹, R²², R²³, R²⁵, and R²⁶ is further independently selected from amino and amido radicals of the formula 3₁

wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and R³² is

60. The composition of Claim 59 wherein m is one; wherein each of R¹ through R¹¹ is independently selected from hydrido, hydroxy, formyl, alkyl, hydroxyalkyl, halo,

polycycloalkylalkyl, haloalkyl, thienylalkyl, phenylacyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl,

alkoxycarbonylaminoalkyl, glutamic acid alkyl ester,

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

H W W W W

II

-OH, -SH, -NR³³, -C-WH, -S-WH, -S-WH, -P-WH, -P-NH and -P-WH

W R^R4 R³⁵ WR³⁶ wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁷; wherein each of R³³, R³⁴, R³⁵, R³⁶ and R³⁷ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,

alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, mercaptocarbonyl, alkylthio, alkylthiocarbonyl, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom;

wherein D is selected from oxygen atom and sulfur atom, wherein R²⁴ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁰, R²¹, R²², R²³, R²⁴ and R²⁶ is

61. The composition of Claim 60 wherein m is one; wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, alkyl, carboxyalkyl, phenyl, phenylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, alkylcarbonyl, alkoxyalkyl, hydroxyalkyl, halo, haloalkyl, thienylalkyl, phenylacyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl, alkoxycarbonylaminoalkyl and glutamic acid alkyl ester; wherein each of R³ through R^{1 1} is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties of the formula

H W W W

-OH, -SH, -NR³³, -C-WH, -S-WH, -S-WH and -P-WH

II

W WW³³ wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁷; wherein each of R³³, R³⁶ and R³⁷ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,

62. The composition of Claim 61 wherein m is one; wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, alkyl, carboxyalkyl, phenyl, phenylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, alkylcarbonyl, dialkoxyalkyl,

alkoxycarbonylaminoalkyl and glutamic acid alkyl ester; wherein each of R³ through R^{1 1} is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio, mercapto and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties of the formula

-Y_nA wherein n is a number selected from zero through two, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

H W W W

-OH, -SH, -NR³³, -C-WH, -S-WH, -S-WH and -P-WH

W WW ³⁶ wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁷; wherein each of R³³, R³⁶ and R³⁷ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R³³ and R³⁶ may be further

independently selected from amino radical of the formula

-

63. The composition of Claim 62 wherein m is one; wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl,

cyclohexyl, cyclopentylmethyl, cyclohexylmethyl,

1,1-difluorobutyl, 1, 1-difluoropentyl, pentafluoroethyl, heptafluoropropyl, thienylmethyl, 2(2-thienyl)ethyl,

2(3-thienyl)ethyl, phenylacetyl, phenyldifluoroethyl,

alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties consisting of CO₂H, CO₂CH₃, SH, CH₂SH, C₂H₄SH, PO₃H_2, NHSO₂CF₃,

NHSO₂C₆F_5, SO₃H, CONHNH₂, CONHNHSO₂CF₃, CONHOCH₃, CONHOC₂H_5, CONHCF₃, OH, CH₂OH, C₂H₄OH, OPO₃H₂, OSO₃H,

wherein each of R⁴⁰, R⁴¹ and R⁴² is independently selected from H, Cl, CN, NO₂, CF₃, C₂F₅, C₃F₇, CHF₂, CH₂F, CO₂CH₃, CO₂C₂H₅, SO₂CH_3, SO₂CF₃ and SO₂C₆F₅; wherein Z is selected from O, S, NR⁴³ and CH₂; wherein R⁴³ is selected from hydrido, CH₃ and CH₂C₆H_5; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R³ through R¹¹ so as to form a fused ring system with one of the biphenyl rings of the biphenyl moiety of Formula II, said fused ring system selected from

and the esters, amides and salts of said acidic moieties.

64. The composition of Claim 63 wherein m is one; wherein R¹ is selected from hydrido, hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n- heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl,

adamantyl, adamantylmethyl, 1-oxoethyl, 1-oxopropyl, 1- oxobutyl, 1-oxopentyl, dimethoxymethyl, diethoxymethyl, 1,1- dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxypropyl, halo, monofluoromethyl, difluoromethyl, 1,1- difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1- difluoropentyl, pentafluoroethyl, heptafluoropropyl,

thienylmethyl, 2(2-thienyl) ethyl, phenylacetyl,

phenyldifluoroethyl, aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein R² is selected from hydrido, carboxyethyl, cyclohexyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4- methylbutyl, tert-butyl, n-pentyl and neopentyl; with the proviso that both R¹ and R² cannot be hydrido simultaneously; wherein each of R³ through R¹¹ is hydrido with the proviso that at least one of R⁵ and R⁹ must be selected from COOH, SH, PO-₃H₂ SO₃H, CONHNH₂ CONHNHSO₂CF₃, OH,

wherein each of R⁴⁰ and R⁴¹ is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein at least one of R ⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

65. The composition of Claim 64 wherein m is one; wherein R¹ is selected from hydroxy, formyl, methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n- octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, adamantyl, adamantylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl,

pentafluoroethyl, heptafluoropropyl, phenylacetyl,

phenyldifluoroethyl, aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein R² is selected from carboxyethyl, cyclohexyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert- butyl, n-pentyl and neopentyl; wherein at least one of R⁵' R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

66. The composition of Claim 65 wherein at least one of R⁵ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

67. The composition of Claim 64 wherein said angiotensin II antagonist compound is selected from compounds, and their pharmaceutically-acceptable salts, of the group of compounds consisting of

5-[4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-propyl-1H-1,2,4-triazol-1-yl)methyl]-[1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-5-isopentyl-1H-1,2,4-triazol-1-yl)methyl]-

[1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1-yl]methyl)-

[1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-dimethoxymethyl-1H-1,2,4-triazol-1- yl)methyl](1,1'-biphenyl-2-yl]-1H-tetrazole;

5- [4 ' [ (5-buty1-3-phenylethyl-1H-1, 2, 4-triazol-1- yl)methyl] (1, 1 '-biphenyl-2-yl] -1H-tetrazole;

1- [ [5-butyl-1-[2 '- (1H-tetrazol-5-yl) [1, 1 '-biphenyl] -4- ylmethyl]-1H-1, 2, 4-triazol-3-yl]methyl] -1-butanone;

5- [4 '- [ (5-butyl-3-methyl-1H-1, 2, 4-triazol-1-yl) methyl] [1, 1 ' - biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(phenylmethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]- 1H-1,2,4-triazole-3-propanol;

5-[4'-[[5-butyl-3-(tricyclo[3.3.1.1^3.7]dec-1-ylmethyl]-1H- 1,2,4-triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]- 1H-1,2,4-triazole-3-propanoic acid;

5-[4'-[[3-(1,1,2,2,2-pentafluoroethyl)-5-butyl-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazol;

5-[4'-[[3-(1,1,2,2,3,3,3-heptafluoropropyl)-5-butyl-1H-1,2,4- triazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; and 5-[4'-[(3-cyclohexylmethyl-5-butyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole.

68. A therapeutic method for treating a

circulatory disorder, said method comprising administering to a subject having such disorder a therapeutically-effective amount of an active compound of Formula II:

alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl,

polycycloalkylalkyl, thienylalkyl, phenylacyl,

phenylhaloalkyl, aminoalkyl, acylaminoalkyl,

alkoxycarbonylaminoalkyl, glutamic acid alkyl ester,

alkylcarbonylthio, alkylthiocarbonyloxy,

alkylthiocarbonylthio, alkylthiothiocarbonyl,

aralkylthiocarbonyloxy, aralkylthiocarbonylthio,

alkylthiocarbonyl, aralkylthiocarbonylthio, mercapto,

alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

wherein X is selected from oxygen atom and sulfur atom;

wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and R³² is

cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl,

69. The method of Claim 68 wherein m is one;

wherein each of R¹ through R¹¹ is independently selected from hydrido, formyl, hydroxy, alkyl, hydroxyalkyl, halo,

polycycloalkylalkyl, thienylalkyl, phenylacyl,

phenylhaloalkyl, aminoalkyl, acylaminoalkyl,

alkoxycarbonylaminoalkyl, glutamic acid alkyl ester,

aralkylthiocarbonylthio, aralkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto,

alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

-Y_nA wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R¹ through R¹⁷, Y and A groups having a substitutable position may be substituted by one or more groups selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl,

wherein X is selected from oxygen atom and sulfur atom;

- 1

wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and R³² is

cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl,

70. The method of Claim 69 wherein m is one;

wherein each of R¹ through R¹¹ is independently selected from hydrido, hydroxy, formyl, alkyl, hydroxyalkyl, halo,

alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, polycycloalkyl, polycycloalkylalkyl, haloalkyl, thienylalkyl, phenylacyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl,

alkoxycarbonylaminoalkyl, glutamic acid alkyl ester,

wherein each of R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ is

H W W W W

-OH, -SH, -NR³³, -C-WH, -S-WH, -S-WH, -P-WH, -P-NH and -P-WH

W R³⁴ R³⁵ W R ³⁶ wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁷; wherein each of R³³, R³⁴, R³⁵, R³⁶ and R³⁷ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,

unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R^{1 1} so as to form a fused-ring system with one of the phenyl rings of the biphenyl moiety of Formula II; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; and wherein any of the foregoing R¹ through R¹⁷, Y and A groups having a substitutable position may be substituted by one or more groups selected from alkyl, alkenyl, aralkyl, hydroxyalkyl, haloalkyl, alkoxy, aryloxy, aralkoxy,

alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl,

wherein X is selected from oxygen atom and sulfur atom;

alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl,

71. The method of Claim 70 wherein m is one;

wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, alkyl, carboxyalkyl, phenyl, phenylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, alkylcarbonyl, alkoxyalkyl, hydroxyalkyl, halo, haloalkyl, thienylalkyl, phenylacyl, phenylhaloalkyl, aminoalkyl, acylaminoalkyl, alkoxycarbonylaminoalkyl and glutamic acid alkyl ester; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein each of R³ through R¹¹ may be an acidic moiety further independently selected from acidic moieties of the formula -Y_nA wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

H W W W

-O-, -SH, -NR³³ , - NC-WH, -S-WH, - lSl-WH and -P ll-WH

72. The method of Claim 71 wherein m is one;

wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, alkyl, carboxyalkyl, phenyl, phenylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, alkylcarbonyl, dialkoxyalkyl,

-Y_nA wherein n is a number selected from zero through two,

W W W

II II

-OH, -SH, -NR ³³ -C-WH, -S-WH, -S-WH and -P-WH

W WR³⁶ wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁷; wherein each of R³³, R³⁶ and R³⁷ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R³³ and R³⁶ may be further

independently selected from amino radical of the formula

73. The method of Claim 72 wherein m is one;

wherein each of R¹ and R² is independently selected from hydrido, hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl,

cyclohexyl, cyclopentylmethyl, cyclohexylmethyl,

2(3-thienyl)ethyl, phenylacetyl, phenyldifluoroethyl,

wherein each of R⁴⁰, R⁴¹ and R⁴² is independently selected from H, Cl, CN, NO₂, CF₃, C₂F₅, C₃F₇, CHF_2, CH₂F, CO₂CH₃, CO₂C₂H₅, SO₂CH₃ SO₂CF₃ and SO₂C₅F₅; wherein Z is selected from O, S, NR⁴³ and CH₂; wherein R⁴³ is selected from hydrido, CH₃ and CH₂C₆H_5; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R³ through R¹¹ so as to form a fused ring system with one of the biphenyl rings of the biphenyl moiety of Formula II, said fused ring system selected from

and the esters, amides and salts of said acidic moieties.

74. The method of Claim 73 wherein m is one;

wherein R¹ is selected from hydrido, hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n- heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl,

thienylmethyl, 2(2-thienyl) ethyl, phenylacetyl,

phenyldifluoroethyl, aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein R² is selected from hydrido, carboxyethyl, cyclohexyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4- methylbutyl, tert-butyl, n-pentyl and neopentyl; with the proviso that both R¹ and R² cannot be hydrido simultaneously; wherein each of R³ through R^{1 1} is hydrido with the proviso that at least one of R⁵ and R⁹ must be selected from COOH, SH, PO-₃H₂ SO₃H, CONHNH₂ CONHNHSO₂CF₃, OH,

wherein each of R⁴⁰ and R⁴¹ is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; wherein at least one of R⁵' R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂ SO₃H, CONHNH₂, CONHNHSO₂CF₃ , OH,

75. The method of Claim 74 wherein m is one;

wherein R¹ is selected from hydroxy, formyl, methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n- octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, adamantyl, adamantylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl,

pentafluoroethyl, heptafluoropropyl, phenylacetyl,

phenyldifluoroethyl, aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein R² is selected from carboxyethyl, cyclohexyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert- butyl, n-pentyl and neopentyl; wherein at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

76. The method of Claim 75 wherein at least one of R⁵ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

77. The method of Claim 74 wherein said active compound is selected from compounds, and their

pharmaceutically-acceptable salts, of the group of compounds consisting of

4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl] 2-carboxylic acid;

5-[4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole; 5'-[(5-butyl-3-chloro-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(3-butyl-5-isopentyl-1H-1,2,4-triazol-1-yl)methyl]-

[1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[(5-butyl-3-isopentyl-1H-1,2,4-triazol-1-yl]methyl)-

[1,1'-biphenyl]-2-yl]-1H-tetrazole;

1-[[5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- ylmethyl]-1H-1,2,4-triazol-3-yl]methyl]-1-butanone;

5-[4'-[(5-butyl-3-methyl-1H-1,2,4-triazol-1-yl)methyl][1,1'- biphenyl]-2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; 5-[4'-[[5-butyl-3-(phenylmethyl)-1H-1,-2,4-triazol-1- yl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-

1H-1,2,4-triazole-3-propanol;

5-[4'-[[5-butyl-3-(1,1-difluoro-2-phenylethyl)-1H-1,2,4- triazol-1-yl]methyl].[1,1'-biphenyl]-1-yl]-1H-tetrazole;

5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-

1H-1,2,4-triazole-3-carboxylic acid;

5-[4'-[(5-butyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-

2-yl]-1H-tetrazole;

5-[4'-[[5-butyl-3-(tricyclo[3.3.1.1^3.7]dec-1-yl]-1H-1,2,4- triazol-1-yllmethyl][1,1'-biphenyl]-2-yl]-1H-tetrazole;

5-butyl-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-ylmethyl]-

1H-1,2,4-triazole-3-propanoic acid;

5-[4'-[[3-(1,1,2,2,3,3,3-heptafluoropropyl)-5-butyl-1H-1,2,4- triazol-1-yllmethyl][1,1'-biphenyl]-2-yl]-1H-tetrazole; and

5-[4'-[(3-cyclohexylmethyl-5-butyl-1H-1,2,4-triazol-1- yl)methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole.

78. The method of Claim 68 wherein said circulatory disorder is a cardiovascular disorder.

79. The method of Claim 78 wherein said cardiovascular disorder is hypertension.

80. The method of Claim 78 wherein said cardiovascular disorder is congestive heart failure.